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Abstract 
Prolonged conjunctival infection with Chlamydia trachomatis leads to an 
inflammatory response, trachomatous inflammation follicular (TF). Over time, repeat 
infection can progress to scarring of the conjunctiva causing the eyelid to turn inward, 
resulting in lashes rubbing against the cornea. This painful stage of the disease is 
called trachomatous trichiasis (TT). TT can damage the cornea, leading to vision 
impairment or blindness.  
Trachoma is targeted for elimination as a public health problem by the year 2020, 
which for TT is defined as less than 1 TT-positive person, who is not already known 
to the health system, per 1,000 population. For trachoma to meet the elimination 
targets, massive resources are required for both mapping and intervention. A 
particularly large knowledge gap exists around identifying areas where TT is likely to 
be found. To better align resources and plan for elimination, the trachoma community 
needs to understand how much TT currently exists and requires management, how to 
accurately measure TT prevalence, and where TT cases are mostly likely to be located. 
Understanding these elements will help position trachoma control programs to meet 
the TT elimination targets. 
In my thesis I first calculate an updated global estimate of TT cases and describe the 
methods involved. Second, I provide a survey design for measuring TT with adequate 
precision for control activities, along with validation exercise results and a brief time-
cost analysis. I then examine the spatial structure of TF and TT and identify areas of 
spatial autocorrelation. Finally, I identify environmental factors associated with 
higher than expected TT prevalence to identify TT hot spots.  
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The outcomes of these activities provide an updated global estimate of existing TT 
cases, a validated tool for measuring TT prevalence at the implementation unit 
(district) level, and insight on where to begin case finding activities in the context of 
the “end game”. These outputs are critical to the continued effort of trachoma 
elimination as a public health problem, specifically providing targeted direction for 
TT resources. 
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 Introduction 
1.1 Background 
Trachoma, a neglected tropical disease (NTD), is endemic in more than 50 countries 
[1] and affects the most impoverished people of the world. Improved living standards 
are credited for the disappearance of trachoma from Europe and North America, but 
in many less developed countries, trachoma is still a public health problem, and 
contributes to the continued suffering and deepening of poverty of millions of people. 
The World Health Assembly Resolution 51.11 of 1998 targets the elimination of 
trachoma as a public health problem [2].  
For trachoma to meet the elimination targets, considerable resources are required for 
both mapping and intervention. An important knowledge gap exists around 
identifying areas where trachomatous trichiasis (TT) is likely to be found. This hinders 
the ability of trachoma programmes to efficiently reach TT patients with services. 
Geospatial techniques can provide valuable insight on the nature and distribution of 
trachoma, which in-turn can provide targeted direction for resources. 
The utility of geospatial tools and techniques to identify disease clusters, patterns, and 
trends have been incorporated into public health operational research for decades. 
More recently, the NTD community has adopted the use of these methods [3-17]. 
Gains in efficiency in identifying areas of endemicity through geospatial approaches 
can lead to more targeted programmatic work.  
The aim of this thesis is to inform estimates of the number of cases of TT (TT backlog) 
at global and national scales, assess a TT specific survey design, describe the 
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geospatial relationship between infectious trachoma (trachomatous inflammation 
follicular as a proxy) and trachoma morbidity (trachomatous trichiasis) and inform the 
possibility of identifying TT hot spots. To do so, I exploit a unique epidemiological 
resource generated through the Global Trachoma Mapping Project (GTMP), the 
largest ever exercise of its kind, which commenced in 2012. The aim of this project 
was to complete the global baseline mapping of trachoma using systematic and 
standardised methods. Through GTMP, 2.6 million people were examined 
representing 1,542 districts in 29 countries [18]. This geolocated data has been made 
available for operational research and provides an evidence base to explore the 
geospatial components of trachoma in a detail previously not possible. 
This chapter provides background information on clinical presentation of trachoma as 
well as detection, diagnosis, and epidemiology. Next, mapping and intervention 
strategies are reviewed and lastly, spatial modelling and geographic information 
systems (GIS) approaches and their applications to TT are outlined.   
1.2 Introduction to trachoma 
The bacterial infection Chlamydia trachomatis is the causative organism of trachoma. 
Repeated ocular chlamydial infection results in chronic inflammation, characterised 
by sub-epithelial follicles in the tarsal conjunctiva, which may be sufficiently large 
and numerous to meet the definition of trachomatous inflammation follicular (TF), a 
key sign for assessing trachoma prevalence [19]. Over time, with repeated reinfection, 
scarring may develop; this scarring can eventually cause the eyelid to turn inwards in 
some people, resulting in eyelashes touching the globe. This stage is TT and is very 
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painful [20]. As an individual with trichiasis blinks, the eyelashes abrade the cornea, 
which can lead to corneal opacity and blindness [21]. 
1.2.1 Detection and diagnosis 
NTD control programmes currently diagnose trachoma based on clinical presentation. 
The World Health Organization (WHO) developed a simplified grading system in an 
effort to standardise trachoma diagnosis in a public health setting [19]. The eye is 
inspected using a binocular magnifying loupe (x2.5). The examiner first inspects the 
lashes and cornea, looking for at least one lash rubbing the eyeball (TT) and easily 
visible corneal opacity over the pupil (CO). The upper lid is then everted, exposing 
the tarsal conjunctiva. The examiner looks for five or more follicles at least 0.5 mm 
in diameter (TF), pronounced inflammatory thickening that obscures more than half 
of the normal deep tarsal vessels (TI) and  presence of scarring (TS) [19] (Figure 1.1). 
A.
 
B. 
 
C.
 
D. 
 
 
E. 
 
F.
 
Figure 1.1 The WHO simplified grading system for assessment of trachoma, Adapted from Thylefors et al. 
(1987) [3]. A) Normal tarsal conjunctive, B) Trachomatous inflammation follicular (TF), C) Trachomatous 
inflammation follicular and intense (TF+TI), D) Trachomatous scarring (TS), E) Trachomatous trichiasis (TT), 
F) Corneal opacity (CO) 
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The simplified grading system identifies clinical signs that are not necessarily 
pathognomonic for trachoma. However, they are reasonably predictive of the 
community situation. In areas where trachoma is endemic, these signs are nearly 
always attributable to trachoma [22]. 
Despite the existence of a standardised grading system, diagnosis based entirely on 
clinical presentation may not always support elimination efforts. When examining 
eyes in a post-intervention setting, it is possible that residual clinical signs may bias 
survey results. Studies in The Gambia have shown, after multiple years of 
intervention, positive clinical signs remain high (TF 12.3%), whilst ocular Chlamydia 
trachomatis infection is low (0.3%) [23]. However, studies in Nepal and Tanzania 
have consistently shown good concordance between clinical and serological diagnosis 
in low endemicity settings [24-26].   
Whilst the simplified grading system aims to provide a consistent diagnostic, it is still 
subjective to the examiners. Great effort has gone into training examiners to 
consistently identify each sign. Examiners participate in practical exercises and are 
graded on their consistent diagnosis. This method works well for identifying TF, 
which is relatively common in training settings. However, because TT is a much less 
common sign it is often difficult to find enough positive cases in a training setting to 
validate a consistent diagnosis.  
It is not always possible to make presumptions as to the aetiology of trichiasis cases. 
Serological testing, similar to those used in the lymphatic filariasis [27] and 
onchocerciasis [28] programmes would be useful. Although current work is underway 
to develop an objective diagnostic tool for trachoma, we do not yet have a rapid test 
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available for routine programmatic use. Such a tool could be extremely useful in the 
“end game” of trachoma elimination. Generally serological surveys have been limited 
to research environments. For example, a 2014 study in Tanzania examined the use 
of serological tools for measuring trachoma in a post-intervention setting. In the 
community, 218 children were examined using the simplified grading system, 
additionally an ocular swab and blood sample were taken from participants. The TF 
prevalence was 6.5%, yet there were zero positive ocular swabs and a 3.5% prevalence 
from the serological assay (with specificity limits of 96-98%) [29]. This small study 
raises concern that residual clinical signs remain in the community after transmission 
is halted. However, several additional studies have collected serologic data along with 
clinical signs and show concordance between the methods. A 2014 cross-sectional 
survey of Achham district in Nepal found TF prevalence within 24 randomly selected 
communities to be 0.3% (CI 0.1%-0.8%) and prevalence of ocular chlamydia 
infection to be 0% (CI 0%-0.3%) [24]. A 2015-2016 cross-sectional survey of four 
districts in Nepal found TF prevalence <1% in all districts. These same districts 
showed seropositivity varying from 1.4% (CI 0.7%-2.6%) to 2.5% (CI 1.3%-4.5%) 
[26]. A 2017 cross-sectional study, of 38 communities of Kongwa district in Tanzania 
found TF prevalence to be 3.2% and ocular chlamydia infection to be 6.5% [25]. 
These studies show that there is often concordance, though it is important to 
acknowledge the occasional discordance between clinical identification of trachoma 
and serological tests. 
1.2.2 Epidemiology  
Chlamydia trachomatis is transmitted through close physical contact. It is reasonable 
to expect that young children infect each other through play and caretakers of these 
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children (often women) also become infected. Individuals with severe inflammatory 
disease are more likely to develop fibrotic sequelae and this is more common after 
repeat infection [30, 31]. Over time, chronic TF can lead to scarring which may results 
in the inverting of the eyelid and eyelashes scrapping the globe (TT) (Figure 1.2). I 
suspect that TF distribution dynamics will almost certainly influence TT distribution.   
 
Figure 1.2 Description of pathway to trachoma infection and progress towards TT 
Many studies have identified the importance of TF transmission between family 
members and close communities [32-42]. These studies consistently found a 
statistically significant relationship between positive TF and sharing a dwelling or 
living in close proximity. Bailey et al. even found that in one Gambian village there 
was clustering within a household [42]. Those who shared a bedroom were more 
genetically similar and/or share similar exposure risk. It is important to note that 
several studies have shown that immune response to C. trachomatis is connected to 
host genetic variation and genetic polymorphisms related to immune system function 
have been associated with TS [43, 44]. The results of these studies provide evidence 
that trachoma is related to close personal contact and that increased exposure increases 
risk of TF and/or a strong genetic predisposition to development of clinical signs 
exists.  
There have also been several studies evaluating behaviour and environmental 
contribution to trachoma transmission. Numerous studies have demonstrated a 
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relationship between TF status and poor personal hygiene. A risk factor of note is 
facial cleanliness  [32, 41, 45-48]. Nasal and ocular discharge [49] contain chlamydial 
bacteria. Washing the discharge away may reduce transmission.  
Improved access to water is necessary to encourage personal hygiene practices. A 
relationship has also been found between distance to water and risk for TF [32, 50-
52]. These studies conclude that distance to water is associated with the use of the 
water. The authors infer that increase risk of disease is not simply a direct function of 
access to water but of value placed on the water. It is reasonable to suggest that when 
water is more readily available it is more likely to be used for bathing (i.e. clean faces). 
Furthermore, eye seeking flies have been shown as possible trachoma vectors. A 
series of investigations were conducted in The Gambia to identify potential fly 
vectors. Two species were found to be present on children’s eyes. 90% of the flies 
found on eyes were Musca sorbens. Children with ocular and nasal discharge had 
twice as many flies than those with no discharge [53]. Additional studies have found 
a significant association between flies on faces and TF [38, 51, 53-56]. Facial 
cleanliness could reduce the transmission resulting from the presence of flies. 
A study in Tanzania also identified altitude as significantly inversely associated with 
TF prevalence (OR 0.55). The authors note, households of higher socioeconomic 
status tend to reside higher up the slopes of Mt. Kilimanjaro. The association with 
altitude may also be a result of fly density decreasing as altitude increases.  This theory 
has been demonstrated in previous studies conducted in central Ethiopia [57, 58]. 
However, increased altitude as a risk factor is inconsistent with finding in the Amhara 
region of Ethiopia where ordinal logistic regression showed a positive associated with 
24 
 
TF prevalence and altitude P-value <0.001 [59]. Additionally, there is evidence that 
perhaps fly density is not associated with increased TF in hyperendemic communities. 
A 2006 single-blind randomized trial in Tanzania where one dose of antibiotic was 
administered to residents in both intervention (community treated with insecticide and 
monitored for fly count) and control groups found no difference in trachoma rates 
[60]. Perhaps there are inherent differences in the socio-economic and geographic 
settings of these areas. There is likely a cause/effect relationship between the 
environmental factors and hygiene behaviour, ultimately resulting in increased 
exposure. 
1.2.2.1 Understanding progression from TF to TT 
Crucially, very few studies have been conducted to evaluate risk factors specifically 
for TT and our understanding of this outcome is limited. Overall, more research is 
needed to understand the relationship between community-level TF prevalence, 
geoclimatic factors and TT occurrence (Table 1.1).  One study in the Amhara region 
of Ethiopia used multivariate logistic regression to explore the relationship between 
risk factors and TT [59]. The results show an association between TT and increased 
age (OR per 5-year increase 1.5), female sex (OR 4.5), increased proportion of 
children with TF (P-value 0.003) and increased altitude (P-value 0.015). These 
findings align with common belief that age and sex are associated with progression to 
TT. Altitude deserves further investigation as a risk factor. It is may also be reasonable 
to infer that increased occurrence of TF results in increased occurrence of TT. 
However, additional evidence is needed to generalize this relationship. 
A 1993 study in Tanzania evaluated risk factors associated with TT in women [61]. 
This study matched women with TT to two women with no clinical signs for trachoma 
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of the same age and from the same village. Logistic regression models showed the 
following factors associated with TT: history of trichiasis in the women's mother (OR 
3.6, CI 2.0-6.5), sleeping in a room with a cooking fire during childbearing years (OR 
1.8, CI 1.2-2.8), a home of wood and earth during childbearing years (OR 2.1, CI 1.3-
3.3), no adult education classes (OR 2.2, CI 1.4-3.4); and five or more deaths among 
her children (OR 2.6, CI 1.3-5.1). These factors all point to a strong socio-economic 
element at play in developing TT. 
The frequency of C. trachomatis infection required to develop trichiasis is unknown. 
It is also unclear if other factors play a role in the speed and intensity of trichiasis 
development.  Long-term longitudinal studies have found TS to be strongly associated 
with TF [62-65]. However, no association was found when C. trachomatis infection 
was compared with progression of previously established TS [63]. Perhaps, 
progression from scarring to TT may not be entirely dependent on re-infection, which 
would mean that there may be progression to TT even once infection is eliminated as 
a public health problem.  
It is argued that conditions promoting eye to eye transmission exacerbate the 
progression from TF to TT [33]. In The Gambia a cohort of trichiasis patients who 
declined surgery were followed over four years [66]. It was observed that trichiasis 
continued to worsen over time, even with low TF prevalence in the community. The 
study found increased age, conjunctival inflammation (OR  2.04) and bacterial 
infection (OR  4.33) were associated with progressive trichiasis. The authors suggest 
chronic inflammation of the conjunctiva may be the central event in the pathogenesis 
of trachoma. This finding is consistent with results from a study in Tanzania, where a 
cohort of children were followed for seven years to determine incidence of scarring 
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[62]. The incidence in children with constant severe inflammatory trachoma (TI, or 
trachoma intense) was 29.2% (OR 4.85) [63].  
Limited studies have demonstrated a potential geoclimatic element at play with the 
development of TT. A study in Mali found high rates of TF prevalence in the northern 
portion of the country (41.1%) [67]. However, prevalence rates of TT increased from 
north to south (1.0% north of the 15th parallel and 2.8% south of the 15th parallel: OR 
2.91). The authors speculate this may be attributed to dry conditions in the north 
contributing to TF and the humid environment in the south contributing to blinding 
complications. It has also been suggested that areas in Sudan with frequent sandstorms 
result in eye trauma [68]. Irritaion of the eyes leads to rubbing with fingers. This 
perhaps hastens the progression of TT.  
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Table 1.1 Studies with focus on risk factors specific for TT 
Year Location Study population Key findings Limitations Citation 
2008 Ethiopia children aged 1–
9 years and 
adults aged ≥15-
years 
Amhara region of Ethiopia used multivariate 
logistic regression to explore the relationship 
between risk factors and TT. The results 
show an association between TT and 
increased age (OR per 5-year increase 1.5), 
female sex (OR 4.5), increased proportion of 
children with TF (P-value 0.003) and 
increased altitude (P-value 0.015). 
The sampling implemented for 
data collection used in this 
analysis was limited to 160 
clusters and so may not 
appropriately represent the 
entire region of Amhara 
Ethiopia described in the 
findings. 
Ngondi J, Gebre T, Shargie EB, Graves PM, 
Ejigsemahu Y, Teferi T, et al. Risk factors for 
active trachoma in children and trichiasis in 
adults: a household survey in Amhara 
Regional State, Ethiopia. Transactions of the 
Royal Society of Tropical Medicine and 
Hygiene. 2008;102(5):432-8. doi: 
10.1016/j.trstmh.2008.02.014. PubMed PMID: 
18394663. 
2006 The 
Gambia 
Individuals with 
trachomatous 
trichiasis in at 
least one eye 
In The Gambia a cohort of trichiasis patients 
who declined surgery were followed over 4 
years. It was observed that trichiasis 
continued to worsen over time, even with 
low TF prevalence in the community. The 
study found increased age, conjunctival 
inflammation (OR 2.04) and bacterial 
infection (OR 4.33) were associated with 
progressive trichiasis. 
In this study, 30% of target 
population was lost to follow-
up, with 19% having died and 
so the findings may be an 
underestimate. 
Burton MJ, Bowman RJ, Faal H, Aryee EA, 
Ikumapayi UN, Alexander ND, et al. The 
long-term natural history of trachomatous 
trichiasis in the Gambia. Investigative 
ophthalmology & visual science. 
2006;47(3):847-52. doi: 10.1167/iovs.05-
0714. PubMed PMID: 16505016. 
2007 Mali children aged 1–
9 years and 
women aged 
≥15-years 
A study in Mali found high rates of TF 
prevalence in the northern portion of the 
country (41.1%). However, prevalence rates 
of TT increased from north to south (1.0% 
north of the 15th parallel and 2.8% south of 
the 15th parallel: OR 2.91). 
This study included data from 
only 202 clusters across the 
entire country limiting the 
generalizability of the findings. 
Schemann JF, Laffly D, Sacko D, Zephak G, 
Malvy D. Trichiasis and geoclimatic factors in 
Mali. Transactions of the Royal Society of 
Tropical Medicine and Hygiene. 
2007;101(10):996-1003. doi: 
10.1016/j.trstmh.2007.05.015. PubMed PMID: 
17658570. 
1959-
1969 
Sudan All reported 
trachoma cases 
This study suggests that areas in Sudan with 
frequent sandstorms result in eye trauma. 
Irritation of the eyes leads to rubbing with 
fingers. This perhaps hastens the progression 
of TT. 
The data used in this study was 
derived from ophthalmological 
records and so populations 
who do not access services are 
surely underrepresented in the 
findings. 
Salim AR, Sheikh HA. Trachoma in the 
Sudan. An epidemiological study. The British 
journal of ophthalmology. 1975;59(10):600-4. 
PubMed PMID: 1191619; PubMed Central 
PMCID: PMC1017417. 
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In summary, most epidemiological research to date evaluates factors associated with 
TF. Factors shown to have an association are exposure, unclean faces, fly density 
(debatably), and access to water. These factors are interrelated. There may be a 
relationship between TT progression and individual bacterial load and geoclimatic 
factors. However, our understanding of the factors driving progression to TT in 
different settings remains too limited.  
1.3 Mapping and control of trachoma 
There has been substantial progress in trachoma mapping over the past five years. 
During this time, a standardised approach was used to complete the global baseline 
mapping of trachoma, with a strong focus on generating local prevalence estimates for 
TF. Less attention has been paid to mapping TT specifically. In this next section, I lay 
out the key strategies that have been used to map trachoma outcomes. 
1.3.1 Mapping strategies  
1.3.1.1 Rapid assessment method 
The trachoma rapid assessment (TRA) is used to identify communities most in need of 
intervention, through an initial desk review and evaluation of high risk communities. 
In this assessment community members are asked a series of questions to help 
determine who in the community is most likely to suffer from TT. An eye exam is 
performed on these individuals to diagnose TT. To measure TF, the selection of 
households is “optimally biased” towards the least advantaged. A minimum of 50 
children aged 1–9 years are examined from the selected households [69]. This method 
is a biased epidemiologic survey but is a useful cost-effective way of determining if a 
population based prevalence survey (PBPS) is warranted.  
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1.3.1.2 Current mapping gold standard 
The WHO endorses a PBPS for trachoma, which is designed to calculate the prevalence 
of TF in children aged 1–9 years with an expected prevalence of 10%. This method 
assumes that children aged 1-9 years are the reservoirs of TF and the results can be 
generalized to the entire population. The design is a two stage cluster random sample 
survey, which uses probability proportional to size (PPS) to select 20-30 clusters and 
examines all children aged 1–9 years for TF and adults aged ≥15-years for TT in the 
selected clusters [22]. TF and TT are evaluated using the simplified grading system.  
This design is powered to provide TF prevalence estimates for the entire population. 
However, the design is not sufficient for estimating TT prevalence with high precision 
for the entire population. A survey powered to provide TT prevalence estimates is 
needed. 
In 2013 the United Kingdom’s department for international development (DFID) 
provided funding for GTMP which has served as a catalyst to systematically complete 
the global trachoma map using standardised techniques in both collecting and analysing 
survey data [70]. GTMP measured trachoma using the gold standard method described 
here. To prevent convenience sampling, the GTMP requires a fixed number of 
households to be enrolled per cluster. Adults living in the selected households are 
examined for trichiasis. These surveys accept the loss in precision in estimating TT 
[71]. The GTMP method was used in 29 countries where 2.6 million people were 
examined providing results for over 1,540 districts [72]. The methodology for analysing 
the datasets involves standardising the calculations by age and sex to account for the 
non-random difference in age and sex which systematically bias the results. 
Anecdotally it has been seen that during household surveys it is more likely that older 
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individuals and women are at home and therefore potentially over sampled. It is 
additionally assumed that persons with TT are more likely to be home as they may be 
unable to work. The findings of the massive mapping campaign show 36% of the 
districts mapped require antibiotic intervention (described in the following section) and 
nearly 80% of those districts are in Eastern Africa (Figure 1.3). 
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Figure 1.3 The global distribution of TF, where light green indicates district-level TF prevalence below the elimination threshold of 5%, yellow indicates district-level TF prevalence below the 
threshold for Mass Drug Administration (MDA) but above the elimination threshold, orange indicates district-level TF requiring a minimum of three years of MDA, and red indicates district-
level TF prevalence requiring a minimum of five years of MDA. 
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1.3.2 Intervention strategies 
The World Health Assembly Resolution of 1998 targets the elimination of trachoma as 
a public health problem by the year 2020 [2]. A series of global trachoma scientific 
meetings (GTSM) resulted in generating the elimination targets for TF as, less than 5% 
prevalence in children aged 1-9 years and TT as less than one person with positive TT 
in either eye, who is not already known to the health system per 1,000 population per 
health district  (TT prevalence of less than 0.1%) [73].   
The strategy to eliminate trachoma as a public health problem is community wide 
intervention, rather than individual treatment. The strategy is named SAFE (Figure 1.4) 
and involves (S) surgery to correct trichiasis, (A) mass drug administration (MDA) of 
azithromycin and improved sanitation and hygiene, focusing on (F) facial cleanliness 
and (E) environmental improvement [2]. This strategy is based on the identification of 
clinical signs, TF and TT. 
 
Figure 1.4 SAFE diagram, provided by the International Trachoma Initiative 
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The A F E intervention recommendations are based on district level TF prevalence. A 
TF prevalence of <5% warrants no intervention. A TF prevalence of 5-<10% warrants 
a sub-district level evaluation. A TF prevalence of 10-<30% warrants three years of 
MDA along with district wide facial cleanliness and environmental improvement 
campaign. A TF prevalence of >=30% warrants a minimum of five years of MDA along 
with district wide facial cleanliness and environmental improvement campaign. Once 
the appropriate number of treatment cycles are completed, impact assessments are 
conducted to re-evaluate the disease burden [73]. The result of the impact assessments 
informs the next steps, which are either continuing or stopping A F E interventions.  
The S intervention is determined based on district level TT prevalence. A TT 
prevalence of <0.1% in the entire population (or 0.2% in adults aged ≥15-years) does 
not warrant surgical intervention. A TT prevalence of ≥0.1% (or 0.2% in adults aged 
≥15-years) warrants surgical campaigns within the district. There is a lack of guidance 
on what to do if TF is below this threshold and TT is above this threshold as there is 
not currently a TT specific survey methodology (Figure 1.5).  
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Figure 1.5 Trachoma programme flowchart demonstrating the decision tree associated with district level prevalence outcomes. Where district level TF is below 10% in children aged 1–9 years 
no AFE interventions are warranted, where TF is between 10% and 30% AFE interventions are warranted for a minimum of three years, where TF is 30% or higher AFE interventions are 
warranted for a minimum of five years. Where district level TT prevalence in the entire population is less than 0.1% no S intervention is warranted and where prevalence is 0.1% or higher in 
the entire population S intervention is warranted. There are gaps in guidance around when to re-evaluate if the TF and TT prevalences are not aligned (i.e. there is transmission but no 
morbidity or there is morbidity and no transmission).
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These recommendations often leave country programmes confused. There is no 
mechanism for evaluating TT in absence of TF or clear surveillance strategy guidelines. 
In the following section I will review each component of the SAFE strategy, focusing 
on the practicality of the interventions. 
1.3.2.1 Surgery 
Trichiasis can be corrected through quality surgery. The decision on who should receive 
surgery is the first step. Burton et al. demonstrated that disease progression can move 
quickly, with 33% of minor TT cases progressing to major TT cases in the Gambia, 
over one year [66]. However, there are different thoughts on providing surgery to those 
individuals with minor TT. Some recommend providing surgery to all TT cases [74] 
whilst others suggest exploring epilation in cases where TT is minor [75]. Weighing 
the cost-benefit of surgery is certainly delicate and specific to individual circumstances. 
Whilst, trachoma examiners grapple with personal ethics on when and to whom surgery 
should be considered the WHO has provided clearer recommendations. The WHO 
recommends  a posterior lamellar tarsal rotation (PLTR) as the surgical technique 
replacing the previously recommended bilamellar tarsal rotation (BLTR) [76], because 
a clinical trial showed that PLTR led to  a lower rate of recurrence [77].  This 
randomised control trail was conducted in Ethiopia and included 1,000 participants with 
trichiasis. The study found 22% recurrence among the BLTR cohort and 13% among 
the PLTR cohort. Successful surgery can halt progression to corneal opacity and relieve 
pain (Figure 1.6). 
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Figure 1.6 Images of trichiasis surgery outcomes adapted from Merbs et al. (2015) [78]. 
Post-surgery trichiasis reoccurrence is frequent and may occur for many different 
reasons, including; preoperative disease severity, quality of surgery, and surgical 
procedure performed [79]. A study in The Gambia was conducted to understand the 
long-term outcome of surgery. A cohort of patients who had undergone surgery three 
to four years earlier were re-assessed through a clinical exam, polymerase chain 
reaction (PCR) and bacterial culture. Examination were performed on 141 people and 
recurrent trichiasis was found in 41.6% of the operated eyes [80]. In 2010, an additional 
study was conducted reviewing the reoccurrence of TT post-surgery. The reoccurrence 
rate remained high ranging from 32%-41% [81].  
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To address surgical quality, the HEAD START programme was established. HEAD 
START involves an enhanced training system where all persons training in trichiasis 
surgery are taught by certified national master trainers and undergo hands on practical 
training using a mannequin [82]. The adoption of life-like simulations is recommended 
by WHO for both new trainings and refresher exercises.  The broad adoption and 
success of this HEAD START for trichiasis surgeries has inspired the development of 
a similar life-like simulation mannequin for lymphatic filariasis (LF) hydrocele surgical 
trainings.  
There has been a substantial recent uptake in trichiasis surgeries being performed, with 
260,000 reported surgeries in 2016 [83] compared to 66,000 reported in 2011 [84]. This 
may partially be a result of an increase focus on TT surgery within trachoma elimination 
programmes along with the institution of HEAD START.  
To plan for surgeries, it is fundamentally necessary to understand how many surgeries 
are needed and where these patients are most likely to live. Current estimates suggest 
7.26 million people are living with TT [84]. This estimate was generated through a 
review of WHO 2011 country reports, where methodologies used in each country to 
generate estimates were not described and so this estimate is extremely limited. I will 
re-evaluate this estimate considering the availability of new data in Chapter 2.  
Whilst my thesis focuses on the TT stage of trachoma, the distribution of TF likely 
influences the distribution of TT. Understanding the rationale around TF interventions 
is important in framing the context of TT distribution. Figure 1.7 demonstrates at what 
stage these intervention strategies effect trachoma progression. Delivery of these 
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interventions interrupt trachoma progression on the pathway to TT. Preventing re-
infection should reduce the amount of TT. 
 
Figure 1.7 Trachoma progression and intervention 
1.3.2.2 Antibiotic 
Current guidelines recommend MDA with azithromycin once annually in trachoma 
endemic districts. A prolonged course of topical tetracycline or a single dose of 
Azithromycin are effective against chlamydial infections. A single dose Azithromycin 
is more effective due to improved compliance [85]. The pharmaceutical company Pfizer 
Inc. has pledged to donate the antibiotic through the International Trachoma Initiative.  
Questions remain surrounding the most efficient treatment cycles of antibiotic. A cross-
sectional survey in Tanzania with baseline trachoma and average MDA coverage data 
was conducted [86]. Coverage was defined as number of persons treated/number of 
persons in the community. A multivariate linear model of trachoma prevalence, 
adjusted for baseline trachoma rate and the average treatment coverage, suggested that 
each additional round of mass treatment beyond three years decreased the prevalence 
by an absolute value of 1.6%. The model suggests communities with baseline TF 
prevalence of 50% and an average annual MDA coverage of 75% would require seven 
years of MDA to bring the TF prevalence below 5%. The findings of this study are 
consistent with a global study conducted in 2014 which used linear and logistic 
regression models to show the probability of achieving the <5% TF target in different 
 
 
39 
 
scenarios [87]. The results showed the probability of achieving the target in areas with 
a baseline TF >=30% was <50%.  Both studies are limited by the data available. MDA 
coverage is extremely difficult to measure. The numerator (number of persons treated) 
is routinely recorded as MDA is carried out. However, the denominator is challenging 
as it fluctuates and is difficult to accurately measure at the time of MDA. Because of 
the lack of reliability in coverage calculations, the second study simply used number of 
rounds of MDA. This is perhaps a more programmatically realistic approach but loses 
information around effective MDA.  
The current guidelines recommend a single round of MDA annually. However, the 
value of biannual rounds of MDA has been explored [88].  Using an age structured 
mathematical model, estimates of the initial doubling time (IDT) for trachoma were 
developed. The model suggests MDA should be annually administered in areas where 
TF prevalence is less than 50% but in areas where TF is greater than 50% MDA should 
be administered biannually.  
A 2011 cluster-randomised trial in Ethiopia, randomly assigned subdistricts to receive 
annual (mean baseline TF prevalence 41.9%) or biannual (mean baseline TF prevalence 
38.3%) azithromycin treatment [89]. The prevalence of ocular chlamydial infection in 
children was not different between the two groups at 18, 30, and 42 months (P-
value>0.99). However, a Cox proportional hazards model shows that the mean 
elimination time in the biannual subdistricts was 7.5 months earlier (2.3-17.3) than that 
of the annual group (P-value = 0.10). 
Additionally, a 2016 cluster-randomized trial in Niger found no significant difference 
in TF prevalence among communities where children were treated annually and 
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biannually [90]. The mean baseline TF in these communities was 27.7% and 24.3% 
respectively.   
All of these study results suggest that the azithromycin donation programmes should 
consider planning additional years of MDA and biannual treatments in areas with very 
high levels of TF prevalence. 
1.3.2.3 Facial Cleanliness 
Facial cleanliness is included as part of the trachoma intervention strategy because 
clean faces reduce the infectious ocular and nasal discharge which attract eye seeking 
flies [53]. This practice may also reduce the occurrence of auto reinfection by removing 
the pathogen from the eye [91]. An intervention trial was undertaken in Kongwa, 
Tanzania where villages were assessed on the impact of face washing intervention with 
MDA or MDA alone [92]. After 12 months of follow-up, the children who received 
face washing intervention along with MDA were 60% more likely to have clean faces 
than those who only received MDA, but there was no difference in the prevalence of 
TF between the intensive face washing and comparison arms. It was further determined 
that a clean face at two or more follow-up visits was protective for TF (OR 0.58). This 
was an intense, very expensive and time-consuming intervention. Sustained hygiene 
behaviour change is associate with reduced TF. However, face-washing is very difficult 
to implement on its own and so should be included in general hygiene behaviour 
practice programmes.  
1.3.2.4 Environmental improvement 
As discussed previously, the presence of M. sorbens is occasionally associated with 
trachoma risk. The larval medium for M. sorbens is human faeces [93]. However, larval 
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stages have not been found in latrines and adult M. sorbens have not been observed 
emerging from latrines [94]. A community-based cluster randomized controlled trail 
was conducted in The Gambia, where seven sets of three village clusters were randomly 
assigned to either (1) receive regular insecticide spray (space-spraying with water-
soluble permethrin every two days for two weeks followed by maintenance spraying 
twice a week) (2) install pit latrines in each household or (3) receive no intervention 
(control).  
In the insecticide villages, the number of flies found on children’s eyes was 88% less 
than the control. In the pit latrine villages, the number of flies found on children’s eyes 
was 30% less than the control. The cluster level trachoma prevalence in the insecticide 
villages demonstrated a statistically significant mean reduction of 56% and the pit 
latrine villages did not demonstrate a statistically significant difference in comparison 
with the mean rate change in the control [95].  
This is a single study and it may not be appropriate to generalize to the larger trachoma 
endemic world. Whilst in The Gambia, M. sorbens seem to be an important vector for 
trachoma, this is not necessarily the case in other settings. A similar study was 
conducted in Tanzania and found that the trachoma rates were not significantly different 
between the intervention (community treated with insecticide and monitored for fly 
count) and control groups [60]. 
A systematic review of the effect of water, sanitation, and hygiene on the prevalence of 
trachoma was conducted in 2014 [96]. The review found evidence to support the F and 
E components of the SAFE strategy. However, the authors highlight the need for 
standardised approaches for measuring progress in this area. Programmes have 
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difficulty implementing a facial cleanliness and environmental improvement 
intervention as it is unclear what is meant by district wide facial cleanliness and 
environmental improvement campaigns. There are no concrete guidelines on what is 
necessary from the water and sanitation stand point to stop the transmission of 
trachoma.  
The S component of the SAFE strategy is clearly the focus for addressing TT morbidity. 
However, the progression of TF to TT can be slowed or even halted through earlier 
interventions such as AFE and is some cases may eliminate the need for future surgical 
interventions. 
1.4 Trachoma in global context 
1.4.1 Sustainable development goals  
In 2015, 193 world leaders committed to adopting the sustainable development goals 
(SDGs), which build upon the Millennium Development Goals (MDGs). The aims of 
the SDGs are to end poverty, protect the planet and ensure prosperity for all [97]. The 
SDGs specifically relevant to trachoma interventions are: (1) end poverty in all its forms 
everywhere, (3) ensure healthy lives and promote well-being for all at all ages, (4) 
ensure inclusive and quality education for all and promote lifelong learning, and (5) 
achieve gender equality and empower all women and girls. Callahan et al. evaluated 
trachoma control initiatives in the context of the MDGs [98] and this evaluation is still 
very applicable to the SDGs. This publication addresses the evidence suggesting SAFE 
interventions as part of trachoma control programmes play a valuable role in the 
reduction of extreme poverty.  
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It is well established that trachoma disproportionately effects women and children [99]. 
Because of the infectious nature of ocular chlamydia, children are the main reservoir 
for the disease. Children wipe nasal and ocular discharge on their clothes, share toys 
and personal space with other children and so continuously re-infect one another. 
Women are typically the caregivers of children in these communities. This means 
women are also more exposed to re-infection [100]. It is commonly believed that the 
re-infection of children and women leads to a pattern of disenfranchisement in women 
and girls. When a woman develops TT and is no longer able to perform household tasks 
someone else must take on her responsibilities. I suspect that this creates as a cycle, 
increasing risk of disease and lack of education in women and girls. For these reasons 
the elimination of trachoma as a public health problem is aligned with the SDG (1) end 
poverty in all its forms everywhere, (3) ensure healthy lives and promote well-being for 
all at all ages, (4) ensure inclusive and quality education for all and promote lifelong 
learning, (5) achieve gender equality and empower all women and girls, (6) ensure 
access to water and sanitation for all, and (17) revitalize the global partnership for 
sustainable development.  
As outlined in the previous section, azithromycin is distributed to entire communities 
during MDA campaigns for trachoma. Azithromycin is a powerful antibiotic which has 
been proven to reduce malaria [101] and treat many sexually transmitted infections 
(STIs) [102, 103]. Furthermore, azithromycin has been shown to significantly reduce 
morbidity associated with diarrheal symptoms [104, 105]. The A component of the 
SAFE strategy directly links to the SDG (3) ensure healthy lives and promote well-
being for all at all ages. 
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The E (environmental improvement) component of the SAFE strategy aligns nicely 
with the SDG (6) ensure access to water and sanitation for all. Trachoma programmes 
prioritize the construction of latrines and improved access to water sources.  
Section 1.5 will discuss why the economic implications of trachoma are important, and 
how trachoma contributes to loss in productivity and increase in poverty [106] aligning 
with SDG (1) end poverty in all its forms everywhere. 
Finally, successful trachoma intervention is only possible with the cooperation of many 
stakeholders, including ministries of health, pharmaceutical partners (Pfizer, donates 
azithromycin (Zithromax®) to endemic countries) and global partners such as WHO. 
Trachoma elimination programmes certainly adhere to SDG (17) revitalize the global 
partnership for sustainable development. 
There is clearly a link between scaling up of trachoma intervention programmes 
(SAFE) and the SDGs. This link has been useful in advocating for trachoma 
intervention resources. 
1.4.2 Trachoma elimination metrics and benchmarks 
In 2011, Accelerating work to overcome the global impact of neglected tropical 
disease: A roadmap for implementation, was approved by the World Health 
Organization’s Strategic and Technical Advisory Group for NTDs (STAG-NTD) [107]. 
This was a substantial moment in the NTD community, where WHO facilitated a clear 
set of targets and benchmarks from which progress to the 2020 elimination goals can 
be measured. Trachoma elimination targets set by country governments in 2011 are 
provided in the roadmap. According to the roadmap, to achieve the goal of global 
elimination of trachoma as a public health problem by the year 2020, 10% of endemic 
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countries would achieve elimination by the year 2013. This means five countries (10% 
of the 52 endemic countries) should demonstrate district level prevalence of TF of <5% 
and district level prevalence of TT of <0.1% in the entire population (or 0.2% in the 
≥15-years population) in all previously endemic districts. Furthermore, 40% of endemic 
countries should achieve elimination by the year 2016. In addition, by 2015 50% of 
people at risk for trachoma should be receiving MDA and 100% of countries endemic 
for trachoma should have a plan of action for integrated MDA. 
The roadmap elaborates on the need to plan for a post-endemic future. Many districts 
and countries are expected to reduce prevalence below the intervention thresholds soon 
and so plans for scaling down intervention and appropriate surveillance techniques need 
to be planned for. The roadmap especially notes the need for preparation and innovation 
now of epidemiological tools, diagnostics and models to help identify maintenance 
strategies.  
Also in 2011, The end in sight: 2020 INSight [108], was published by the international 
coalition for trachoma control (ICTC). This document provided metrics and 
benchmarks for reaching 2020 and has played a critical role in securing resources for 
scaling up trachoma elimination efforts. The ability to measure and set clear 
expectations is crucial for advocacy and donor relationships. 
Inspired by the roadmap, the London Declaration on Neglected Tropical Diseases 
(2012) Ending the neglect and reaching 2020 goals [109], renewed the call for control 
and/or elimination by 2020. 
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1.4.3 Scaling of resources 
In part, as a response to the roadmap and 2020 INSight metrics the UK government 
(DFID) pledged to provide ₤10.6 million and the US government (USAID) pledged to 
provide an additional ₤6 million to complete the baseline mapping of trachoma. This 
initiative was named the GTMP and successfully completed trachoma baseline 
mapping in 29 countries (2.6 million people examined) between December 2012 and 
January 2016. 
In 2013, the Queen Elizabeth Diamond Jubilee Trust pledged ₤42.8 million to fight 
trachoma in the commonwealth countries in Africa [110]. The specific plans for this 
funding are to (1) provide trichiasis surgery to an estimated 200,000 people, (2) 
facilitate MDA for an estimated 12.4 million people, (3) improve messaging around 
community hygiene and sanitation practices, and (4) work with stakeholders to improve 
access to safe water sources. 
In 2014, DFID pledged ₤39 million to support the elimination of trachoma as a public 
health problem through the SAFE strategy [110].  
1.5 Economics of trachoma 
Along with the epidemiology of trachoma it is also important to understand the 
economic impact of the disease. Economics are a driving force in society and so the 
ability to frame a disease in the context of cost-benefit is crucial for programme growth. 
To understand the economic implications of trachoma, it is first necessary to determine 
the disability associated with TT. Because TT is the morbidity stage of trachoma it is 
the stage where economic implications can most clearly be identified. To truly 
appreciate the economic consequences of TT it is imperative to understand the burden. 
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The 2016 estimated disability-adjusted life years (DALYs) attributed to trachoma was 
245 thousand (162-355 thousand CI). This estimate was made based on published data, 
with the most recent citation occurring in 2014. No results from the GTMP were 
included and much of the data was derived from publications of rapid blindness 
surveys. With an updated estimate of the global burden of TT available, the DALY 
estimate could be much improved.   
1.5.1 Visual impairment 
The most recently available estimate of visual impairment was published by WHO in 
2012, representing the situation in 2010 [111]. The prevalence of visual impairment 
and blindness were calculated for each WHO region and can be found in Table 1.2.  
Table 1.2 Adapted from Global Data on Visual Impairments 2010. Values represent estimated millions of people 
with visual impairment. (1) excludes India (2) excludes China 
WHO Region Total population 
(percentage) 
Visual Impairment 
(percentage) 
African  804.9 (11.9) 26.3 (9.2) 
Americas 915.4 (13.6) 26.6 (9.3) 
Eastern Mediterranean 580.2 (8.6) 23.5 (8.2) 
European 889.2 (13.2) 28.2 (9.9) 
South-East Asian1 579.1 (8.6) 27.9 (9.8) 
western Pacific2 442.3 (6.6) 14.7 (5.2) 
India 1,181.4 (17.5) 62.6 (21.9) 
China 1,344.9 (20 75.5 (26.5) 
World 6,737.5 (100) 285.4 (100) 
A global estimate of the prevalence of trachomatous blindness and low vision was 
generated in 1990 [112, 113]. The study estimated a total of 2.9 million cases of 
trachomatous blindness and 3.8 million cases of visual impairment. Whilst, the estimate 
provided in Table 1.2 and the trachomatous blindness estimate generated in 1990 are 
taken from different time points and cannot be directly compared, these values do 
provide a context for the scale of visual impairment resulting from trachoma. Through 
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understanding the current burden and distribution of TT these values could be more 
discreetly defined. 
The 1990 study incorporated the years of life lost resulting from premature mortality 
and the years lived in a handicapped state to create a single measure of disease burden, 
handicap adjusted life years (HALYs). The HALYs were multiplied by the prevalence 
of trachomatous visual impairment to generate an estimate of global burden of trachoma 
visual impairment of 80 million HALYs.  
1.5.2 More than vision loss 
Whilst the obvious economic measurement from trachoma is derived from visual 
impairment, it is also important to consider the pain and photophobia associated with 
trichiasis. This important element is pointed out by Frick et al. [114]. A study in 
Tanzania found that having trichiasis even without visual acuity loss limits the ability 
to perform ADL tasks (activities of daily living). The study also found those with visual 
acuity loss and trichiasis had a greater limitation than those with visual acuity loss from 
other causes [115, 116]. This is a relevant finding, highlighting the possibility that only 
using vision loss in calculating economic loss may be resulting in an underestimate. 
The fact that individuals with trichiasis report more difficulty in conducting ADL tasks 
than those with visual acuity loss from other causes means there is an additional factor 
influencing the ability to conduct these tasks, not only vision loss. 
1.5.3 Cost effectiveness 
The cost associated with lost productivity caused by trachoma was estimated in 1995 
to be $2.9 billion (USD) annually [117].  More recent (2003) estimates suggest a total 
loss in productivity between $3.5 billion (USD) and 5.3 billion (USD) [117]. 
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Trachoma exacerbates the cycle of poverty by increasing the burden of blindness and 
low vision [3]. Prevention of blindness along with reducing trachoma burden through 
the S, F, and E components of the SAFE strategy reduces disability and improves 
productivity in communities.  
Trichiasis surgery is a very cost effective intervention [118]. A study in The Gambia 
estimated the average cost of untreated trichiasis to be $89 (USD), based on life-time 
lost economic productivity. In The Gambia, on average, the surgery costs $6.13 (USD).  
To fully appreciate the finances needed for TT elimination, understanding the burden 
and distribution of the burden is essential. 
1.6 GIS and Geostatistical methods 
The above review highlights the limited understanding of TT burden distribution. There 
is a great selection of GIS resources that can be used to improve this understanding, 
providing better characterisation and exploration. In this section I will describe existing 
GIS resource and spatial modelling for trachoma. I will then outline additional potential 
approaches to spatial modelling and their applications to trachoma. 
1.6.1 Geostatistical methods 
Tobler’s first law of geography, “everything is related to everything else, but near things 
are more related than distant things” [119] is the guiding principle applied in 
geostatistical methods. Semi-variograms are used to test whether this law is applicable 
to a dataset. A semi-variogram illustrates the rate of decay of spatial autocorrelation 
between observations. Semi-variance is generally low when locations are near to each 
other and increase as distance grows between observations until a point is reached 
where the locations are independent of each other [120, 121].  
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1.6.1.1 Semi-variograms 
 A semi-variogram illustrates the rate of decay of spatial autocorrelation between 
observations through plotting half of the mean squared difference between a pair of 
observations as a function of the distance separating the observation location (lag) [121] 
(Figure 1.8).  The semi-variogram formula is defined as 
𝑦 ̂(ℎ) =  
1
2𝑛(ℎ)
∑(𝑥(𝑥𝑖) − 𝑧(𝑥𝑖 + ℎ))
2
𝑛(ℎ)
 
where 𝑥 is the given location; 𝑧 is the value of an attribute; ℎ is a given separate distance 
between observations (lag); 𝑛(ℎ) is the number of pairs of sample points of 
observations of the value of 𝑧 separated by distance ℎ. 
Semi-variograms invoke Tobler’s first law of geography [119]. This means that semi-
variance is generally low when locations are near to each other and increase as distance 
grows between observations until a point is reached where the locations are independent 
of each other. The nugget is the variability in data that cannot be explained by distance 
between observations. The sill is the maximum variability observed. The difference 
between the sill and the nugget (partial sill) is the amount of observed variation that can 
be explained by distance between observations.  The range is the point where semi-
variance stops increasing and observations are considered independent.  
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Figure 1.8 Example semi-variogram, where the sill is the maximum value of semi-variance, the range is the lag 
distance at which the sill is reached and the nugget is the variability at a distance smaller than the sample spacing 
1.6.1.2 Cluster detection 
It is often necessary to not only determine whether there is a spatial structure to the 
data, but if there is clustering within the data. Knox et al. defines a cluster as, a 
geographically and/or temporally bound group of occurrences of sufficient size and 
concentration to be unlikely to have occurred by chance [122]. A variety of methods 
can be used for cluster detection, outlined in Table 1.3.  
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Table 1.3 Overview of cluster detection methods for geostatistical analysis 
Type Method Application Disadvantages 
Global  
Cuzick and Edwards 
k-nearest neighbour 
Tests for spatial clustering whilst 
taking into account the 
distribution of the population at 
risk. The test uses the locations of 
cases and randomly selected 
controls and includes a spatial 
scale parameter. The test counts 
how many of the k-nearest 
neighbours are also cases [123]. 
The user determines the value 
for the scale parameter, 
making this parameter 
subjective. 
Moran’s I Quantifies the similarity of a 
variable among areas that are 
defined as spatially related. A 
weights matrix is used to define 
the spatial relationship so that 
areas close in space are given 
greater weight then those that are 
distant [124]. 
Assumes population at risk is 
evenly distributed within the 
area and correlation is the 
same in all directions. 
Ripley’s k function Compares a given point 
distribution with a random 
distribution. 
There are no first order effects 
in the spatial pattern. Variance 
increases with distance, not 
suitable for estimating 
clustering over large distances 
[125]. 
Mantel’s test Compares inter-event distances in 
space and time against a null 
hypothesis that time and space 
distances are independent [126].  
Assumes a linear correlation 
[127]. Low statistical power 
with small number of cases 
[128]. 
Local  
Getis and Ord’s local 
statistic 
An indicator of local clustering 
that measures the concentration of 
a spatially distributed attribute 
variable. Through comparing 
local estimates of spatial 
autocorrelation with global 
averages, the statistic identifies 
hot spots [129]. 
Results are dependent on the 
size of the features being 
analysed. When large areas 
tend to have low values and 
smaller areas tend to have high 
values. 
Kulldorff’s spatial 
scan statistic 
SaTScan – for each specific 
location a series of circles of 
varying radii is constructed. Each 
circle absorbs the nearest 
neighbouring locations that fall 
inside it and the radius of each 
circle is set to increase 
continuously from zero until a 
fixed percentage of the total 
population is included [130]. 
Imposes a shape on the 
clusters, and irregularly 
shaped cluster may not be 
detected. 
Local Moran’s I  Detects local spatial 
autocorrelation in aggregated 
data.  
Small geocoding errors can 
significantly influence results 
[131]. 
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Spatial clustering of disease can be measured through global or local methods [132]. 
Global methods are used to determine whether clustering is present throughout the 
study area by providing a single statistical measure of the degree of spatial clustering. 
These methods simply identify if spatial clustering exists, but they do not identify 
where. Importantly, these methods identify if observed patterns are significantly 
different from spatial randomness. Local methods define the location and extent of 
clustering. These methods scan an entire dataset, but only measure spatial dependence 
in pre-defined limited portions of the study area.  
Understanding if clustering of TT exists - and then disentangling risk factors associated 
with identified clusters is important for designing intervention strategies. Identifying 
groups of community-level TT prevalence that are higher than expected from spatial 
randomness, could be used for targeting placement of TT surgical camps. As noted 
previously during the end-game of trachoma elimination TT prevalence is expected to 
be very low (approaching 0.2% in adults aged ≥15-years), making it difficult to find 
and offer services to those affected. Cluster detection and a stronger understanding of 
spatially distributed risk factors could guide strategies and improve efficiency in case 
finding. 
1.6.2 GIS and trachoma 
Trachoma is mainly found in Sub-Saharan Africa, the Middle East and Asia [133]. The 
Global Atlas of Trachoma (www.trachomaatlas.org) serves as the global repository for 
current prevalence information gained from PBPS and TRAs (Figure 1.9). The atlas 
uses maps to illustrate the distribution of both TF and TT. This resource has been 
invaluable in informing country level planning as well as informing global burden 
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estimates. Calculations based on information provided to the atlas estimate in Africa 
129.4 million people live in trachoma endemic (TF >=5%) settings [134]. The maps 
provided in the atlas illustrate the cross-border prevalence of trachoma and highlight 
the great burden of disease in Eastern Africa.  
 
Figure 1.9 The global atlas of trachoma (www.trachomaatlas.org) 
1.6.3 Characterising the spatial distribution of trachoma 
Whilst the aggregate maps generated from these surveys are valuable planning tools, 
they are limited in that they do not provide information about how and why risk varies 
within areas. Understanding this variance would be particularly useful for TT 
intervention planning. Unlike TF, where an entire district receives treatment when 
prevalence is high, TT intervention (surgery or epilation) requires identification of 
actual afflicted individuals. As prevalence drops through both secular change and 
programme interventions, it will become more difficult to find the final TT cases. This 
 
 
55 
 
has been the experience of other disease elimination programmes such as Guinea worm 
[135] and leprosy [136-139]. Studies have identified spatial clustering of leprosy and 
have been useful in identifying high risk areas, informing where targeted intervention 
is needed [140-144]. Similarly, it may be possible to identify communities with a 
comparatively high number of TT cases, or hot spots.  
A hot spot is often described as a small foci of intense disease within a generally low 
prevalence area.  However, because available TT data was collected through a random 
sampling of clusters, it is expected that an occasional high prevalence community will 
be present in the data. I do not consider this single community a hot spot, rather an 
outlier or random artefact of the sampling technique that is not of public health 
significance. If the identified hot spot is larger than a single community, it is likely a 
true hot spot worthy of investigation. In my thesis I consider a TT hot spot, a community 
where the proportion of TT in surrounding communities is high and the value in the 
specified community is significantly higher than that in the surrounding communities. 
Great efforts have been made in hot spot identification and analysis in malaria 
transmission. Specifically, predictive models have been developed to identify 
geographic areas of high levels of transmission intensity [145].  These models identify 
clusters of high intensity using a spatial scan method and then a regression model to 
determine significant covariates. Whilst the malaria community is at the forefront of 
hot spot identification and analysis, there are inherent differences in the epidemiology 
of malaria and trachoma. Malaria has an obligate vector and so clustering by indices 
for mosquitos makes biological sense. However, there is no obligate vector for 
trachoma and so the rational for suspected clustering is slightly different. As described 
in detail in section 1.2.2 trachoma is transmitted through close personal contact [30, 
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31], the transmissive nature of chlamydia trachomatis provides a strong hypothesis that 
local clustering of TF is expected. Additionally, the important role of sanitation and 
hygiene in TF transmission [32, 41, 45-48] suggests between community clustering.  If 
it is also accurate to say that there is a spatial association between TF and TT (which is 
explored in Chapter 5:), there is reason to suspect that models could identify TT 
clustering (which is explored in Chapter 6:). 
Very few spatially explicit analyses of trachoma have been published and of these, only 
two publications include TT in their analysis. These spatially explicit analyses of 
trachoma are outlined in (Table 1.4). With the availability of the GTMP geolocated 
data, it is now possible to build upon these earlier findings and expand analyses to 
multiple country settings.   
Table 1.4 Summary of trachoma geostatistical published work 
Year Location Summary Limitations Citation 
2010 South 
Sudan 
A trachoma risk map was 
created using Bayesian 
geostatistical models 
incorporating TF 
prevalence data in South 
Sudan TF in children 
along with long-term 
average rainfall, land 
cover, and geostatistical 
random effects describing 
spatial clustering of 
trachoma were included in 
the model. With a 
significant negative 
correlation between TF 
and rainfall (OR 0.21), 
Clements et al. concluded 
in South Sudan the spatial 
variation of trachoma is 
associated with aridity.  
The model is limited in 
that it is static. Rainfall 
was used as a major 
predictor and seasonality 
may greatly affect the 
results. Hot and arid may 
simply be a proxy for 
poverty. 
Clements AC, Kur LW, 
Gatpan G, Ngondi JM, 
Emerson PM, Lado M, et 
al. Targeting trachoma 
control through risk 
mapping: the example of 
Southern Sudan. PLoS 
neglected tropical 
diseases. 2010;4(8):e799. 
doi: 
10.1371/journal.pntd.0000
799. PubMed PMID: 
20808910; PubMed 
Central PMCID: 
PMC2923154. [11] 
2015 Nigeria This analysis examined the 
relationship between 
climatic factors and TT 
and corneal opacity (CO) 
in Nigeria, whilst 
accounting for individual 
risk factors and spatial 
The data used in the model 
was derived from a 
national blindness survey, 
including 304 clusters with 
large geographic areas not 
represented.  
Smith JL, 
Sivasubramaniam S, Rabiu 
MM, Kyari F, Solomon 
AW, Gilbert C. Multilevel 
Analysis of Trachomatous 
Trichiasis and Corneal 
Opacity in Nigeria: The 
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correlation. Data were fit 
to Bayesian hierarchical 
logistic models. The risk 
of TT/CO was associated 
with factors at both the 
individual and cluster 
levels. This study found 
strong evidence that 
environmental factors at 
the cluster-level were 
associated with a greater 
risk of TT/CO. The 
findings from this study 
are very promising and 
deserve further analysis in 
additional countries.  
Role of Environmental and 
Climatic Risk Factors on 
the Distribution of 
Disease. PLoS neglected 
tropical diseases. 
2015;9(7):e0003826. doi: 
10.1371/journal.pntd.0003
826. PubMed PMID: 
26222549; PubMed 
Central PMCID: 
PMCPMC4519340. [146]  
2010 Mali The aims of this study 
were to disentangle the 
relative importance of 
clustering at different 
levels and to assess the 
respective role of 
individual, socio-
demographic, and 
environmental factors TF 
prevalence in Mali. TF 
data were categorized into 
a hierarchy and village 
level environmental 
variables were identified. 
Bayesian hierarchical 
logistic models were fit to 
the data. Clustering was 
found to be significant at 
all four hierarchy levels. 
The model showed that 
individual level (age, dirty 
faces), caretaker-level 
(wiping after body 
washing), household-level 
(wealth), and village-level 
(women's association and 
climate) were associated 
with TF prevalence. This 
analysis highlights the 
need to not only focus 
interventions on positive 
cases, but also 
communities. This aligns 
with the existing SAFE 
strategy, where AFE are 
population based, rather 
than individual. 
This study included data 
from only 202 clusters 
across the entire country 
limiting the 
generalizability of the 
findings. 
Hagi M, Schemann JF, 
Mauny F, Momo G, Sacko 
D, Traore L, et al. Active 
trachoma among children 
in Mali: Clustering and 
environmental risk factors. 
PLoS neglected tropical 
diseases. 2010;4(1):e583. 
doi: 
10.1371/journal.pntd.0000
583. PubMed PMID: 
20087414; PubMed 
Central PMCID: 
PMC2799671. [38] 
 
2007 Mali This study analyzed the 
role of geoclimatic factors 
in TF and TT distribution 
in Mali. Multiple linear 
regression models 
including latitude and 
The limitations in this 
study are the same as those 
listed above. 
Schemann JF, Laffly D, 
Sacko D, Zephak G, 
Malvy D. Trichiasis and 
geoclimatic factors in 
Mali. Transactions of the 
Royal Society of Tropical 
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longitude explained 6.1% 
of the variance for TF and 
14.0% for TT. When 
environmental risk factors 
were added to the model, 
the coefficient of 
determination increased to 
11.2% for TF and to 
19.6% for TT. The outputs 
from these regression 
models were plotted in a 
predictive map and 
demonstrated an opposite 
spatial distribution of TF 
and TT, with a gradient 
from south-south-east to 
north-north-west for TF 
and a gradient from north-
east to south-west for TT. 
Medicine and Hygiene. 
2007;101(10):996-1003. 
doi: 
10.1016/j.trstmh.2007.05.0
15. PubMed PMID: 
17658570. [67] 
 
1.6.4 Using Geospatial approaches to guide post-treatment surveillance 
Many countries have implemented successful trachoma control programmes, and now 
need improved guidance on where and how to conduct post-MDA surveillance. Ghana 
is an example of a country that has implemented the SAFE strategy with great success. 
The post-intervention surveys show a reduction of TF below the elimination targets and 
so MDA has been discontinued in the country [147]. However, Ghana needs guidance 
on how to approach surveillance to ensure the disease does not return. The country also 
estimates nearly 5,000 people remain with TT; this backlog of surgical candidates 
clearly needs to be addressed.  
Mali is also a country that has had great success with the SAFE strategy (Figure 1.10). 
The country has been implementing a community by community approach to 
surveillance. However, it is unrealistic for all programmes to survey every community 
within a district to ensure the disease is truly gone and so geostatistical techniques 
should be harnessed to improve efficiencies in surveillance activities. 
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Figure 1.10 Impact of the SAFE strategy on TF prevalence in Mali. The historic map represents trachoma 
endemicity prior to MDA intervention, the treatment scale-up map identifies when MDA began in each district, 
and the recent mapping map represents trachoma endemicity after MDA.  
Lietman et al. evaluated the use of mathematical models to predict community level 
infection in areas where trachoma is disappearing [148]. With longitudinal infection 
data from two sites in Ethiopia the fit of eight discrete distributions was assessed 
(geometric, binomial, Poisson, discrete weibull, negative binomial, beta binomial and 
zero-inflated geometric, and zero-inflated Poisson).  In both survey sets the geometric 
distribution had the most parsimonious fit and the goodness-of-fit testing was also 
consistent with the community level data drawn from the geometric distribution. This 
model shows a long tail, which suggests that it is expected to have an occasional high 
prevalence community when the disease is on the way out and this community is not 
necessarily a sign of re-emergence. This work points to the ability to model at the end-
stage. However, the longitudinal datasets used in this study come from Ethiopia. 
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Ethiopia has extremely high baseline prevalence values and information gleaned from 
this country may not be applicable to other settings.  
Geospatial modelling may serve as a valuable tool in informing surveillance strategies 
for trachoma. With the large amount of data now available from GTMP, it may be 
possible to implement geospatial modelling techniques to explore the dynamics 
between trachoma and environmental factors in a global setting. This type of work has 
been done for other diseases, including tuberculosis [149, 150], podoconiosis [4], 
schistosomiasis [3, 5, 10, 13, 15, 151, 152], cholera [153] and leprosy [144]. These 
analyses have been used to identify spatial correlation with demographic and 
environmental factors which influence prevalence, as well as cluster detection. 
The malaria community is at the forefront in applying geospatial methods in elimination 
programmes. Spatial prediction models as well as spatial decision support systems have 
been developed to enhance resource allocation [154]. Many studies have investigated 
the association between climatic and environmental drivers and malaria infection [155-
161]. Associations have been found to exist between malaria prevalence and rainfall, 
temperature, normalised difference vegetation index, distance to rivers and streams, 
altitude, slope, land-cover class, and forest cover. These associations have been used to 
predict malaria outbreaks. 
It may be possible to use additional elements as proxy measurements to predict where 
trachoma re-emergence is most likely to occur first. The ability to visualise the 
distribution of the disease at a micro level will lead to more focused and strategic 
intervention and surveillance strategies. 
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1.7 Justification 
My thesis will focus on understanding the spatial heterogeneity of trachoma. I will 
particularly focus on the TT stage of the disease. As outlined in the previous sections 
there are knowledge gaps surrounding trichiasis surgical needs, with TT burden 
estimates outdated and generated from inconsistent methodologies. There is also a need 
for a purpose-designed, robust strategy for determining the TT burden at the 
implementation unit level. Extremely few studies have examined the spatial structure 
of TT nor have they disentangled the spatial association between TF and TT. A stronger 
understanding of TT distribution and spatial structure could provide valuable insight 
around where to focus TT intervention strategies.  Understanding the spatial 
distribution may also inform whether the district (currently implementation unit) is the 
appropriate scale for addressing TT surgical needs. This work is timely, with the newly 
available GTMP data and specific requests from the global trachoma community for 
guidance on effectively reaching and providing surgery to those who need and want it.  
1.8 Thesis aims and objectives 
The dual aims of my thesis are to quantify the current global distribution of TT, and 
to explore spatial heterogeneity in TT at fine spatial scales.  Addressing these aims 
will provide evidence to guide strategic use of resources for implementing TT 
management campaigns. These aims will be reached through the following objectives: 
1. To quantify the global burden of TT in 2016, with associated uncertainty 
2. To design and validate a robust strategy to assess TT burden in defined 
implementation units 
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3. To explore the relationship between community-level TF and TT, and identify 
factors that modify this relationship in a variety of country settings 
4. To characterize the extent of spatial clustering of community-level TT, and 
identify factors influencing the level and degree of clustering  
1.9 Thesis outline 
Chapter 2 introduces the Global Trachoma Mapping Project (GTMP) dataset, which is 
referenced throughout this thesis. Chapter 3 describes the methodology and results of 
recalibrating and updating national and global TT burden estimates for 2016. Chapter 
4 outlines the design and validation of a TT specific survey, which measures with 
precision appropriate for meeting the WHO elimination target. This chapter also assess 
the time costs associated with a TT specific survey. Chapter 5 evaluates the community 
level spatial distribution of TT and the association between TF prevalence and TT 
prevalence. This chapter further explores how additional risk factors effect this spatial 
relationship. Chapter 6 presents a methodology for identifying TT hot spots using 
geostatistical methods and identifies environmental factors associated with these hot 
spots. Lastly, Chapter 7 discuss the findings of this work and highlights implications 
on trachoma control programmes. 
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 Understanding the GTMP dataset 
2.1 Overview 
Much of the data used thought this thesis came from the GTMP. The GTMP was funded 
by (1) a grant from DFID (ARIES: 203145) to Sightsavers, and (2) USAID, through 
the ENVISION project implemented by RTI International under cooperative agreement 
number AID-OAA-A-11-00048, and the END in Asia project implemented by FHI360 
under cooperative agreement number OAA-A-10-00051. 
2.2 Background 
The GTMP launched in December 2012 with the aim to complete the baseline map of 
trachoma through conducting standardised PBPS’s. This project was funded by the UK 
government (£10.6 million) with additional funds provided by USAID (£6 million) and 
led by Sightsavers. The collaborative nature of the GTMP implementation ensured 
success. The GTMP partnership was made up 30 ministries of health (MoH), the 
London School of Hygiene & Tropical Medicine (LSHTM), the International 
Trachoma Initiative, the World Health Organization (WHO) and over 20 non-profits.  
2.3 Methods 
Standardised training materials were developed, and workshops conducted to ensure 
consistent quality grading of the trachoma clinical signs, particularly TF and TT. All 
GTMP graders participated in a “grader qualifying workshop”, during which they 
received classroom- and field- based training. Only those who passed both a slide- and 
field-based test of diagnostic accuracy became members of the GTMP survey team. 
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Data collected during the GTMP was systematically entered into an android phone and 
synchronized to an amazon server. The recorders, who entered the data into the system, 
participated in the training workshop and only those recorders who passed a test of data 
capture accuracy became members of the GTMP survey team. Further detail of the 
training methodology is described elsewhere [71]. 
The PBPS were conducted at the evaluation unit- (EU) level, which typically equated 
to a district with a population of between 100,000-250,000. Within each EU, all 
residents one year or older from the randomly selected households in each of the 
randomly selected clusters were invited to be examined for trachoma clinical signs, 
specifically TF in children aged 1–9 years and TT in adults aged ≥15-years. Along with 
individual clinical trachoma data, the survey teams collected geolocated household-
level water, sanitation and hygiene data. 
2.4 Results 
The GTMP completed in January 2016 and had collected data from 2.6 million people 
in 1,542 districts in 29 countries (Figure 2.1). 
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Figure 2.1 Map outlining where mapping was completed prior to GTMP, during GTMP (along with methods), and where mapping is still needed (all outstanding districts were unable to be 
reached through GTMP because of security risks to the survey teams). This map was generated for the “Completing the Global Trachoma Map” manuscript, which is pending publication. 
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Of the 1,542 districts, 47% were above the district-level TF elimination threshold of 
5% in children aged 1–9 years and 53% were above the district-level TT elimination 
threshold of 0.2% in adults aged ≥15-years (Table 2.1).  
Table 2.1 GTMP district count and distribution of TF and TT within each country by elimination threshold 
categories 
Country Districts TF>= 5% TT>= 0.2% 
Benin 26 8 19 
Cambodia 14 0 1 
Chad 48 19 34 
Colombia 3 3 1 
Congo 6 0 0 
Cote d' Ivoire 11 10 2 
DRC 30 17 23 
Egypt 4 4 4 
Eritrea 8 8 4 
Ethiopia 506 465 458 
Fiji 1 0 0 
Guinea 15 7 5 
Kiribati 1 1 1 
Laos 106 0 0 
Malawi 25 14 8 
Mexico 1 0 0 
Mozambique 118 46 35 
Nigeria 288 43 138 
Pakistan 49 7 4 
Papua New Guinea 7* 6 0 
Senegal 17 1 8 
Solomon Islands 4 4 0 
Sudan 45 14 28 
Tanzania 21 3 13 
Uganda 4 0 1 
Vanuatu 1 1 0 
Yemen 164 31 19 
Zambia 3 1 2 
Zimbabwe 16 11 10 
Total 1,542 724 818 
*Data transmission challenges delayed the release of the final prevalences 
associated with one district in Papua New Guinea 
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The largest number of districts surveyed were in Ethiopia (506) followed by Nigeria 
(288). Excluding, Ethiopia and Nigeria, the mean number of districts surveyed in each 
country was 28 (Figure 2.2).  
 
 
Figure 2.2 Distribution of GTMP surveys, by country and categorized by elimination targets. The blue bar 
represents the total number of districts surveyed, the red bar represents the number of districts surveyed showing 
TF above the elimination threshold of 5% and the green bar represents the number of districts surveyed showing 
TT above the elimination threshold of 0.2% in adults.  
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In Chapter 5 and Chapter 6, community level data is explored from ten GTMP 
collaborating countries, namely Benin, Cote d’ Ivoire, Democratic Republic of the 
Congo (DRC), Ethiopia, Guinea, Malawi, Mozambique, Nigeria, Sudan and Uganda; 
encompassing 15,051 clusters (or communities) within 624 EUs.  
To ensure country ownership, a systematic process for accessing the GTMP data was 
constructed. Study proposals desiring to conduct secondary analyses of GTMP datasets 
were submitted for review to the “GTMP Data Application Panel”. After approved by 
the panel, data sharing agreements were distributed to relevant ministry of health 
officials on behalf of the researchers. Once the ministry of health authorized the data 
sharing agreements, the GTMP released the approved data to the research team. 
Through this system, countries generously provided the detailed data which I will 
describe here.  
The dataset includes 15,051 communities, of which, 9,590 (63.7%) had zero TT cases, 
9,657 (64.3%) had a prevalence of positive TT of <1% and 13,994 (93.0%) had a 
prevalence of positive TT of <5%. The TT and TF table presented here illustrate the 
cluster-level distribution of TT and TF within each country (Table 2.2). Table 2.2 
clearly shows that Benin, DRC, Ethiopia and Nigeria have the greatest variation in 
community-level TT prevalence.  
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Table 2.2 Distribution of community-level TT and TF prevalence by country. 
TF Prevalence 
Country Minimum 
First 
Quartile 
Median Mean 
Third 
Quartile 
Maximum 
Benin 0.0% 1.5% 3.4% 7.7% 8.9% 65.9% 
Cote d'Ivoire 0.0% 3.5% 8.5% 11.0% 15.0% 65.4% 
DRC 0.0% 1.7% 6.4% 9.4% 13.8% 86.3% 
Ethiopia 0.0% 3.0% 14.8% 21.9% 36.4% 100.0% 
Guinea 0.0% 0.0% 2.5% 4.0% 5.8% 24.1% 
Mozambique 0.0% 0.0% 0.0% 4.4% 5.7% 75.0% 
Malawi 0.0% 0.0% 3.5% 6.2% 8.6% 50.9% 
Nigeria 0.0% 0.0% 0.0% 3.0% 3.6% 59.7% 
Sudan 0.0% 0.0% 0.0% 4.2% 5.0% 60.7% 
Uganda 0.0% 0.0% 0.0% 3.1% 4.4% 19.2% 
TT Prevalence 
Country Minimum 
First 
Quadrant 
Median Mean 
Third 
Quadrant 
Maximum 
Benin 0.0% 0.0% 0.0% 1.6% 1.9% 52.6% 
Cote d'Ivoire 0.0% 0.0% 0.0% 0.2% 0.0% 7.2% 
DRC 0.0% 0.0% 0.0% 2.7% 3.2% 75.0% 
Ethiopia 0.0% 0.0% 0.0% 1.9% 2.7% 34.5% 
Guinea 0.0% 0.0% 0.0% 0.3% 0.0% 6.3% 
Mozambique 0.0% 0.0% 0.0% 0.4% 0.0% 12.2% 
Malawi 0.0% 0.0% 0.0% 0.5% 0.0% 9.5% 
Nigeria 0.0% 0.0% 0.0% 1.4% 1.9% 21.8% 
Sudan 0.0% 0.0% 0.0% 1.1% 1.9% 14.3% 
Uganda 0.0% 0.0% 0.0% 0.3% 0.0% 3.1% 
The GTMP dataset provides a robust resource for trachoma analysis and as a result it is 
now possible to generate detailed generalizable analyses around trachoma. In the next 
chapter I will use the GTMP dataset to update the global TT burden estimate, I will 
then inform the design of a TT specific survey through disentangling the design effect 
associated with TT and confirm the age distribution of TT cases using multiple country 
datasets. In Chapter 5, I will use the GTMP dataset to closely examine the community-
level relationship between TF and TT whilst accounting for additional covariates. 
Finally, in Chapter 6, I will identify high TT prevalence clusters, hot spots, and their 
associated risk factors.  
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 Describing the global trichiasis burden 
3.1 Overview 
A series of global trachoma scientific meetings resulted in defining  the  elimination as 
a public health problem thresholds for trachoma as a prevalence of TF of less than 5% 
in children aged 1–9 years, and a prevalence of TT of less than one case unknown to 
the health system per 1,000 total population (0.1%), in each previously-endemic health 
district [73].  The TT threshold can also (perhaps more appropriately) be stated as a 
prevalence of TT unknown to the health system of <0.2% in adults aged ≥15-years 
[162]. Trichiasis is the blinding stage of trachoma, thus appropriate management of 
individuals with trichiasis is the priority of every trachoma elimination programme. An 
accurate estimate of the number of persons with TT and their geographical distribution 
can help to effectively align resources for surgery and other services. Previous work 
estimated global TT backlogs of 8.2 million (2009) [163] and 7.3 million (2012) [84].  
This section describes the process of updating this estimate through (1) obtaining the 
most recent data for a district; (2) applying age- and sex-standardization to historic 
survey data, where raw data were available; (3) using historic prevalence estimates and 
adjusting for bias for districts for which raw data were unavailable; and (4) obtaining 
expert opinion for districts for which no data were available.  
Data used for this study came from several sources. The GTMP outlined in Chapter 2, 
supported collection of the data described for 29 countries. The health ministries (or 
equivalent) in the following countries provided data used in this analysis: Benin, 
Cambodia, Cameroon, Central African Republic, Colombia, Congo, Côte d’Ivoire, 
Democratic Republic of the Congo, Eritrea, Ethiopia, Guatemala, Guinea, Guinea-
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Bissau, Kenya, Lao People’s Democratic Republic, Malawi, Mali, Mauritania, 
Morocco, Mozambique, Nepal, Niger, Nigeria, Pakistan, Papua New Guinea, Senegal, 
Solomon Islands, South Sudan, Sudan, Togo, Uganda, United Republic of Tanzania, 
Vanuatu, Yemen, Zambia,  Zimbabwe. The study was funded by the World Health 
Organization (SPHQ14-APW-4886). 
I assembled the datasets, conducted the analysis, and wrote the manuscript (pending 
publication) informed by the information presented in Chapter 3. These results were 
also presented at the second Global Scientific Meeting on Trachomatous Trichiasis.   
3.2 Background 
Through high quality surgery, which involves correcting the position of the in-turned 
eyelid [78] it is possible to reduce the number of people with TT. An accurate estimate 
of the number of persons with TT (the TT backlog) and their geographical distribution 
are needed in order to effectively align resources for surgery and other necessary 
services.  
In 2009, Mariotti et al. estimated the global TT backlog to be 8.2 million people [163]. 
This estimate was derived by summarising a combination of published and unpublished 
information. First, a literature review was performed to identify published prevalence 
data. Where published data were not available, unpublished data were compiled from 
the Eleventh (2007) Meeting of the World Health Organization (WHO) Alliance for the 
Global Elimination of Trachoma by 2020 [164]. Where information was still missing, 
unpublished reports were provided by health ministries. Finally, if none of these 
resources were available, data were extrapolated from a proxy country believed to have 
common epidemiological conditions and demographic structure.  
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There are many uncertainties inherent in the 2009 estimate [163]. First, where PBPS 
data were available, the results were not systematically standardised by age and sex. 
This is problematic because I suspect that women and the elderly are more likely than 
men and younger adults, to be at home at the time that a house-to-house survey team 
calls, and to have TT. Second, in countries for which data were available, survey 
coverage was generally far from complete. Though not an invariable rule, surveys to 
estimate the prevalence of neglected diseases have a tendency to be done first in areas 
of high prevalence; for the 2009 estimate, if any data were available for a particular 
country, the TT prevalence figure from it was applied across the yet-to-be-mapped 
suspected-endemic population. Third, the use of proxy countries is extremely 
subjective.  
In 2012, WHO collected and collated provisional 2011 country reports, and published 
an updated figure for the global TT backlog. The total given was 7.3 million people, 
but the methodologies used in each country to generate national backlog figures were 
not described [84]; they are likely to have been highly heterogeneous. 
In July 2012, the DFID provided funding for the GTMP which sought to systematically 
complete the global trachoma map using standardised techniques for both collecting 
and analysing survey data [71]. GTMP measured trachoma prevalence using gold 
standard PBPSs conducted at district level. People of all ages living in selected 
households of 1,542 districts across 29 countries were examined for trachoma, resulting 
in the examination of 2.6 million people [18]. GTMP analyses included standardising 
trichiasis prevalence estimates against national population pyramids in an attempt to 
partially account for systematic differences in age and sex of those examined. 
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As a result of the GTMP, there are now high-quality PBPS data available for most 
suspected-endemic areas that were previously unsurveyed. The availability of these 
data has catalysed the current attempt to generate a new estimate of the global trichiasis 
backlog. The aim of this chapter is to describe the methodology used to update the 
backlog estimate and provide the national and global results, highlighting the 
limitations involved in this type of analysis. 
3.3 Methodology 
3.3.1 Assembling the datasets 
I updated previous global estimates using the best available data, according to the 
following hierarchy. First, where GTMP data [71] were available, I used the age- and 
sex-standardised trichiasis prevalence estimates for adults in each evaluation unit. In 
August 2014, GTMP added examination for the presence or absence of TS [19] for all 
eyes determined to have trichiasis; prior to this, and for all non-GTMP data, trichiasis 
prevalence estimates used must be considered to be estimates of “all trichiasis” rather 
than “trachomatous trichiasis”.  
Second, where PBPSs had been done without the support of the GTMP, I requested raw 
survey data from national health ministries. Where those data were provided by 1 
March 2016, I applied the same age- and sex- standardization as was used in the GTMP 
[71].  
Third, where PBPSs had been done but raw data were not available, prevalence 
estimates (whether standardised for age and sex or not) were obtained from country 
programmes.  
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Fourth, if prevalence estimates were not available, I reviewed previous estimates 
through desk reviews and communications with country programmes. If there was 
adequate evidence to revise the estimates, new estimates were used; otherwise, the 2009 
estimates [163] were retained. 
The population data used in this analysis were derived from the UN population division 
(UNdata) [165] and www.worldpop.org [166]. As trachoma is a disease primarily 
affecting rural populations [21], rural population pyramids were obtained from UNdata. 
Microsoft Excel (2007) was used to organize the datasets into 5-year age bands 
stratified by sex for each country. The percentage of the population within each stratum 
was estimated from the bands. District level populations were derived from 
www.worldpop.org data [166] using the zonal statistics tool in ArcGIS 10.3 [167]. A 
sensitivity analysis was also performed, comparing the www.worldpop.org population 
estimates, and district population estimates provided by national trachoma elimination 
programmes. The mean ratio between the national programme estimates and 
www.worldpop.org was 0.97. Because of this close correlation, and for the purposes of 
standardising our methods, the www.worldpop.org data were used throughout this 
analysis.  
3.3.2 Analysis 
The statistical software package R [168] was used to perform age- and sex- 
standardisation. First, the crude prevalence was calculated for each cluster. Second, the 
prevalence was standardised for each cluster by weighting the proportion of each sex-
specific five-year age band observed to have trichiasis by the proportion of the adults 
aged ≥15-years expected to have that age and sex in that district, if available, or (if not 
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available), nation-wide.  Third, the un-weighted arithmetic mean of the standardised 
cluster-level trichiasis proportions was taken as the district-level prevalence. Once the 
initial standardization was completed, bootstrapping was undertaken on the dataset for 
each individual evaluation unit to derive 95% confidence intervals. For an evaluation 
unit surveyed by examining individuals in n clusters, this involved bootstrap resampling 
(with replacement) of n clusters, over 10,000 replications. The R code is provided in 
Appendix A. 
The standardised prevalence estimates were then multiplied by the corresponding 
evaluation unit-level adults aged ≥15-years (projected to 2016) to provide an estimate 
of the number of persons with trichiasis.  
A sensitivity analysis was performed using ratios from proxy countries in situations 
where communications with country programmes estimated a value of zero (Appendix 
B). Proxy countries were chosen based on similar geography, hygiene and sanitation 
situation. Hygiene and sanitation data were derived from the WHO/UNICEF Joint 
Monitoring Programme for Water Supply, Sanitation and Hygiene (JMP) [169]. 
3.4 Results  
Data from 1,355 districts in 31 countries were age- and sex- standardised and contribute 
an estimated 676 thousand cases to the global total. On average, adjusting prevalence 
estimates by age and sex reduced raw district-level estimates by a factor of 0.45 (range 
0.03–2.28). Where it was possible to adjust the datasets by age and sex, the country 
level backlog reduced by a mean factor of 0.56 (range 0.22–0.94). Estimates from 
PBPSs in 398 districts could not be standardised by age and sex because the original 
datasets were unavailable; the unadjusted backlogs in these districts totalled 781 
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thousand cases. I adjusted these estimates by multiplying them across the board by 0.45, 
yielding 411 thousand cases. Based on new expert opinion, it was determined that eight 
countries no longer have a trichiasis backlog. For six countries, local expert opinion 
generated revised, non-zero estimates. For one country, other published estimates [108] 
were used. Finally, there were seven countries for which the 2009 estimates were 
retained. Overall, data included in these analyses had been collected from 2000 to 2016 
(Appendix C). 
Through the inclusion of GTMP data, adjusting older datasets by age and sex, and 
canvassing current local expert opinion, the global backlog estimate reduces from 8.2 
million [163] (or 7.3 million [84]) to 2.8 million (Table 3.1).  The updated estimate 
reduced to zero cases in twelve countries, namely; Angola, Botswana, Burundi, Congo, 
The Gambia, Namibia, Iran, Iraq, Morocco, Mexico, Fiji and Nauru. Updated survey 
data demonstrated a zero prevalence in Congo, The Gambia, Morocco and Fiji. Whilst, 
ministries of health in Angola, Botswana, Burundi, Namibia, Iran, Iraq, Mexico and 
Nauru reported no evidence of trichiasis in 2016. The sensitivity analysis performed in 
the countries where the ministry of health reported no evidence of trichiasis in 2016, 
suggests these zero estimates may contribute to a global underestimate of 13,285. 
In the estimates, data collected in GTMP surveys set up prior to August 2014 include 
all trichiasis, irrespective of the presence or absence of trachomatous conjunctival 
scarring, whilst data collected in GTMP surveys set up after August 2014 provide 
estimates of trichiasis only in eyes that also demonstrated trachomatous conjunctival 
scarring (or had an eyelid that could not be everted, due to presumed dense scar), 
thereby including only those cases of trichiasis attributable to trachoma.  In both 
scenarios the data represent both “managed” and “unmanaged” trichiasis, irrespective 
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of whether individuals have previously been offered corrective surgery or epilation 
[73]. 
Table 3.1 Estimated region-level trichiasis backlogs, 2016, with comparisons to the corresponding estimates for 
2009 
WHO Region 2009 
Estimate 
2016 Estimate Proportion 
change Retained 
previous estimate 
or expert opinion 
Unstandardized 
(reduced by a 
factor of 0.45) 
Standardised 
(95% CI) 
Total 
estimate 
African 3,846,500 915,274 247,570 547,151 
(283,052-913,841) 
1,709,995 0.45 
Americas 58,050 58,000 566 48 
(0-123) 
58,614 1.01 
Eastern 
Mediterranean 
660,000 126,875 66,171 106,003 
(39,337-196,230) 
299,049 0.52 
South-East 
Asia 
485,000 443,000 25,240 3,252 
(462-7,323) 
471,492 0.97 
Western 
Pacific  
2,630,000 166,900 71,288 5,947 
(810-13,027) 
244,135 0.09 
Total 8,248,050 1,710,049 410,835 662,403 
(323,661-
1,130,5430) 
2,783,285 0.35 
3.5 Discussion 
Trichiasis remains a significant public health problem in many countries, with a global 
backlog estimated for 2016 at 2.8 million people, 61% of whom live in sub-Saharan 
Africa. Whilst there were methodological challenges in generating the 2009 estimate, 
it was the best estimate that could be made with the information available at the time. 
The considerable reduction from that estimate to the one generated here is likely to be 
the result of a combination of factors. First, there are now more, and better data derived 
from rigorous surveys. Second, in many countries, there has been an impressive 
programmatic scale up to manage TT, conducted by a complex network of governments 
and their partners. Third, there is likely to be an effect on the incidence of TT from the 
intensive efforts to reduce active trachoma prevalence in many contexts; such efforts 
have been ramping up in endemic countries since the World Health Assembly’s 1998 
commitment to global elimination of trachoma [2]. Teasing out the relative contribution 
of each of these factors is not possible at the present time, but regardless of cause, the 
reduction is welcome news for global health.  
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An understanding of the backlog and distribution of trichiasis cases is necessary to 
effectively plan for surgical services and other components of management of 
individuals with trichiasis. To reduce TT prevalence in each district of each endemic 
country to <0.2% in adults, which is the defined elimination threshold for TT [162], at 
least 2.0 million people will need to have their TT appropriately managed. From 
available data, it is estimated that 56% of people with trichiasis have bilateral trichiasis.  
Whilst these calculations lessen the uncertainty around the global backlog estimate, 
important limitations remain. Expert opinion was used for 13 endemic countries 
(representing 37% of the estimate), in eight of which the estimate was zero cases. The 
sensitivity analysis performed on these eight countries suggests that the zero estimates 
may contribute to a global underestimate of 13,285. Ethiopia, Mali, and Niger have 
undergone intensive surgical scale up in the time since the most recent round of 
prevalence surveys. Because of this programmatic output, and a lack of consensus 
around how to counterbalance backlog reduction with new incident cases and post-
surgical recurrence (both of which are inescapable, but presently impossible to 
quantify) these countries provided results based on expert opinion. Uncertainty is 
greatest among the nine countries in which previous estimates were retained; these 
countries accounted for 848 thousand cases of trichiasis (30% of the global estimate) 
and further investigation is needed. India, which accounts for 443,000 cases of trichiasis 
(52% of the total retained estimate) is a particular priority.  
A second ongoing uncertainty stems from the unavailability of raw data for 398 
districts, for which, as a result, age- and sex-standardization was not possible. As noted 
in the calculations, there is a mean prevalence reduction against the raw prevalence 
estimate of 0.45, which was applied to the unstandardized districts.  
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Ongoing lack of trichiasis (and TF) prevalence data for 235 suspected-endemic districts 
is due to local insecurity, and the global trachoma community stands ready to support 
national governments to undertake the needed mapping in those populations, when and 
if security conditions improve to allow safe conduct of fieldwork. 
It is recognized [71] that the PBPS methodology described earlier is potentially 
imprecise in estimating TT against the WHO elimination target of ≤0.2% in adults. 
Thus, at district level, the uncertainty around the estimates of the TT backlog can be 
large. At national, regional and global level, I expect that the precision of overall 
estimates derived from multiple appropriately standardised PBPS datasets, in which the 
total number of clusters and total number of adults examined is very large, will be 
reasonably tight. In the next chapter, I will describe a more reliable methodology for 
estimating the district-level prevalence of TT. 
At present, the diagnosis of TT is based on the presence of clinical trichiasis (one or 
more lashes touching the globe or evidence of recent epilation of in-turned eyelashes) 
plus residence in a (presumed) trachoma-endemic setting. This definition is by nature 
somewhat circular and may need review, as it inevitably leads to classification of 
trichiasis as TT regardless of whether trachomatous conjunctival scarring is present or 
not. Trichiasis without trachomatous conjunctival scarring may be age-related or due 
to trauma, distichiasis, epiblepharon or other inflammatory disease [170]; the sight-
threatening potential and optimal management strategies for non-trachomatous 
trichiasis still require further investigation [171].  
Assumptions were made when adjusting the data for age and sex. First, I assumed that 
five-year age bands were accurate. However, it is reasonable to hypothesise that during 
 
 
81 
 
a survey, individuals demonstrate a terminal age preference. Second, this analysis 
assumed that UNdata rural population pyramids used were representative of all districts 
for which survey data were available. Finally, because many studies have demonstrated 
a high correlation between trichiasis and increased age [33, 59, 66, 67], I assumed zero 
trichiasis cases in the population aged 14 years and younger.  
These calculations of national and global TT burdens are point-prevalence estimates 
based on data of differing vintages; they will change as additional surveys, baseline or 
impact, are undertaken.  Other than for Ethiopia, Mali and Niger, the estimates do not 
consider the number of surgeries done during the period between the most recent survey 
and this analysis. Nevertheless, estimates of current national TT backlog are essential 
for countries to appropriately allocate resources for surgical campaigns. Future district-
level impact surveys or surveillance strategies in countries with trachoma elimination 
programmes will provide progressively improved evidence for countries to assess their 
residual TT burden and, ultimately, validate elimination of trichiasis as a public health 
problem. Baseline surveys of trachoma are still needed in a handful of countries (e.g., 
Egypt, Somalia and Central African Republic); these will lead to revisions in national 
estimates. In some settings, there will be a need to undertake trichiasis-specific surveys 
in order to assess progress to elimination. Unfortunately, insecurity may continue to 
limit surveys in a few, but not all, of the settings in which previous estimates were 
retained. Where possible, surveys should be undertaken. Such data will help drive 
towards, and demonstrate success in, the global elimination of trachoma as a public 
health problem. 
With an updated estimate of the backlog it is now possible to organize resources to 
focus on intervention in the high burden areas. However, a survey suitable for 
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measuring TT prevalence with precision against the WHO elimination target is needed. 
In the next chapter, I describe the design of a TT survey as well as it’s validation. I will 
then explore the spatial heterogeneity of TF and TT and ultimately evaluate the ability 
to identify TT hot spots. 
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 Design and validation of a trachomatous trichiasis (TT) 
specific survey 
4.1 Overview 
The previous chapter described the global burden of trichiasis estimated using the best 
data currently available. This information is valuable in aligning resources and planning 
for intervention campaigns. However, as country programmes approach the elimination 
targets, the necessity of a strategy to precisely assess TT burden within districts has 
been highlighted.  
The district has typically been identified as the implementation unit for trachoma 
intervention and mapping for practical reasons. A district is often an administrative 
boundary comprising of between 100,000 to 250,000 individuals. There is often an 
organised administrative body associated with a district which can facilitate both MDA 
and mapping.  
The WHO endorses a PBPS for trachoma, which is designed to estimate the prevalence 
of TF in children aged 1–9 years. The template design is a two stage cluster random 
sample survey, which uses PPS sampling to select 20-30 clusters; everyone aged over 
one year living in selected households is examined [22]. TF and TT are evaluated 
against the criteria set out in the WHO simplified trachoma grading system [19].   
However, TT disproportionately affects older people [33, 66, 67], and is a much less 
common sign than TF, and so the number of adults examined is generally not sufficient 
for estimating TT prevalence with good precision. These surveys simply accept the loss 
in precision in estimating TT [71].  
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In this chapter I present the design of a TT specific survey and validation of the design. 
The health ministries (or equivalent) in Benin, Malawi and Nigeria provided data used 
to inform the survey design. The validation exercise was implemented in United 
Republic of Tanzania, Uganda, Cameroon, and Chad with funding from Hellen Keller 
International and Sightsavers. I was responsible for the design of the survey, 
coordinated the validation exercises and conducted the validation analysis. 
Recommendations generated by this work were presented at the WHO, Eighth NTD-
STAG Global Working Group Meeting on Monitoring and Evaluation of NTDs held 
February 2017. A report of these findings and recommendations was published by 
WHO with the accompanying protocol made available for use in national programmes 
in 2017 [172]. 
4.2 Background 
As trichiasis is the morbidity stage of trachoma, appropriate management of afflicted 
individuals is major priority of all trachoma elimination programmes. Precise data on 
TT prevalence is therefore essential to help programmes plan surgical services, monitor 
progress, and assess whether the trichiasis component of trachoma elimination has been 
successfully achieved.  
A number of different approaches have been developed for estimating the burden of 
trachoma [173]. The low threshold for determining TT elimination triggers the question 
of whether a survey is the best strategy. In other disease control programmes with small 
elimination thresholds, such as Leprosy, active case detection is the typical strategy 
used. Leprosy control programmes follow up with newly diagnosed cases through home 
studies where family members and close neighbours are also examined [137, 138]. 
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Another technique to consider is patient screening, where persons who seek health 
services are examined for TT as part of their clinical exam. Both of these strategies are 
problematic for the task at hand, TT is often found among the poorest and most remote 
individuals, these isolated individuals are expected to have greater barriers in seeking 
care [174, 175]. Appropriately powered household surveys would be more likely to find 
these patients.  
Typically, trachoma surveys are conducted at the district-level and so for practicality 
this survey will be designed similarly. However, during the validation process, 
oversampling will be conducted in an effort to confirm a sufficient number of 
communities are included and that the design effect is adequate. 
The WHO endorses a PBPS for trachoma [176], which is primarily designed to estimate 
the prevalence of TF in children aged 1–9 years [22]. This approach to mapping 
trachoma is cost effective and practical for a public health intervention. 
Until now, the prevalence of TF (in children aged 1–9 years) and the prevalence of TT 
(in adults aged ≥15-years) have usually been measured at the same time. However, as 
programmes evolve, there are three broad scenarios where a TT specific survey may be 
necessary or desirable. In two of these scenarios the PBPS results may indicate either 
no need for intervention for TF and in-turn no need for re-evaluation of TF, or a long 
span of intervention for TF and subsequently a delay for re-evaluation of TT. In these 
scenarios, the programme may wish to re-estimate the TT prevalence without TF 
(Figure 4.1). The third scenario is if a survey at any stage of the programme estimated 
the prevalence of TT with a questionable methodological approach, the programme 
may wish to conduct a TT-specific survey. 
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Figure 4.1 Flow diagram illustrating the time points when a TT specific survey may be needed 
I set out to develop a methodology for undertaking a TT specific population based 
prevalence survey. This approach was maintained not only because programmes are 
familiar and comfortable with it, but also because it will provide robust estimates that 
enabling programmes to calculate their burden of disease. In developing the 
methodology, I felt it important to focus on an appropriate balance between feasibility 
and precision. In the context of a public health initiative it is necessary for a survey to 
be realistically costed, whilst maintaining sufficient precision. I explored various 
elements of the design through simulations with existing trachoma prevalence survey 
data, then field-tested a draft methodology in four trachoma-endemic districts at 
different stages of progress towards elimination in four different countries.  
4.3 Informing a TT specific survey design 
4.3.1 Data sources  
The population data used in this analysis were derived from the United Nations 
Statistics Division [165] and www.worldpop.org [166]. Microsoft Excel (2007) was 
used to organize the datasets into 5-year age bands stratified by sex for each country. 
The percentage of the population within each stratum was estimated from the bands. 
The district level populations were derived from www.worldpop.org data [166] using 
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the zonal statistics tool in ArcGIS 10.3 [167]. A sensitivity analysis was performed 
comparing the www.worldpop.org population estimates, and district population 
estimates provided by national programmes. The mean ratio between the national 
programme estimates and www.worldpop.org was 0.97.  
I used existing datasets to understand two key components influencing the optimal 
design of a TT-only survey: (1) the age distribution of TT and (2) the design effect (DE) 
of the TT estimate. Health ministries of Benin, Malawi and Nigeria provided datasets 
from 271 surveys undertaken from 2012–2016 with the support of the GTMP [71, 177-
184]. These countries were selected based on the availability of high quality data and 
diversity of the known trichiasis situation (Table 4.1). 
Table 4.1 Summary of survey data used in analysis 
Country ([State], where applicable) No. surveys Range of trichiasis prevalences 
Benin 27 0.0 – 1.9 
Malawi 24 0.0 – 0.6 
Nigeria [Bauchi] 20 0.1 – 3.3 
Nigeria [Benue] 23 0.0 – 0.4 
Nigeria [FCT] 6 0.0 – 0.3 
Nigeria [Gombe] 11 0.5 – 3.9 
Nigeria [Jigawa] 4 1.9 – 3.1 
Nigeria [Kaduna] 23 0.0 – 0.8 
Nigeria [Kano] 44 0.0 – 2.9 
Nigeria [Katsina] 34 0.0 – 3.6 
Nigeria [Kebbi] 2 0.4 – 1.8 
Nigeria [Kogi] 4 0.0 – 0.0 
Nigeria [Kwara] 8 0.0 – 0.2 
Nigeria [Niger] 25 0.0 – 0.4 
Nigeria [Sokoto] 3 0.3 – 1.0 
Nigeria [Taraba] 13 0.0 – 0.8 
Each one was a PBPS [185] using a methodology described in detail elsewhere [71]. 
These surveys did not collect information on  presence or absence of TS of the 
conjunctiva [19] in eyes with trichiasis [186]. The surveys were conducted prior to the 
addition of this information within the GTMP’s training and fieldwork systems [187, 
188]: these datasets therefore include data on all trichiasis, irrespective of the presence 
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or absence of TS, and it is not possible to make presumptions as to the aetiology of the 
cases.  
4.3.2 Analysis 
4.3.2.1 Age Structure 
National-level population pyramids were used. To ensure that national-level age 
distributions were representative of local age distributions, the national trachoma 
programme district level population datasets were compared to district level datasets 
extrapolated from www.worldpop.org (Figure 4.2). The national distributions track 
closely to the local distributions and so the former was used in the analyses. 
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➔ district level population distribution 
➔ national level population distribution 
  
  
  
Figure 4.2 Comparison of national and local population distributions. 
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4.3.2.2 Age prevalence curves 
Using R statistical software, trichiasis prevalence by age and sex was calculated. The 
R script first groups raw data by cluster, then age and sex. The sum of residents 
examined along with the number of cases per group is determined, then each group is 
weighted by the expected proportion of residents with that age and sex. The unadjusted 
proportion is calculated per group by dividing cases over total examined. The 
proportion is then multiplied by the assigned weight. The sum of the weighted 
proportion for groups within each cluster is calculated as the cluster-level age- and sex-
adjusted proportion. Finally, the mean of the cluster-level result is taken as the adjusted 
prevalence for the EU.  
When exploring the requirements of a TT specific survey powered to estimate TT 
prevalence in different age ranges, I assumed that programme interventions [189] 
would reduce the prevalence of TT uniformly across all age groups; adults aged ≥40-
years constitute 34% of the adults aged ≥15-years; and 85% of TT cases among adults 
aged ≥15-years occur in adults aged ≥40-years. Using these assumptions, a prevalence 
of 0.2% in those adults aged ≥15-years would correspond to a prevalence of 0.5% in 
those adults aged ≥40-years. 
4.3.2.3 Design Effect 
The DE estimates of variance arising from the cluster-sampled design and was 
calculated for each EU as 𝐷𝐸 = 1 + 𝑚𝛼2𝜇, where 𝑚 is cluster size, α is the standard 
deviation over the mean and μ is the mean prevalence.  
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4.3.2.4 Sample size 
Sample size was calculated as 𝑛 = 𝐷𝐸 × (
𝑧𝑎
2
2×𝑝(1−𝑝)
𝑒2
) where 𝑧𝑎
2
 = the standard normal 
deviate corresponding to 95% confidence intervals, 𝑝 = the expected prevalence, and 𝑒 
= the desired absolute precision, expressed as half the width of the desired confidence 
interval [190]. 
The number of clusters needed was calculated as 𝑐 =
𝑛
(ℎ×𝑎)
 where h = the number of 
households that can be seen by one team in one day and 𝑎 is the expected number of 
adult residents in each house.   
4.3.3 Results 
The EU-level prevalence curves and percent of cases by age were plotted to visualise 
the heterogeneity of trichiasis curves within a country. The mean of the EU curves was 
taken as the country curve (Figure 4.3). Variation in age prevalence is observed. 
However, there does appear to be a consistent increase in prevalence around age 30 - 
40 years. Across the three countries, on average, trichiasis prevalence increases from 
0.3% (adults aged 25-29 years) to 0.4% (adults aged 30-34 years), to 0.5% (adults aged 
35-39 years) to 0.9% (adults aged 40-44 years). Trichiasis prevalence of 100% is 
reached among the 65-69, 70-74, and 75+ age groups in four EUs in Nigeria. However, 
in these scenarios only one individual was enrolled in the age group and so the 
denominator is one. 
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Figure 4.3 Trichiasis prevalence by age group. The solid lines represent the mean prevalence observed by age 
group within each country and the dotted lines represent the mean prevalence observed by age group within each 
EU. In total 271 EUs are represented. . A gap in the dotted line can be observed in one EU. This is a result of no 
individuals identifying themselves as being between the ages of 65 and 69 during data collection in this EU.  
Further exploration of prevalence of trichiasis cases in relation to percentage of 
population within the age groups shows over 90% of cases are found in the adults aged 
≥30-years and 86% in the adults aged ≥40-years (Table 4.2), with moderate variation 
between countries. 
Table 4.2 Proportion of trichiasis cases within each age group 
 ≥15 years ≥30 years ≥40 years 
Malawi 100% 92% 89% 
Benin 99% 95% 85% 
Nigeria 97% 92% 83% 
The DE associated with the different surveys ranged from 1.1 to 5.1, and 92% of the 
surveys had a DE of 2 or lower (Table 4.3, Figure 4.4). Ordered from smallest to largest, 
the 75th centile of DEs in the 271 datasets was 1.47. The 1.47 value was carried forward 
in the sample size calculation for validation. Whilst it is reasonable to argue that a larger 
DE should be used in determining the sample size, feasibility and practicality must also 
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be considered. The validation exercises described in the next section demonstrate that 
a larger DE is not necessary. 
Table 4.3 Distribution of design effects for trichiasis (Benin, Malawi and Nigeria), Global Trachoma 
Mapping Project, 2012–2016 
DE interval Cumulative Percent 
1 23.85% 
1.0-1.5 76.15% 
1.0-2.0 91.74% 
1.0-2.5 97.71% 
1.0-3.0 98.62% 
1.0-3.5 99.08% 
1.0-4.0 99.54% 
1.0-4.5 99.54% 
1.0-5.1 100.00% 
 
Figure 4.4 Frequency of design effect (DE) found among included datasets 
To estimate an expected prevalence of 0.2% with an absolute precision of ±0.20%, the 
sample size would be: 𝑛 = 𝐷𝐸 × (
𝑧2×𝑝(1−𝑝)
𝑒2
) = 𝑛 = 1.47 × (
1.962×0.002(1−0.002)
0.0022
).  
where z = the standard normal deviate corresponding to 95% confidence intervals, p = 
the expected prevalence, and e = the desired absolute precision, expressed as half the 
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width of the desired confidence interval. This gives a sample size of 2,818 adults aged 
15 years and older. 
On this basis, I calculated a range of sample sizes, displayed in Table 4.4. The sample 
size required decreases as the age group widens. This is because the variance increases 
as the expected proportion increases towards 50%, then declines again beyond 50%. If 
the required absolute precision is held constant, therefore, a larger sample size is needed 
the closer the expected prevalence is to 50%, to allow the signal to be discerned beyond 
the noise. 
Table 4.4 Sample sizes required to estimate the elimination threshold prevalence of trachomatous trichiasis in 
different age groups for different precisions, design effect=1.47 
Age group sampled 
Expected  
prevalence (%) 
Absolute precision 
±0.15% ±0.20% ±0.25% ±0. 50% 
adults aged ≥15-years 0.2 5010 2818 1803 451 
adults aged ≥40-years 0.5 12487 7024 4496 1124 
4.4 Validating a TT specific protocol 
4.4.1 Protocol methods 
In 2016, four field-based district-level surveys were executed to test the validity of this 
proposed design. Four districts (Am-Timan, Chad; Budaka, Uganda; Monduli, United 
Republic of Tanzania; and Touboro, Cameroon) were surveyed. Each district was in a 
different stage of progress towards trachoma elimination as a public health problem. 
Protocols (Appendix D) were approved by the Cameroon Ministry of Public Health (18 
July 2016); Chad Ministry of Health (002/PR/PM/MESRS/SG/CNBT/2014); Uganda 
Ministry of Health (HS 2012); National Institute for Medical Research, United 
Republic of Tanzania (NIMR/HQ/R.8a/Vol.IX/2085); and the Research Ethics 
Committee of the London School of Hygiene & Tropical Medicine (10360). 
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In the 491 the GTMP survey datasets from Benin, Malawi and Nigeria, there was a 
mean of 3.0 (survey-level range in means 1.4–6.1) people aged ≥ 15 years per selected 
household; a mean of 2.3 (1.2–4.6) people aged ≥ 30 years per selected household; and 
a mean of 1.5 (1.0–2.2) people aged ≥ 40 years per selected household. If 30 households 
are sampled per cluster (as was often done within the Global Trachoma Mapping 
Project), then 32 clusters would be needed to include 2,818 residents aged ≥ 15 years, 
ignoring non-response. The validation exercise involved increasing the number of 
clusters sampled to 60 to ensure enough data for computer simulations.  
The validation exercises involved a two-stage sampling of one evaluation unit from 
each country. In Cameroon, Chad and Uganda all individuals living in the selected 
households in a random selection of half the selected clusters were examined for signs 
of TT based on the WHO Simplified Trachoma Grading Scheme and individuals aged 
40 years and older were examined in the remaining clusters. In Tanzania, all individuals 
living in the selected households in all selected clusters were examined for signs of TT 
based on the WHO Simplified Trachoma Grading Scheme. 
When TT was found in an eye, the eyelid of that eye was everted and inspected for TS 
based on the WHO Simplified Trachoma Grading Scheme. Data was collected and 
stored using the LINKS electronic data collection system. 
4.4.1.1 Scarring and lower lid trichiasis 
The second Global Scientific Meeting on Trachomatous Trichiasis was held in 
November 2015 [171]. A group of experts discussed the optimal diagnostic method for 
TT in a survey setting. Consensus was not reached for a change to the definition of TT 
to require trichiasis (or evidence of recent epilation of in-turned eyelashes) AND either 
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(1) the presence of TS in the same eye, or (2) inability on the part of the grader to evert 
the eyelid to examine the conjunctiva; rather, the meeting concluded that collection of 
data on TS should continue, with the question to be revisited at a later date. Trichiasis 
without TS could be age-related or due to trauma, distichiasis, epiblepharon or other 
inflammatory disease [170]. The meeting further recommended including both upper 
and lower lid trichiasis in the survey.  This information was included in the TT specific 
survey validation protocol (Appendix D). 
4.4.1.2 Training 
To ensure high quality and consistent diagnostic practices, a standardised training 
system was developed by a consortium of experts, using as templates the GTMP 
training schedule [187]. The presentation slides and manual can be accessed at 
tropicaldata.knowledgeowl.com.  
The manual highlights the need to use a variety of different teaching methods, including 
discussion with the assistance of PowerPoint slides, role play, practical exercise and 
evaluation of students. This training method focuses on involving the students in the 
discussion and demonstrations rather than lecturing.  
Students are taught how to examine eyelids by practicing on one another, this is 
especially important as it reminds the student to be gentle when examining eyelids in 
the field.  The training included an objective structured clinical exam (OSCE) to 
provide an objective measure for ensuring quality standardised grading. 
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4.4.1.3 Sample selection 
Along with preparing the survey team for the examination of patients, the training 
period was also used as an opportunity to prepare the logistics of the survey work. The 
evaluation units to be surveyed were pre-determined and will be discussed in detail in 
the following sections.  
In order to generate data for subsequent simulations, oversampling was undertaken in 
each survey: nearly two times the calculated number of clusters, 2 ×
𝑛
(ℎ×𝑎)
= 64. For 
practicality in the field the teams sampled 60 clusters per district. 
The first and second stage clusters within the evaluation unit were defined using the 
following method (1) clusters (villages or communities) were selected based on 
population proportion to size of 60 clusters using systematic random sampling 
procedures (2) 30 households within each selected cluster were randomly selected to 
be included in the survey.   
4.4.1.4 Data Management 
The exercise was carried out using LINKS [191], the electronic data collection system 
used for the GTMP. LINKS is a smart-phone- and cloud-based system for data 
collection and reporting which was used in 29 countries for the GTMP, and an 
additional six countries for surveying other NTDs.  Best practices for data management 
were used, which included data managers independent of the national programme, 
regular calculation of descriptive statistics and generation of point maps showing 
cluster locations during the data collection process. Data were stored on a secure server 
which was backed up hourly. Age- and sex- adjusted prevalence calculations were 
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provided to the appropriate MOH for review and approval. Upon MOH approval, 
national programmes shared the results with WHO to facilitate global monitoring of 
progress and assistance with alignment of resources for intervention with country-
specific needs.   
4.4.2 Implementing the validation exercise 
The four validation surveys commenced in 2016. The characteristics of these districts 
are summarized in Table 4.5. 
. 
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Table 4.5 Characteristics of four districts involved in the trachomatous trichiasis (TT)-specific survey validation exercise, 2016.  
District Population Proportion of 
adults within 
the ≥15-years 
population who 
are aged ≥40-
years (%) 
Baseline TT 
prevalence estimate 
in those adults aged 
≥15-years (%)  
[year of survey] 
Baseline TF prevalence 
estimate in children aged 
1–9 years (%)  
[year of survey; year 
MDA commenced] 
Next TF 
prevalence 
estimate due 
(year) 
Rationale for conducting 
a TT survey 
Am-Timan, 
Chad 
233,447 30 6.2 [2002] 26.9  
[2002, 2014] 
2017 The survey estimated the prevalence of TT with a 
questionable methodological approach and at the 
region-level. The programme wished to conduct a TT-
only survey.1 
Budaka, 
Uganda 
192,853 28 3.1 [2012] 2.2  
[2012, not indicated] 
Not indicated At baseline the survey estimated prevalence of TF 
in children <5% and of TT in adults ≥0.2%, an 
impact survey to measure TF prevalence is not 
indicated; after interventions, a TT-only survey to 
re-estimate the TT prevalence is indicated. 
Monduli, 
Tanzania 
174,482 34 5.5 [2004] 57.6  
[2004, 2015] 
2018 At baseline the survey estimated prevalence of TF in 
children ≥30% and of TT in adults ≥0.2%, at least 5 
years of A, F and E interventions are recommended 
before an impact survey to again measure the TF 
prevalence. During this time, the programme wished to 
undertake a TT-only survey to assess progress in 
addressing the TT backlog, facilitating adjustments in 
delivery of S interventions, if needed.  
Touboro, 
Cameroon 
287,087 35 0.5 [2011] 3.0  
[2011, not indicated] 
Not indicated At baseline the survey estimated prevalence of TF 
in children <5% and of TT in adults ≥0.2%, an 
impact survey to measure TF prevalence is not 
indicated; after interventions, a TT-only survey to 
re-estimate the TT prevalence is indicated. 
1 Baseline survey conducted at region-level. 
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4.4.2.1 Am-Timan, Chad 
Am-Timan District (population 233,447) is in Salamat Region of Chad. Adults aged 
≥40-years make up 30% of adult aged ≥15-years [165]. A pre-intervention (baseline) 
region level survey conducted in 2002 demonstrated a TF prevalence of 26.9% and TT 
prevalence (in adults aged ≥15-years) of 6.2% (Figure 4.5).  Since disaggregating the 
region level results dramatically reduces the precision of the district level estimates, a 
new survey was needed.   
 
Figure 4.5 Location of Am-Timan district in Chad and the surrounding district level trichiasis prevalences from 
the most recently available surveys [17, 18] 
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4.4.2.2 Budaka, Uganda 
Budaka District (population 192,853) is in Eastern Region of Uganda. Adults aged ≥40-
years make up 28% of adults aged ≥15-years [165]. A pre-intervention (baseline) 
survey conducted in 2012 demonstrated a TF prevalence of 2.23% and TT prevalence 
(in adults aged ≥15-years) of 3.1% (Figure 4.6).  Since the district was below the WHO 
recommended threshold for intervention with the A, F and E components of SAFE; no 
impact survey was planned.  However, the TT prevalence was above the WHO 
threshold for declaring trachoma elimination as a public health problem and it was 
therefore important to re-evaluate the status of TT in this district. 
 
Figure 4.6 Location of Budaka district in Uganda and the surrounding district level trichiasis prevalences from 
the most recently available surveys [192, 193] 
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4.4.2.3 Monduli, Tanzania 
Monduli District (population 174,482) is in Arusha Region of Tanzania. Adults aged 
≥40-years make up 34% of adults aged ≥15-years here [165]. Pre-intervention surveys 
conducted in 2004 demonstrated a TF prevalence of 57.6% and TT prevalence (in adults 
aged ≥15-years) of 5.5% [63] (Figure 4.7). Systematic mass drug administration 
(MDA) was started in 2015 and there are plans to conduct an impact survey in 2018. 
Because 12 years have passed since the last TT evaluation, it was felt necessary to re-
evaluate TT now rather than wait for the 2018 impact survey. An updated TT 
prevalence estimate is needed for resources to be appropriately aligned in Monduli.  
 
Figure 4.7 Location of Monduli district in Tanzania and the surrounding district level trichiasis prevalences from 
the most recently available surveys [19, 20] 
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4.4.2.4 Touboro, Cameroon 
Touboro District (population 287,087) is in Nord Region of Cameroon. Adults aged 
≥40-years make up 35% of adults aged ≥15-years [165]. A pre-intervention (baseline) 
survey conducted in 2011 demonstrated a TF prevalence of 3.0% and TT prevalence 
(in adults aged ≥15-years) of 0.5% (Figure 4.8).  Since the district was below the WHO 
recommended threshold for MDA intervention no impact survey was planned.  
However, the TT prevalence was above the WHO threshold for declaring trachoma 
elimination as a public health problem and it was important to re-evaluate the status of 
TT in this district. 
 
Figure 4.8 Location of Touboro district in Cameroon and the surrounding district level trichiasis prevalences from 
the most recently available surveys [17, 18] 
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4.4.2.5 Field work 
In Monduli, all consenting individuals who were aged ≥1-year and living in the selected 
households were included in the survey. For Budaka, Touboro, and Am-Timan, in half of the 
clusters; eligibility was the same as in Monduli, and in the other half, all consenting individuals 
who were adults aged ≥40-years and living in the selected households were included in the 
survey. Field work began immediately following the three-day training. Monduli deployed 12 
graders who also recorded the data. The survey teams in Budaka, Touboro and Am Timan were 
composed of a grader and a designated recorder (six graders and six recorders, five graders and 
five recorders, four graders and four recorders respectively).  
4.4.3 Analysis methods 
Analyses were conducted using R statistical computing packages [168, 194-198] (Appendix 
E). In each district, I calculated the proportion of all TT cases found within each age group 
(<15 years, 15–39 years, and ≥40 years), and the unadjusted and age- and sex-adjusted EU-
level prevalence for adults aged ≥15-years and adults aged ≥40-years. Then, the cluster-level 
proportion of cases in the adults aged ≥40-years was calculated, along with the DE.  Again 
using the adults aged ≥40-years, prevalence estimates were calculated with 95% confidence 
intervals determined by bootstrapping [199] over 10,000 replications with 1) resampling all 
clusters (to determine the 95% confidence intervals of the “true” prevalence), and 2) 
resampling half the clusters. In each bootstrapping set, the 2.5th and 97.5th centiles of the 
ordered means were used as the lower and upper bounds, respectively, for the confidence 
interval.  
To understand the precision associated with reducing the number of clusters, data from the 
Monduli District dataset (in which everyone aged ≥1 year was invited to be examined) were 
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bootstrapped, with replacement, over 10,000 replications, three times: first selecting 30 
clusters, then 40 clusters, then 50 clusters in each resample.  
4.4.4  Validation results 
In Monduli, 7,811 individuals from 1,894 households within 60 clusters were examined. In 
Budaka, 6,839 individuals from 1,729 households within 60 clusters were examined. In 
Touboro, 5,278 individuals from 1,816 households within 60 clusters were examined. In Am-
Timan, 4,071 individuals from 1,798 households within 60 clusters were examined. 
In Monduli, 96.5% (136) of the TT (trichiasis + scarring) cases were found in adults aged ≥40-
years, 2.8% (4) of the cases were found in adults aged 15-39-years, and 0.7% (1) were found 
in children aged <15-years. For the other districts, the following results are derived from the 
clusters where individuals aged ≥1-year were examined. No TT cases were found in individuals 
under the age of 40 years in Budaka. In Touboro 86.7% (26) of the TT cases were found in 
adults aged ≥40-years, 13.3% (4) of the cases were found in adults aged 15-39-years and no 
cases were found in children aged <15-years. In Am-Timan, 89.2% (25) of the TT cases were 
found in the adults aged ≥40-years, 10.7% (3) of the cases were found in adults aged 15-39-
years and again no cases were found in those aged <15-years (Table 4.6).  
Table 4.6 Summary of TT results by age group 
Location Age group 
(years) 
Persons 
examined 
TT cases Percent of cases  Unadjusted 
prevalence 
Am-Timan <15 1,713 0 0% 0% 
15-39 722 3 10.7% 0.4% 
40+ 353 25 89.2% 7.1% 
Budaka  
 
<15 2,541 0 0% 0% 
15-39 1,542 0 0% 0% 
40+ 1,340 50 100% 3.7% 
Monduli <15 2,877 1 0.7% 0.03% 
15-39 1,782 4 2.8% 0.2% 
40+ 3,149 136 96.5% 4.3% 
Touboro <15 1,446 0 0% 0% 
15-39 1,501 4 13.3% 0.3% 
40+ 1,160 17 86.7% 2.2% 
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In Am-Timan, the EU level age- and sex-adjusted prevalence of trichiasis in adults aged ≥15-
years was 1.0% (CI 0.5%-1.5%) and that for the adults aged ≥40-years was 2.0% (CI 1.9%-
3.9%). In Monduli, the EU level age- and sex-adjusted prevalence of trichiasis in the adults 
aged ≥15-years was 1.2% (CI 0.9%-1.7%) and that for the adults aged ≥40-years was 3.0% (CI 
2.1%-4.1%). In Budaka, the EU level prevalence for the adults aged ≥15-years population was 
0.6% (CI 0.3%-0.8%), being 2.5% (CI 1.7%-3.1%) in the adults aged ≥40-years. In Touboro, 
the prevalences for the adults aged ≥15-years and adults aged ≥40-years were 0.9% (CI 0.5%-
1.2%) and 2.0% (1.4%-2.6%) respectively (Table 4.7, Figure 4.9).  
Table 4.7 Summary of results  
Location Age group 
(years) 
TT 
prevalence 
(unadjusted) 
TT prevalence (age- 
and sex- adjusted) 
Lower 
bound 
of CI 
(95%)  
Upper 
bound 
of CI 
(95%) 
Design 
effect 
Am-Timan 15+  2.5% 1.0% 0.5% 1.5% 1.2 
40+ 3.6% 2.0% 1.9% 3.9% 1.11 
Budaka 15+  0.9% 0.6% 0.3% 0.8% 1.2 
40+ 3.2% 2.5% 1.7% 3.1% 1.03 
Monduli 15+  1.9% 1.2% 0.9% 1.7% 3.5 
40+ 4.4% 3.0% 2.1% 4.1% 1.05 
Touboro 15+  1.1% 0.9% 0.5% 1.2% 1.3 
40+ 2.4% 2.0% 1.4% 2.6% 1.02 
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Am-Timan Budaka 
  
Monduli Touboro 
  
Figure 4.9 Comparative results of TT random selection with 10,000 replications from the adults aged ≥15-years and adults 
aged ≥40-years  
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The cluster-level age- and sex- adjusted proportions of TT in adults aged ≥40-years in Monduli 
ranged from 0% to 21.5% with a DE of 1.05. In Budaka, the proportions ranged from 0% to 
11.3% with a DE of 1.03. In Touboro, the proportions ranged from 0% to 12.5% with a DE of 
1.02. In Am-Timan the proportions ranged from 0% to 18.4% with a DE of 1.11 (Figure 4.10). 
These results tell us that observations within clusters are only very marginally more similar 
than observations from different clusters.    
 
Am-Timan Budaka 
 
 
Monduli Touboro 
 
 
Figure 4.10 Cluster level proportions calculated for adults aged ≥40-years in Monduli, Budaka, Touboro, and Am-Timan 
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The non-response rates of the adults aged ≥15-years derived from our validation surveys in the 
clusters where individuals aged ≥1-years were examined ranged from 1.8% to 7.7%. 
In all four scenarios the proportion of positive cases trends up as age increases and this uptick 
appears to occur between age 40 and 50 (Figure 4.11).  
Am-Timan, Chad 
 
Budaka, Uganda 
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Monduli, Tanzania 
 
Touboro, Cameroon 
 
Figure 4.11 Demonstration of the proportion of TT cases found in each age group with 95% confidence intervals.  
As expected, the number of individuals examined generally decreases with increased age. 
However, in Budaka, Monduli, and Touboro there is a marked spike in participation among the 
40-44 age group (Figure 4.12). 
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Budaka, Uganda 
 
Monduli, Tanzania 
 
Touboro, Cameroon 
 
Figure 4.12 Age distribution of persons examined 
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In the Monduli dataset, a comparison of bootstrapping (with 10,000 replications) with selection 
of 60 clusters versus selection of 30 clusters, using only data from adults aged ≥40-years, 
produced confidence intervals of 2.1%-4.1% and 1.8%-4.6%, respectively. For Budaka, the 
same simulation exercise resulted in confidence intervals of 1.7%-3.1% and 1.5%-3.4%, 
respectively. In Touboro, the confidence intervals were 1.4%-2.6% and 1.3%-3.0%, 
respectively. In Am-Timan the confidence intervals were 1.9%-3.9% and 1.5%-4.4% (Figure 
4.13).  
Monduli Budaka 
  
Touboro Am-Timan 
  
Figure 4.13 Comparing a selection of 30 clusters and 60 clusters in adults aged ≥40-years with 10,000 replications 
generated through bootstrapping cluster level results. Dashed vertical lines indicate 95% confidence intervals. 
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Results from bootstrapping with 10,000 replicates using the adults aged ≥15-years from the 
Monduli dataset are shown in Table 4.8. 
Table 4.8 Results from randomly selecting 30, 40 and 50 clusters from the adults aged ≥15-years clusters from the Monduli 
dataset with 10,000 replications 
Location Number of clusters Prevalence of TT 
Mean SD Low CI (95%) Upper CI (95%) 
Monduli 30 1.23% 0.30% 0.69% 1.86% 
40 1.23% 0.26% 0.77% 1.77% 
50 1.22% 0.23% 0.80% 1.76% 
 
4.4.5 Discussion 
Precise data on the numbers affected with blinding trachoma are essential to enable national 
control programmes to effectively target surgeries, to evaluate ongoing interventions, and to 
determine if elimination thresholds have been reached. The design and validation of this TT 
specific survey provides a practical and reproducible tool to guide trachoma elimination 
programmes. Based on the evidence shown here, a TT specific survey targeting 30 clusters and 
examining at least 2,818 adults aged ≥15-years will enable programmes to estimate an expected 
TT prevalence of 0.2% with absolute precision of 0.2%.  Results from the validation exercise 
suggest this design provides consistent prevalence estimates with reasonable precision for 
public health decision making. 
PBPS’s remain the gold standard methodology for obtaining accurate disease estimates when 
case detection and reporting through the health system is incomplete. Thirty clusters is often 
taken as a rule of thumb for PBPS, but there has been little empirical evidence to support this 
selection.  Through bootstrapping, I evaluated the stability of a 30-cluster survey. As seen in 
Figure 4.13, the estimates for 30 clusters and 60 clusters were closely aligned with only slightly 
wider confidence intervals. This is especially evident when examining the Tanzania results in 
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Table 4.8, where all 60 clusters include data on adults aged ≥15-years, the precision gained in 
estimating the adults aged ≥15-years prevalence by including additional clusters is minimal 
and not an efficient use of resources. 
In the context of a public health initiative, it is necessary that a survey does not only provide 
sufficient precision but is also affordable. In an effort to reduce the necessary sample size, and 
therefore lessen time in the field, I evaluated potential target age ranges, including the exclusion 
of adults aged ≥40-years. Whilst I consistently demonstrate across multiple settings that >85% 
of TT cases will be found in the adults aged ≥40-years, a comparison with the data obtained 
when including the adults aged ≥15-years highlighted some important limitations of age-
specific recruitment.  First, I observed a spike in the 40-44 years age group. This may represent, 
in part, a terminal digit preference for multiples of ten when self-reporting age, and/or 
demonstrate an age bias in individuals examined. Introducing a bias by limiting enrolment to 
those adults aged ≥40-years is concerning, since a desire to be examined on the part of 
individuals aged <40-years may systematically alter the prevalence estimate obtained. It is also 
notable that, within the four surveys conducted here, the ratio between the prevalence estimated 
in those adults aged ≥40-years and those adults aged ≥15-years, varied from 2.0 to 4.2. 
Continuing to use adults aged ≥15-years as the sampled population will help minimize bias and 
ensure practicality. Resulting prevalence calculations should of course incorporate adjustment 
for age and sex of those examined, using the methods published by the Global Trachoma 
Mapping Project [200]. 
It is important to note that, whilst this survey was designed for an expected prevalence of 0.2%, 
the TT prevalence estimates from all four validation districts are all higher. This does 
potentially limit generalizability to very low prevalence settings. Validation districts were 
selected under the assumption that they would have very low TT prevalence, based on previous 
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prevalence estimates and an understanding of the interventions that had taken place since. 
There are several potential explanations. First, prior TT prevalence estimates may have been 
inaccurate, especially when non-standardised approaches were taken, such as was seen for Am-
Timan. Alternatively, surgery campaigns may have lost momentum or had poor uptake, as has 
been observed for the Maasai population living in Monduli [201]. This may have been a 
particular problem for Budaka and Touboro, where no other trachoma control activities (such 
as MDA) were indicated. Cross border dynamics may have also influenced survey results for 
rarer outcomes such as these.  
The TT-specific survey methodology presented here provides an appropriate balance between 
feasibility and precision in a public health setting. This proposed methodology has been 
validated through simulations in four trachoma-endemic districts representing different 
elimination stages, and the results yielded are consistent and defendable. A report of these 
findings and the following recommendations was published by WHO [172] making the 
protocol described here available for use by national programs. To date this survey design has 
been implemented in over five countries with plans to expand to all areas that qualify for a TT 
specific survey. 
4.5 Recommendations 
When undertaken, a TT specific survey should be implemented as a PBPS designed to estimate 
the prevalence of TT in adults aged ≥15-years.  The sample size is calculated to estimate, with 
95% confidence, an expected TT prevalence of 0.2% with absolute precision of 0.2% and a 
design effect of 1.47, yielding 2,818 as the target number of adults aged ≥15-years to be 
examined. This should be appropriately inflated to account for the expected non-response rate. 
The number of clusters, c, that would ideally be included is given by 𝑐 = (2,818 × [𝑛𝑜𝑛 −
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𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑖𝑛𝑓𝑙𝑎𝑡𝑜𝑟])/(ℎ × 𝑎), where h is the number of households that can be seen by one 
team in one day, and a is the expected number of adults resident in each house, as determined 
by the most recent census or recent population-based trachoma survey experience. If c, 
determined by the above formula, is ≥30, 30 clusters should be used. 
When trichiasis is observed, the eye should be evaluated for the presence or absence of TS, as 
defined within the WHO simplified trachoma grading scheme [19], and the subject should be 
asked scripted questions to determine whether interventions to manage the trichiasis in that eye 
have previously been recommended by health care workers [186, 187]. 
Prevalence calculations should incorporate adjustment for age and sex of those examined, using 
the methods published by the GTMP [200]. 
4.6 Time effectiveness of a trachomatous trichiasis (TT) specific survey 
A public health survey must be time effective to be practical to implement. In the next section 
I will outline the time-costs associated with a TT-specific survey where adults aged ≥15-years 
are included in comparison with a survey where adults aged ≥40-years are included. This 
information is useful to country programmes when budgeting for mapping. 
The purpose of this exercise is to compare the amount of time needed for a TT-specific survey 
where adults aged ≥15-years are included in comparison with a survey where adults aged ≥40-
years are included to determine if the time saved in the ≥40-years survey is beneficial enough 
to further explore the terminal age preference identified in Chapter 4.4.4. 
In the validation exercise, 60 clusters were selected per EU in both Monduli, Tanzania and 
Budaka, Uganda. In Monduli, all consenting individuals who were aged ≥1-year and living in 
the selected households were included in the survey. In Budaka, 30 clusters included 
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individuals aged ≥1-year and 30 clusters included only adults aged ≥40-years.  For clarity in 
this chapter I will refer to the Budaka clusters where individuals aged ≥1-year were included 
as clusters(1) and where only adults aged ≥40-years were included as clusters(40). Time-
stamps were included throughout the questionnaire, providing useful information for 
estimating time-cost at each stage of the survey.  
The time associated with each component of the data collection process was calculated by 
determining the mean time across clusters. First, the difference between the time of arrival at 
the first household in a cluster (time point B) and the time of arrival at that cluster (time point 
A) was calculated. Second, the difference between the start of the first exam in a household 
(time point C) and arrival at that household (time point B) was determined. Then the difference 
between the start (time point C) and end of each exam (time point D) was calculated for each 
individual. The difference between the end of the final exam in a household (time point E) and 
the arrival at the household (time point B) was determined. Finally, the difference between 
completion of the final exam in a cluster (time point F) and the time of arrival in the cluster 
(time point A) was calculated (Table 4.9, Figure 4.14).  
Table 4.9 Time point associated with each component of the data collection process 
Time Point Event 
A Team arrives in cluster 
B Team arrives in first household 
C Team starts first exam in first household 
D End of first exam in the first household 
E End of the final exam in the first household 
F End of last exam in the last household (departure from the 
cluster) 
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Figure 4.14 1) difference between arriving at household and arriving at cluster quantifies time spent preparing cluster (i.e. 
sensitizing village leader) 2) difference between start of first exam and arriving at household quantifies time spent 
organizing and explaining process to household 3) difference between start and end of each exam quantifies time spent 
examining each individual 4) difference between end of final exam in household and arrival at household quantifies time 
spent at each household 5) difference between end of final exam in final household and arrival at cluster quantifies time 
spent in each cluster 
Next, time associated with examining individuals with positive TT was calculated and a 
comparison of time and positive cases was performed. Time spent in a cluster was determined 
using the following calculation: 𝑡 + (𝑏 ×  ℎ) + (ℎ ×  𝑒 ×  𝑎) + (𝑐 ×  ℎ), where t is the time 
preparing for data collection, b is average time spent organizing households, h is number of 
households, e is average time spent per examination, and a is average number of examinations 
per household and  𝑐 is average travel time between households per cluster. 
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4.6.1 Results 
The mean time spent in a household in Monduli was 15 minutes 10 seconds. In Budaka the 
mean time spent in a household was 4 minutes 58 seconds in cluster(1) and 5 minutes in 
cluster(40) (Table 4.10). 
Table 4.10 Mean time spent at each stage of the survey in Monduli and Budaka with 95% confidence intervals 
 Monduli Budaka cluster(1) Budaka cluster(40) 
Time spent preparing to begin data 
collection 
0:40:42 
(0:33:15-0:48:10) 
0:06:54 
(0:04:59-0:08:49) 
0:10:18 
(0:08:07-0:12:29) 
Time spent organizing household 
prior to first exam 
0:03:38 
(0:03:05-0:04:10) 
0:01:08 
(0:01:02-0:01:14) 
0:02:18 
(0:01:46-0:02:50) 
Time spent 
examining 
individuals 
≥1 year 0:01:27 
(0:01:26-0:01:29) 
0:00:30 
(0:00:29-0:00:30) 
 
≥15 years 0:01:36 
(0:01:34-0:01:38) 
0:00:33 
(0:00:32-0:00:33) 
≥40 years 0:01:43 
(0:01:40-0:01:45) 
0:00:39 
(0:00:38-0:00:41) 
0:00:59 
(0:00:57-0:01:01) 
Time spent at household 0:15:10 
(0:13:31-0:16:49)  
0:04:58 
(0:04:40-0:05:17) 
0:05:00 
(0:04:15-0:05:46) 
The mean time spent examining individuals with positive TT in Monduli was 3 minutes 35 
seconds, in Budaka cluster(1) 1 minute 40 seconds, and in Budaka cluster(40) 2 minutes 12 
seconds. Whilst the mean of negative cases was 1 minute 25 seconds, 29 seconds and 51 
seconds in Monduli, Budaka cluster(1) and Budaka cluster(40) respectively (Table 4.11). 
Table 4.11 Mean examination time for positive and negative TT cases in Monduli and Budaka with 95% confidence intervals 
 Monduli Budaka 
cluster(1) 
Budaka 
cluster(40) 
Time examining 
positive cases 
0:03:35 
(0:03:11-
0:03:59) 
0:01:40 
(0:01:28-
0:01:52) 
0:02:12 
(0:01:54-0:02:29) 
Time examining 
negative cases 
0:01:25 
(0:01:23-
0:01:28) 
0:00:29 
(0:00:29-
0:00:30) 
0:00:51 
(0:00:50-0:00:52) 
Overall the mean time per cluster to examine the ≥40 population was 4 hours 43 minutes, the 
adults aged ≥15-years was 5 hours and 25 minutes and the individuals aged ≥1-year was 6 
hours and 47 minutes in Monduli.  The mean time per cluster in the Budaka cluster(1) was 4 
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hours 40 minutes for the adults aged ≥40-years, 5 hours 16 minutes for the adults aged ≥15-
years and 6 hours 30 minutes for the individuals aged ≥1-year. In Budaka cluster(40) the mean 
time was 3 hours and 51 minutes (Table 4.12).  
Table 4.12 Mean time by age group 
Project Age  Househol
d count 
Persons 
examined per 
household 
(mean) 
Time per 
cluster 
(mean) 
Percent of positive TT 
cases found per age 
group 
Monduli ≥1 year 32 4.1 6:47:32 0.71% 
≥15 years 32 2.6 5:25:19 2.84% 
≥40 years 32 1.8 4:43:08 96.45% 
Budaka 
Cluster(1) 
≥1 year 31 5.8 6:30:58 0.00% 
≥15 years 31 3.1 5:16:41 0.00% 
≥40 years 31 1.7 4:40:22 100% 
Budaka 
Cluster(40) 
≥40 years 27 1.7 3:51:32 100% 
4.6.2 Discussion 
Time spent preparing a cluster to begin data collection varies depending on the quality of 
sensitization provided prior to the start of the survey as well as the individual interest of the 
village leader and the experience of the examination team.  Time spent preparing a household 
for examination also varies depending on the familiarity of the head of household with public 
health surveys and willingness to participate. In Budaka it took longer to prepare the 
households in the cluster(40) sample. It may be that more time was spent explaining why only 
some individuals would be examined.  
The examinations in Monduli took longer than the examinations in Budaka. The Monduli 
survey teams did not include dedicated recorders, whilst the Budaka teams did. The two-person 
teams in Budaka were able to move through an exam quicker than the one-person in Monduli. 
However, the Monduli teams were able to enrol multiple households at a time so the time 
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essentially evened out between a two-person (recorder/examiner team) and two one-person 
teams. 
A survey which only includes adults aged ≥40-years takes marginally less time than a survey 
which examines adults aged ≥15-years. The time difference in an adults aged ≥40-years and an 
adults aged ≥15-years survey in Monduli was 42 minutes. The additional 42 minutes taken to 
examine the individuals aged 15-39-years provided an extra 2.9% of TT cases. In Budaka the 
difference between examining adults aged ≥40-years in cluster(40) and adults aged ≥15-years 
in cluster(1) was 1 hour and 25 minutes. No TT cases were found in adults aged <40-years in 
Budaka and so the additional time did not add any value in that particular situation.  
4.6.3 Conclusion 
Limited additional information is gained by including individuals aged 15-39-years in the 
survey. However, the time saved by not including this age group does not reduce the direct 
costs. Trachoma survey teams are familiar with adults aged ≥15-years cut-off and confusion 
may arise if this cut-off is changed to ≥40-years. Additionally, as demonstrated in the previous 
chapter, a ≥40-years cut-off introduces a recruitment bias. It should be noted that whilst there 
are no direct cost implications, the enthusiasm of the survey team could be positively impacted 
by the saved time. The majority of time spent in the survey is sensitising village leaders and 
households, which is not strongly related to the age being examined. Continuing to include 
adults aged ≥15-years is desirable. 
In the previous chapters I estimated the national and global burden of TT, designed and 
validated a TT specific survey and outlined the time-cost associated with the recommended 
survey design. Whilst these pervious chapters clearly aim to inform programmatic work within 
trachoma elimination programmes the following chapters provide a more robust understanding 
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of the geographical distribution of TT. In Chapter 5, I explore the community-level spatial 
heterogeneity of TT with focus on its relationship with the distribution of TF.  I then present a 
method for identifying TT community-level hot spots. 
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 Understanding the spatial distribution of trichiasis and its 
association with trachomatous inflammation follicular 
5.1 Overview 
The previous chapter provided a validated design for a trachomatous trichiasis (TT) specific 
survey. This methodology has been made available for national trachoma control programs 
through the support of the WHO, Eighth NTD-STAG. This survey design is programmatically 
useful and has since been implemented in numerous countries. As countries approach 
elimination targets it will become even more difficult to find the final TT cases. In the following 
chapters I will present geostatistical methods that may contribute to TT case finding in the 
context of the end game for trachoma control.  
With the availability of the GTMP dataset, I have estimated the burden of TT and designed and 
validated a TT specific survey. I will now use country specific exerts for the GTMP dataset, 
namely; Benin, Cote d’Ivoire, DRC, Guinea, Ethiopia, Malawi, Mozambique, Nigeria, Sudan 
and Uganda to explore the spatial heterogeneity of TF and TT. I will specifically identify the 
association between community-level TF and TT and how this is influenced by environmental 
risk factors. 
I built the geostatistical models and conducted the analysis presented here. I also wrote the 
manuscript informed by the information presented in this chapter.  
5.2 Background 
Trachoma is a blinding disease caused by recurrent ocular Chlamydia trachomatis infection 
which results in chronic inflammation of the tarsal conjunctiva. This is characterised by sub-
epithelial follicles, which may meet the definition to be classified as TF [21]. TF is the sign 
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used to determine whether public health-level interventions against active trachoma are needed 
[19]. Through repeated reinfection, scarring may develop, eventually causing the eyelashes to 
turn inward and touch the globe, a state known as TT. Inturned eyelashes that abrade the cornea 
can result in corneal opacity and blindness [21]. Corrective surgery [74, 77] or epilation [75] 
are used to manage these TT cases. As ocular chlamydial transmission declines in many 
countries [83, 202], it becomes important to focus on areas where TT remains a public health 
problem in the absence of TF.  
The natural progression of trachoma, as implicitly conceptualized within WHO 
recommendations for programme-level interventions, follows that episodes of TF are pre-
requisites on the causal pathway to TT, with moderate to high prevalences of TF being a proxy 
for current transmission of ocular C. trachomatis, and TT a proxy for historic transmission. 
The prevalences of these signs are therefore taken as signals for C. trachomatis infection at 
different time points (TF is current, and TT is historic). Even though these signs are markers 
of transmission at different timepoints, the driving factors (water, sanitation and hygiene) for 
community-level TF distribution gradually change and I expect; in areas where antibiotic MDA 
for trachoma [203] has not yet occurred, current community-level TF (as a proxy measure of 
trachoma transmission) to be a good predictor of current community-level TT. However, this 
is not always the case. 
Many country programmes [83] have successfully reduced district-level TF prevalence in 
children aged 1-9-years below the elimination threshold of 5%  [73, 133, 204]. However, to 
eliminate trachoma as a public health problem, district-level TT prevalence must also be 
reduced below 0.2% in adults aged ≥15-years [133, 162]. Whilst TF is no longer considered a 
public health problem in these districts, in many, TT still is. This is particularly evident in 
Nigeria where 94 local government areas (LGAs) in six states mapped through the GTMP 
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yielded a district-level TF prevalence below the elimination threshold and district-level TT 
prevalence above the threshold [180-184, 205, 206]. This is attributable to historic rather than 
contemporary transmission intensity. It is therefore important to better understand what factors 
influence the development of TT so as to develop more targeted control interventions. 
Understanding where TT cases are likely to occur could help to guide strategic placement of 
TT intervention services.  
Thanks to the GTMP, there has been an increasing availability of high quality geolocated 
trachoma and water, sanitation and hygiene (WASH) data. The GTMP was launched in 
December 2012 with the aim of mapping the global prevalence of trachoma through PBPS’s. 
The GTMP systematically collected trachoma and WASH data across 1,542 districts in 29 
countries in areas where control activities including mass drug administration (MDA) had not 
yet occurred [71].  These data can be used to further our understanding of TT distribution. 
In this study, I attempted to identify risk factors that, in addition to TF, might contribute to the 
variation in community-level TT prevalence. I fitted binomial mixed models with random 
effects at community-level to GTMP data from ten countries. I then tested for residual spatial 
correlation and, in countries where this was detected, used geostatistical methods to model the 
variation in TT prevalence between countries.   
5.3 Data  
Ten GTMP collaborating countries provided data for this study: Benin, Cote d’ Ivoire, 
Democratic Republic of the Congo (DRC), Ethiopia, Guinea, Malawi, Mozambique, Nigeria, 
Sudan and Uganda. Data provided were from 15,051 clusters (or communities) within 624 EUs. 
Individual-level information on the presence or absence of TF and TT, as well as water and 
sanitation conditions of geolocated households, were provided. Community-level TT 
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prevalence was calculated as the ratio between the number of adults aged ≥15-years with 
trichiasis in at least one eye and the number of adults aged ≥15-years examined. Community-
level TF prevalence was calculated as  the ratio between the number of children aged 1–9 years 
with TF in at least one eye and the number of children aged 1–9 years examined. 
Table 5.1 Summary of GTMP data included in the analysis 
Country 
No. of 
communities 
TF in children aged 1–9 years TT in adults aged ≥15-years 
No. 
examined 
No. positive 
(%) 
No. communities 
prevalence ≥5% 
No. 
examined 
No. positive 
(%) 
No. communities 
with prevalence 
≥0.2% 
Benin 213 18,781 
1,594  
(8.5%) 
94  
(44.1%) 
16,170 
254  
(1.6%) 
89  
(41.8%) 
Cote d’Ivoire 256 17,658 
1,829  
(10.4%) 
174  
(68%) 
18,771 
39  
(0.2%) 
26  
(10.2%) 
DRC 1,023 74,142 
7,022  
(9.5%) 
610  
(59.6%) 
52,200 
1,137  
(2.2%) 
511  
(50%) 
Ethiopia 4,480 186,308 
40,131  
(21.5%) 
3,119  
(69.6%) 
289,230 
4,711  
(1.6%) 
2,154  
(48.1%) 
Guinea 295 19,488 
832  
(4.3%) 
98  
(33.2%) 
21,955 
66  
(0.3%) 
53  
(18%) 
Malawi 1,948 82,185 
3,437  
(4.2%) 
561  
(28.8%) 
110,815 
358 
(0.3%) 
259  
(13.3%) 
Mozambique 696 34,602 
2,133  
(6.2%) 
297  
(42.7%) 
35,895 
155  
(0.4%) 
117  
(16.8%) 
Nigeria 5,364 337,962 
10,070 
(3%) 
1,105  
(20.6%) 
371,928 
4,815  
(1.3%) 
2,035  
(37.9%) 
Sudan 667 33,830 
1,394  
(4.1%) 
172  
(25.8%) 
40,501 
327  
(0.8%) 
197  
(29.5%) 
Uganda 109 6,019 
183  
(3%) 
26  
(23.9%) 
7,445 
21  
(0.3%) 
20  
(18.3%) 
Total 15,051 810,975 
68,625  
(8.5%) 
6,256  
(41.6%) 
964,910 
11,883 
(1.2%) 
5,461  
(36.3%) 
Physical and social environmental factors play an important role in the natural history of 
trachoma. These factors can accelerate progression to TT (Figure 5.1). 
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Figure 5.1 Conceptual framework describing the progression of TF to TT in the context of environmental risk factors. Proxy 
indicators are displayed in green boxes with the mechanism of influence in blue diamonds. Here I suspect that access to 
water for hygiene and fly density contribute to reoccurrence of TF. This reoccurrence leads to TS and TT. I suspect eye 
irritation hastens the progress from TS to TT and access to health services influences continued presence of TT. 
Facial cleanliness is a well-established association of TF [32, 41, 45-48] and access to water is 
necessary to facilitate personal hygiene practices. Previous studies have indeed found an 
association between distance to water and risk for trachoma [32, 50-52]. It has also been 
reported that there is an association between flies on faces and TF [38, 51, 53-56]. M. sorbens 
prefers to breed on human faeces left exposed on the soil [53, 93].  For this analysis, 
community-level WASH indicators were created from the GTMP household WASH dataset 
(Appendix F). The categorization of these indicators were informed by the WHO/UNICEF 
Joint Monitoring Programme for Water Supply and Sanitation (JMP) [169]. I then calculated 
the ratio of access to each categorized WASH indicator. 
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Previous studies have shown that lower precipitation levels and higher temperatures can lead 
to an increase in the risk of TF [207]. Therefore, I selected climate-related factors including 
annual total precipitation, mean temperature, aridity index and potential evapo-transpiration 
(PET) for this analysis. Gridded maps at 1 km2 resolution of annual total precipitation and mean 
temperature were extracted from the WorldClim database [115]. WorldClim averages the 
climate data for minimum, mean, and maximum temperature and precipitation for 1970-2000. 
The aridity index and PET raster datasets of 1 km2 resolution, were obtained from the 
Consortium for Spatial Information (CGIAR-CSI) [208]. CGIAR-CSI modelled aridity index 
and PET using the data available from WorldClim as input parameters. 
It has been suggested that areas in Sudan with frequent sandstorms result in eye trauma [68]. 
Irritation of the eyes leads to rubbing with fingers which may accelerate the progression of TT. 
Hence, in this analysis I consider the proportion of sand in topsoil, as a potential risk factor for 
TT. These data were obtained from the ISRIC-World Soil Information project included in the 
Harmonized Soil Map of the World (revised in 2012) [209].  
I speculate that access to healthcare and other services are associated with developed 
infrastructure, and therefore sought an infrastructure indicator. Light density at night has been 
shown to be correlated with local economic activity and gross production rate at different scales 
[210, 211]. Night light (NL) emission captured by the Operational Linescan System (OLS) 
instrument on board a satellite of the Defence Meteorological Satellite Program was used as a 
proxy measure of poverty across Africa [212, 213]. A gridded map of straight line distances to 
stable lights, namely NL emissivity > 0, was subsequently produced from the raw NL raster 
for 1997. This historic year was chosen because I was interested in a measure of infrastructure 
during the childhood of those likely to have TT at the time of survey data collection, rather 
than that at the time of the surveys themselves.  
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All the aforementioned environmental datasets were derived from georeferenced raster files 
and converted to a standardised resolution of 5 km × 5 km. I considered a 5km buffer a good 
catchment area for rural communities, considering this as a regular distance people can cover 
around communities. The georeferenced data were constructed in ArcGIS 10.1 (ESRI, 
Redlands, CA, USA). When shrinkage of spatial resolution was needed for the 1 km2 resolution 
covariates, I estimated the mean value in a 5 km × 5 km window using the aggregate tool 
available in the Spatial Analyst toolbox of ArcGIS 10.1 (Appendix G). 
To identify collinearity among the selected variables, I used the variance inflation factors (VIF) 
[214], defined as 
𝑉𝐼𝐹𝑗 =
1
1−𝑅𝑗
2  
where Rj
2 is the fraction of explained variance in the j-th explanatory variables by the other 
explanatory variables. 
5.4 Model formulation 
The models use community-level data, however because I use random effects 𝑈𝑖 to represent 
the unexplained extra binomial variation between communities these are defined as binomial 
mixed models [215]. I assume communities will have inherent differences which are not 
explained by community-level variables but are captured in differences in space (i.e. 𝑈𝑖).  Let 
pi denote the probability of having TT, 𝛽0 is the intercept and 𝑈𝑖 is community-level 
unstructured random effects (let 𝑖 denote the 𝑖-th community). In this model I then fit the 
following nested binomial mixed models, where 𝛾𝑇𝐹𝑖is the regression coefficient for the effect 
of TF prevalence on the log-odds of TT: 
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𝑀1: 𝑙𝑜𝑔 (
𝑝𝑖
1 − 𝑝𝑖
)  =  𝛽0 + 𝑈𝑖; 
𝑀2: 𝑙𝑜𝑔 (
𝑝𝑖
1 − 𝑝𝑖
)  =  𝛽0 + 𝛾𝑇𝐹𝑖 + 𝑈𝑖; 
𝑀3: 𝑙𝑜𝑔 (
𝑝𝑖
1 − 𝑝𝑖
)  =  𝛽0 + 𝛾𝑇𝐹𝑖 + ∑
𝑗=1
𝛽𝑗𝑑𝑖𝑗+𝑈𝑖, 
where in M3; 𝛽𝑗 are the regression coefficients of the explanatory variables dij and dij are the 
explanatory variables described in the previous section with 𝑖𝑗 as the 𝑗 -th variable within the 
𝑖-th community. In fitting M3, I also carried out variable selection using a backward stepwise 
approach, starting from the mixed effects model with all the variables included. The models 
were fitted in lme4 using the Laplace approximation of the lme4 package [216]. I use the 
likelihood ratio test to select among the three models defined above.  
The likelihood ratio test compares the log likelihoods of the different models using the 
following formula: 
𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑 𝑟𝑎𝑡𝑖𝑜 𝑡𝑒𝑠𝑡 𝑠𝑡𝑎𝑡𝑖𝑠𝑡𝑖𝑐 =  2(𝑙𝑙(𝑚2) − 𝑙𝑙(𝑚1)) 
where 𝑙𝑙(𝑚𝑥) is the log likelihood with 𝑚1 being the more restrictive model and 𝑚2 the less 
restrictive model. The statistic approximately follows a chi-square distribution and statistical 
significance is determined through considering degrees of freedom equal to the difference in 
variables between the models.  
To assess the presence of residual spatial correlation, I first obtained a point estimate of the 
community-level unstructured random effects Ui from the best model identified in the previous 
step, and then computed the empirical semi-variogram. A semi-variogram provides insights 
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into the rate of decay of spatial autocorrelation in the data by computing the mean squared 
difference between pairs of residuals as a function of the distance between their associated 
geographical locations. A flat semi-variogram is interpreted as evidence against the presence 
of spatial correlation. To test for spatial correlation more formally, I also generated 95% 
confidence intervals under the assumption of spatial independence. These intervals were 
obtained by computing semi-variograms on 1,000 randomly permuted point estimates of Ui 
while holding the geographical locations fixed.  For each simulation, data values were 
randomly allocated to the spatial locations. The empirical variogram was computed for each 
simulation using the same lags as for the variogram originally computed for the data. The 
envelops were computed by taking, at each lag, the maximum and minimum values of the 
variograms for the simulated data.  
In cases where I found evidence of spatial correlation, I fitted the model using PrevMap. 
PrevMap [217] is an R package which implements fitting and spatial prediction of a 
geostatistical model used in the context of prevalence mapping [218]. Parameters are estimated 
by Monte Carlo maximum likelihood using importance sampling techniques to approximate 
the high-dimensional intractable integral that defines the likelihood function.  
I fitted the following geostatistical binomial logistic model, in which the function  𝑆(𝑥) 
represents a spatial Gaussian process, and the Gaussian process is assumed to be stationary and 
isotropic and defined as having a mean of zero, variance of Σ2 with the correlation function 
Corr(𝑆(𝑥),𝑆(𝑥′)) being an exponential correlation function with a scale parameter  
representing the rate of decay in the correlation. In the fitted geostatistical model,  and Σ2 
were estimated from the data; initial values for  and Σ2 were derived from the empirical semi-
variogram, and maximum likelihood-based estimates of these parameters were then derived 
from the fitted geostatistical model: 
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𝑀4: 𝑙𝑜𝑔 (
𝑝𝑖
1−𝑝𝑖
) =  𝑑′𝛽 + 𝑆(𝑥)+𝑈𝑖, 
where 𝑑 is a vector of covariates with the associated regression coeffiencts 𝛽, 𝑆(𝑥)are spatial 
random effects that account for spatial variation in TT prevalence between communities not 
explained by the predictors, and 𝑈𝑖 is unstructured random effect representing extra-binomial 
variation within communities. The script can be found in Appendix H.  
The likelihood ratio test was used to compare the binomial mixed model with the geostatistical 
model. To assess the fit of the geostatistical model the observed TT prevalence values were 
plotted against the predicted values along with the predictive 95% confidence intervals. Then 
the percent of observed values that fall within the 95% predictive confidence intervals was 
calculated.  
5.5 Results 
The output for the cluster-level multicollinearity test suggests that temperature, precipitation, 
aridity index, and PET interact with one another (Table 5.2). Since aridity was highly correlated 
with each of these indicators, I only retained this variable and excluded the remainder.  
Table 5.2 Multicollinearity test results for gridded covariates 
Variable VIF 
Annual mean temperature 5.4 
Annual total precipitation 47.6 
Aridity Index 62.3 
PET 6.4 
Euclidean distance to ground water 1.2 
Sand/soil fraction 2.0 
Stable Night Light (1997) 1.2 
Accessibility 1.3 
The strength of association for variables in the full mixed effect model varied between country 
(Table 5.3). There was very strong evidence of positive association (P<0.05)  between 
community-level TF prevalence and TT prevalence in all countries except Guinea and Uganda. 
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In contrast, there was evidence of a negative association with access to latrines in two of ten 
countries (DRC and Malawi (p<0.01)), with access to improved latrines in Nigeria (p<0.01), 
and with improved water source on property in Nigeria (p<0.01). There was evidence of a 
positive association with access to latrines in three of ten countries (Ethiopia, Mozambique and 
Nigeria (p<0.01)), with access to improved latrines in Uganda (p<0.05), and with water source 
variables in three countries (Ethiopia, Nigeria (water source on property) and Guinea (water 
source distance more than 30 minutes) (p<0.05)). Observed relationships with environmental 
factors was equally heterogeneous with; negative associations observed for aridity index in 
DRC, Ethiopia, and Nigeria; positive association observed for aridity index in Sudan; positive 
associaiton with sand/soil fraction in Benin; negative association with sand/soil fraction in 
Ethiopia; positive association with night light in DRC, Mozambique and Nigeria; and negative 
association with night light in Ethiopia. 
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Table 5.3 Relative increase in odds derived from a multivariate binomial logistic model where community-level prevalence of TT in adults aged ≥15-years is dependent on a 10% increase in 
community-level prevalence of TF in children aged 1–9 years. Community-level household prevalence of improved sanitation and hygiene facilities as well as gridded covariates were included 
along with community-level prevalence of TF.  
Covariate 
type 
Covariates Benin Cote d’Ivoire DRC Ethiopia Guinea 
OR p-value OR p-value OR p-value OR p-value OR p-value 
Trachoma 
transmission 
TF prevalence 1.779 <0.001 1.854 0.010 1.527 <0.001 1.226 <0.001 1.427 0.311 
WASH Latrine defecation 0.596 0.087 0.909 0.421 0.902 <0.001 1.046 <0.001 1.067 0.254 
Improved latrines 1.664 0.109 1.153 0.324 0.961 0.110 0.990 0.489 0.950 0.362 
Improved water source 0.978 0.554 0.925 0.280 0.978 0.067 1.015 0.005 1.022 0.683 
Improved water source on property 1.328 0.191 0.854 0.469 0.948 0.758 1.011 0.801 1.075 0.708 
Water source on property 0.805 0.283 1.522 0.052 0.951 0.618 1.031 0.506 1.083 0.699 
Water source distance more than 30 minutes 0.948 0.105 1.033 0.688 1.015 0.224 1.008 0.170 1.133 0.031 
Large scale 
environmental 
Aridity Index 0.854 0.402 0.904 0.729 0.919 0.006 0.881 <0.001 0.903 0.121 
Sand/soil fraction 1.962 0.033 1.444 0.450 1.002 0.977 0.798 <0.001 0.973 0.899 
Poverty Stable night light (1997) 0.293 0.200 10.257 0.371 1.311 0.003 0.807 0.003 0.397 0.414 
            
Covariate 
type 
Covariates Malawi Mozambique Nigeria Sudan Uganda 
OR p-value OR p-value OR p-value OR p-value OR p-value 
Trachoma 
transmission 
TF prevalence 1.486 0.001 1.739 <0.001 1.196 <0.001 1.638 <0.001 2.157 0.163 
WASH Latrine defecation 0.835 0.034 1.082 0.001 1.051 <0.001 0.983 0.410 1.104 0.470 
Improved latrines 0.830 0.116 0.973 0.412 0.976 <0.001 0.998 0.963 1.259 0.020 
Improved water source 1.061 0.111 1.019 0.285 1.011 0.078 1.008 0.644 0.979 0.883 
Improved water source on property 1.026 0.942 0.852 0.244 0.944 <0.001 0.870 0.151 0.000 0.055 
Water source on property 0.916 0.792 1.135 0.283 1.023 0.023 1.052 0.628 812.073 0.058 
Water source distance more than 30 minutes 0.992 0.844 1.015 0.446 0.993 0.406 0.981 0.318 1.283 0.263 
Large scale 
environmental 
Aridity Index 0.978 0.779 0.902 0.070 0.565 <0.001 2.293 <0.001 2.095 0.400 
Sand/soil fraction 1.112 0.526 1.047 0.551 0.977 0.438 0.950 0.457 0.540 0.226 
Poverty Stable night light (1997) 1.538 0.640 2.160 0.001 2.121 <0.001 1.295 0.265 16.041 0.259 
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The nested mixed effects models in Table 5.4 show that when TF was added in as a fixed effect, 
the proportional reduction in variance (taken as one minus the variance explained by M1 over 
variance explained by M2) ranged from 0.06 (in Nigeria) to 0.42 (in Benin).  When 
environmental risk factors were added, the proportional change in variance (taken as one minus 
the variance explained by M1 over variance explained by M3) ranged from 0.25 (in Ethiopia) 
to 0.71 (in Cote d’Ivoire). In all countries, variance continued to decrease as TF and then 
environmental risk factors were added to the model. Full R outputs can be found in Appendix 
I. 
Table 5.4 Comparison of variance explained by each mixed effects model. 
 Null 
model 
TF only 
model   
TF prevalence +  
risk factors model 
Benin 
Variance 2.25 1.3 1.17 
Proportional 
reduction 
Null model   0.42 0.48 
TF only model     0.10 
Cote d'Ivoire 
Variance 13.75 10.28* 2.95 
Proportional 
reduction 
Null model     0.71 
TF only model       
DRC 
Variance 1.52 1.23 1.05 
Proportional 
reduction 
Null model   0.19 0.31 
TF only model     0.15 
Ethiopia 
Variance 1.22 1.01 0.92 
Proportional 
reduction 
Null model   0.17 0.25 
TF only model     0.09 
Guinea 
Variance 1.88 1.87* 1.66 
Proportional 
reduction 
Null model     0.11 
TF only model       
Malawi 
Variance 2.17 1.96 1.73 
Proportional 
reduction 
Null model   0.1 0.20 
TF only model     0.12 
Mozambique 
Variance 4.45 3.52 3.08 
Proportional 
reduction 
Null model   0.21 0.31 
TF only model     0.13 
Nigeria 
Variance 1.93 1.82 0.99 
Proportional 
reduction 
Null model   0.06 0.49 
TF only model     0.46 
Sudan 
Variance 1.98 1.85 1.18 
Proportional 
reduction 
Null model   0.07 0.40 
TF only model     0.36 
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The best models selected using the likelihood ratio test are shown in Table 5.5. DRC, Ethiopia 
and Nigeria maintained the largest number of variables significant at the 5% level. These three 
countries also had the largest quantities of data available.  
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Table 5.5 Relative increase in odds derived from a multivariate binomial logistic model where community-level prevalence of TT in adults aged ≥15-years is dependent on a 10% increase in 
community-level prevalence of TF in children aged 1–9 years. Community-level household prevalence of improved sanitation and hygiene facilities as well as gridded covariates were included 
along with community-level TF.  
Covariate type Covariates Benin Cote d’Ivoire DRC Ethiopia Guinea 
OR p-value OR p-value OR p-value OR p-value OR p-value 
Trachoma 
transmission 
TF prevalence 1.834 <0.001 1.417 0.187 1.566 <0.001 1.227 <0.001   
WASH 
 
Latrine defecation     0.895 <0.001 1.045 <0.001   
Improved latrines           
Improved water source       1.014 0.005   
Improved water source on property           
Water source on property           
Water source distance more than 30 minutes         1.102 0.048 
Large scale 
environmental 
Aridity Index     0.911 0.001 0.879 <0.001   
Sand/soil fraction       0.795 <0.001   
Poverty Stable night light (1997)     1.409 <0.001 0.806 0.003   
            
Covariate type Covariates Malawi Mozambique Nigeria Sudan Uganda 
OR p-value OR p-value OR p-value OR p-value OR p-value 
Trachoma 
transmission 
TF prevalence 1.481 <0.001 1.721 <0.001 1.193 <0.001 1.640 <0.001   
WASH 
 
Latrine defecation 0.819 <0.001 1.085 <0.001 1.056 <0.001     
Improved latrines     0.977 <0.001   1.251 0.006 
Improved water source           
Improved water source on property     0.955 0.001     
Water source on property     1.018 0.039     
Water source distance more than 30 minutes           
Large scale 
environmental 
Aridity Index     0.570 <0.001 2.752 <0.001   
Sand/soil fraction           
Poverty Stable night light (1997)   2.155 0.001 2.093 <0.001     
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Semi-variograms generated with the Pearson’s residuals of the best fitting non-spatial binomial 
model suggest presence of residual spatial correlation in DRC, Ethiopia, Mozambique and 
Sudan. The 95% confidence intervals generated under the assumption of spatial independence 
demonstrate spatial correlation in these countries (Figure 5.2).  
DRC Ethiopia  
  
Mozambique  Sudan  
   
  
 
Figure 5.2  Semi-variograms were generated with the Pearson’s residuals derived from the best fitting non-spatial mixed 
methods model. The 95% confidence intervals (red dashed lines) and semi-variogram (black dashed line) created through 
generating 1,000 simulations are displayed here. The x-axis was determined through taking half the maximum distance 
between communities and grouping into 15 classes of distance (bins). All distances are in kilometres.  
The distance at which spatial correlation fell below 5% (taken as the minimum values of the 
variograms for the simulated data), also known as the semi-variogram range, spanned from 3.0 
km (in Ethiopia) (95% credible interval 1.6-6.0 km) to 14.2 km (in Mozambique) (95% credible 
interval 3.4-58.9 km), corresponding with a very rapid decline in spatial correlation with 
distance at larger scales, after accounting for covariates (Table 5.6).  The calculated distance 
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at which spatial correlation fell below 5% corresponds with the plots (Figure 5.2) when 
accounting for the wide 95% confidence intervals (Table 5.6). The spatial correlation in these 
four countries is larger than the minimum distance between communities and so I consider 
there to be evidence of residual spatial correlation. 
Table 5.6 Scale of community-level TT prevalence spatial correlation in kilometres when accounting for covariates 
significant at the 5% level, by country with 95% confidence intervals 
Country scale of spatial 
correlation 
95% confidence 
intervals 
DRC 7.7 km 3.0 - 20.1 km 
Ethiopia 3.0 km 1.6 – 6.0 km 
Mozambique 14.2 km 3.4 – 58.9 km 
Sudan 2.8 km 0.9 - 10.8 km 
The large likelihood ratio test statistics lead to small p-values, suggesting that the geostatistical 
models are a better fit than the best fitting binomial mixed effect models in all four countries 
(Table 5.7).  
Table 5.7 Likelihood ratio test values 
Country Likelihood ratio test 
statistic 
p-value 
DRC 2802.412 <0.0001 
Ethiopia 12053.222 <0.0001 
Mozambique 1805.792 <0.0001 
Sudan 1147.988 <0.0001 
Whilst the geostatistical models are better fitting than the mixed effect models, they are still 
very limited. The observed values plotted against the predicted values (Figure 5.3) demonstrate 
low predictability in the models. In DRC, Ethiopia, Mozambique and Sudan the percent of 
observed TT prevalence values that fell within the 95% confidence intervals of the predicted 
values were 12.4%, 38.1%, 1.0%, and 3.4% respectively.   
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DRC Ethiopia 
 
 
Mozambique Sudan 
  
Figure 5.3 Plot of observed vs. predicted TT prevalence values as assessment of fit for the geostatistical models. The blue 
values fall within the 95% confidence intervals of the predicted values and the red values fall outside of the 95% confidence 
intervals. 
5.6 Discussion 
Remarkably few studies have specifically examined TT in the context of environmental risk 
factors and spatial distribution [67, 68, 146].  Here, I utilise the uniquely expansive and 
standardised GTMP datasets covering ten countries to demonstrate a large degree of 
heterogeneity in the relationship between community-level TT and TF, which I use as a proxy 
for contemporary transmission. The models also suggest that whilst community-level TF 
prevalence is the strongest predictor of TT, it does not fully explain the variation in community-
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level TT prevalence, thus implying that occasionally high TT communities will be found where 
TF is low.  However, associations with other potential risk factors are inconsistent, suggesting 
that the clinical history of trachoma may vary substantially between settings and emphasising 
the importance of understanding local context when designing interventions for at-risk 
populations. It is important to consider that even the better fitting geostatistical models 
demonstrate a great deal of uncertainty and so whilst informative, these models should not be 
overly interpreted. 
Many studies have identified potential risk factors for the occurrence of TF, including socio-
economic, demographic and environmental correlates  [32, 51, 207, 219], and have explored 
its spatial distribution at different geographic scales  [11, 37, 52, 220, 221]. The minimal studies 
that have addressed spatial distribution of TT however were limited in the amount of available 
data and so had constraints on generalizability of their outcomes [67, 68, 146]. The models 
presented here, with large datasets across ten countries reached similar conclusions and so 
provide some additional validation to this previous work.  
I observe that whilst a 10% increase in community-level TF prevalence leads, on average, to 
an increase in the odds for TT of 55%, this varies from as little as 20% for Nigeria to 86% for 
Cote d’Ivoire.  There are several potential explanations for the heterogeneous associations 
observed between TT and TF. High odds ratios such as those seen for Benin, Cote d’Ivoire and 
Mozambique, lead me to speculate that progression from TF to TT in these communities is 
unusually quick, or that trachoma transmission situation has not drastically changed over time. 
The relatively low odds ratios in Ethiopia and Nigeria, where a 10% increase in community-
level TF prevalence is associated with an increase in TT odds of 23% and 20% respectively, 
suggest either very slow rates of progression, or a reduction in transmission intensity over time. 
Alternatively, both scenarios could be attributed to historic population movement. 
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In addition to differing magnitudes of association, for all countries, adjusting for TF leaves a 
substantial proportion of variance in TT unexplained. For example, the proportion of variance 
explained by TF ranges from as little as 6% in Nigeria, to 42% in Benin. Environmental 
covariates, on average, explain an additional 9% (in Ethiopia) to 46% (in Nigeria) of variance. 
It has been widely observed that dry conditions, which would be consistent with a low aridity 
index, are risk factors for TF in children [11, 38, 50, 222].  I found this same association for 
TT in three of the countries, where there was a negative association with aridity. However, I 
did observe an unexpected positive association between community-level TT prevalence and 
aridity index in Sudan. Interestingly, a 1997 study in Mali also found a conflicting relationship 
between TF and TT prevalence [32], with the authors speculating this may be attributed to dry 
conditions in the north contributing to TF and the humid environment in the south contributing 
to blinding complications. It has been shown that coinfection with other bacteria [223], such 
as Streptococcus pneumoniae and Staphylococcus aureus [66], could affect progression of TT 
[80].  These coinfections may be more prominent in humid climates.  
Latrine defecation, aridity index and night light maintain strong significance in three of the ten 
countries. This, sometimes counter-intuitively, suggests that hygiene practices, dry/hot climate 
and historic infrastructure may contribute to increased community-level TT in some settings, 
but generally they do not. Previous study have clearly shown the association between WASH 
and TF [32, 51, 207, 219] and so it is not surprising that our models, which account for TF 
prevalence, generally do not maintain significant associations between TT and WASH.  The 
variation in direction of association may be an artefact of WASH improvements over time or 
in fact the latrines themselves may contribute to fly population if not appropriately maintained. 
Further, it is possible that the fly population is not influencing recurrent transmission [60]. 
Current TT is caused by many previous infections and so areas that historically had poor 
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WASH may still have TT even though the situation has improved. Other variations in identified 
covariates can mostly be explained by country context.  
There may be several explanations for the inconsistency of association between large-scale 
indicators and community-level TT seen between countries. This modelling approach does not 
capture population movement. Migration could certainly play a role in the geographic 
distribution of TT. It is also important to note that different ethnic groups may have different 
progression rates to TT. For example, a study in The Gambia found the polymorphism in the 
TNF-α gene promoter was associated with scarring and more frequent among Mandinkas than 
other ethnic groups [224].  
I observe residual spatial correlation in four countries (DRC, Ethiopia, Mozambique, and 
Sudan), suggesting in the remaining countries that there are no outstanding large-scale 
environmental factors influencing the progression to TT. In the geostatistical models, I 
identified a very rapid decline in spatial correlation with distance at larger scales after 
accounting for covariates. This suggests that clustering of TT occurs only at small spatial 
scales. 
Whilst these findings are not generalizable across country context, they can provide general 
direction for where to initiate case finding activities. As has been found in the Guinea Worm 
eradication experience, active surveillance and case finding will be essential as trachoma 
elimination nears [135] and these activities become more expensive as prevalence drops [225]. 
This uniquely large and standardised analysis provides important insight into the variation in 
community-level TT distribution and identifies substantial variation in the relationship between 
community-level TF and TT prevalence. However, the many differences seen across counties 
in these models suggest that it is unwise to rely on modelling on its own when undergoing TT 
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case finding. These models may serve as a starting point but should not replace current case 
finding techniques. For some countries important environmental risk factors were identified 
which can be used to inform targeting of active case finding through providing insight on where 
TT cases are more likely to be found in these countries. The findings suggest that in some 
countries it may be possible to inform strategic location of TT management services, improving 
efficiency in the end-stage of trachoma elimination.  
The geostatistical models presented here identified a very rapid decline in spatial correlation, 
suggesting small clusters. In the next chapter I will look more closely at the clustering of TT 
and identify communities containing a disproportionate amount of TT (hot spots). I will then 
follow methods similar to those described here where I will identify large scale environmental 
covariates associated with these hot spots. 
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 Identifying trachomatous trichiasis (TT) hot spots 
6.1 Overview 
As estimated in Chapter 3, the number of TT cases requiring management in 2016 was an 
estimated 2.8 million. The logistical challenge of finding these positive cases is a serious issue 
country programmes face when planning for and implementing TT interventions. It is 
necessary to strategically place surgical clinics and resources to ensure those who need surgery 
have access to it. One way to do this is through identifying and describing TT hot spots, or 
areas of higher-than-expected prevalence.  
Whilst, in Chapter 5, I built geostatistical models identifying a rapid decline in spatial 
correlation, in this chapter I will further explore the spatial structure of community-level TT 
through identifying hot spots. I conducted the analysis presented here and built the 
geostatistical models. I also wrote the manuscript informed by the information presented in this 
chapter.  
6.2 Background 
TF is the clinical sign for identifying active trachoma transmission, an outcome of repeated 
Chlamydia trachomatis infection [19]. Recurrent infection leads to chronic inflammation of 
the tarsal conjunctiva [21]. Over time, scarring can lead to an everted eyelid where eyelashes 
touch the globe, TT. This trauma may lead to corneal opacity and blindness [21]. Quality 
surgery can correct the in-turned eyelid, relieving pain and stopping progression of TT [74, 77, 
78]. For less severe cases, epilation is often used as a management technique [75]. The 
logistical challenge of finding positive TT cases is a serious issue country programmes face 
when planning for and implementing TT interventions. It is necessary to strategically place 
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surgical clinics and resources to ensure those who need interventions have access to them. The 
identification of TT hot spots could be used to guide decision making around placement of TT 
management resources.  
Here, the term hot spot is used to describe a group of communities with a TT prevalence higher 
than expected from spatial randomness. It is well established that C. trachomatis is transmitted 
through close physical contact, with transmission highest between family members and close 
communities [32-42], indicating clustering at local scales. Given the role of sanitation and 
hygiene in TF transmission [32, 41, 45-48] and differences in access and practices, between 
community clustering is also expected. Chronic TF can lead to scarring which may results in 
TT and so it is sensible to anticipate a similar clustered phenomenon for TT.    
Clustering of environmental risk factors or increased TF prevalence may contribute to 
clustering of high TT prevalence communities. As observed in the previous chapter, adjusting 
for TF in the binomial mixed models leaves a substantial proportion of variance in TT 
unexplained. In some countries, this variance was further explained by environmental 
covariates. It is reasonable to expect that a similar relationship will be observed when TT hot 
spots are the dependent variable. 
Whilst disease distribution is heterogeneous at various scales, few spatial explicit analyses have 
been conducted for TT. A 2015 study examined the spatial relationship between TT and CO in 
Nigeria and determined risk associated at both individual and cluster-levels. In this evaluation 
14% of variance was attributed to the cluster-level [146]. Whilst there are no publications 
where TT hot spots are identified, computations have been conducted for other diseases, such 
as TB where local indictors of spatial association (LISA) indicated spatial clustering of high 
response to or elevated rate of TB infection and Getis-Ord Gi defined the hot spots [150]. 
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This study seeks to identify community level TT hot spots and determine if these can be 
attributed to environmental risk factors or current trachoma transmission (TF prevalence). 
During the end-game of trachoma elimination, TT prevalence is expected to be very low 
(approaching 0.2% in adults aged ≥15-years) [133, 162], making it difficult to find and offer 
services to those affected. Hot spot detection and a stronger understanding of spatially 
distributed risk factors could guide strategies and improve efficiency in case finding.  
6.3 Methods 
6.3.1 Data 
The data used in this analysis were collected through the GTMP [71] and derived from 
georeferenced raster files converted to a standardised resolution of 5 km by 5 km (Appendix 
G). These data were described in detail previously (5.3). Briefly, ten of the 29 GTMP countries 
made their data available for this analysis, namely; Benin, Cote d’ Ivoire, Democratic Republic 
of the Congo (DRC), Ethiopia, Guinea, Malawi, Mozambique, Nigeria, Sudan and Uganda. 
These GTMP data include information on TT, TF and WASH representing 15,051 
communities in 624 EUs. The georeferenced raster files provided data on aridity [208], 
sand/soil fraction [209] and night light density [210, 211].  
6.3.2 Hot spot detection 
To test for the existence of spatial heterogeneity and spatial autocorrelation a Moran’s I 
statistics was run. The Moran’s I statistic measures spatial autocorrelation, or the similarity 
between observations as a function of space. Global Moran’s I can be used as a cluster detection 
technique, which quantifies similarities among spatial related areas [124].  The Moran’s I 
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statistics is described with, n = number of spatial united indexed by  𝑖 and 𝑗; Z = variable of 
interest; 𝑊𝑖𝑗 = measure of closeness of areas 𝑖 and 𝑗. 
𝐼 =  
𝑛Σ𝑖Σ𝑗𝑊𝑖𝑗(𝑍𝑖 − ?̅?)(𝑍𝑗 − ?̅?)
(Σ𝑖Σ𝑗𝑊𝑖𝑗)Σ𝑘(𝑍𝑘 − ?̅?)2
 
A Moran’s I analysis was performed for each country using the software package GeoDa [226]. 
Distance weighting was generated as Euclidean distance and k-nearest neighbours (KNN). To 
mimic a queen selection (Figure 6.1), the K value was taken as 8.  
  
Figure 6.1 Illustration of a k-nearest neighbour of eight 
 
To further understand the discreet spatial structure of TT, a Local Moran’s I statistic was used. 
The local indicators of spatial association (LISA) technique evaluates clustering of individual 
units [227].  
Spatial clustering of disease can be measured through global or local methods [132]. Global 
Moran’s I determine whether clustering is present throughout the study area by providing a 
single statistical measure of the degree of spatial clustering; identifying if spatial clustering 
exists. The LISA method defines the location and extent of clustering.  
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A LISA statistic classification of high-high or low-low, indicate positive spatial autocorrelation 
and are often considered spatial clusters. High-low and low-high classifications indicate 
negative spatial autocorrelation and are often considered spatial outliers. A high-high 
classification for this analysis indicates that the proportion of TT in surrounding communities 
is high and the value in the specified community is significantly higher than the surrounding 
communities. A low-low classification in this analysis indicates that the proportion of TT in 
the surrounding communities is low and the value in the specified community is significantly 
lower than the surrounding communities. A low-high classification indicates the surrounding 
communities have a high proportion of TT and the specified community has a significantly 
lower proportion. Finally, a high-low classification indicates the surrounding communities 
have a low proportion of TT and the specified community has a significantly higher value. 
Here I consider communities classified as high-high to be hot spots. Because the data used in 
this analysis were derived from random sampling, it is unlikely that by random chance only 
neighbouring homogeneous communities were selected. Therefore, a high prevalence 
community surrounded by other high prevalence communities may be a signal of on outlier of 
public health importance. Through identifying these hot spots, case finding could practically 
start with the hot spot community and then move to the eight nearest neighbour surrounding 
communities.  
A 2015 study by Lietman et al. determined that when prevalence of ocular chlamydial infection 
is decreasing in a district, high prevalence communities will be present and are not expected to 
interfere with progress [148].  These communities would be considered high-low in this 
analysis and so are considered as isolated high-prevalence communities that are not of major 
public health importance. The LISA statistics for community level TT proportion was 
generated in GeoDa [226].  
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A boxplot was created to explore the association between TT hot spots and community-level 
TF prevalence, as a proxy for C. trachomatis transmission intensity.  
6.3.3 Model formulation 
The models use community-level data, however because I use random effects 𝑈𝑖 to represent 
the unexplained extra binomial variation between communities these are defined as binomial 
mixed models [215]. Let pi denote the probability of being a TT hot spot (binary high-high 
communities = 1 and other communities = 0), 𝛽0 is the intercept and 𝑈𝑖 is community-level 
unstructured random effects (let 𝑖 denote the 𝑖-th community). I then fit the following nested 
binomial mixed models, where 𝛾𝑇𝐹𝑖is the regression coefficient for the effect of TF prevalence 
on the log-odds of TT hot spots: 
𝑀1: 𝑙𝑜𝑔 (
𝑝𝑖
1 − 𝑝𝑖
)  =  𝛽0 + 𝑈𝑖; 
𝑀2: 𝑙𝑜𝑔 (
𝑝𝑖
1 − 𝑝𝑖
)  =  𝛽0 + 𝛾𝑇𝐹𝑖 + 𝑈𝑖; 
𝑀3: 𝑙𝑜𝑔 (
𝑝𝑖
1 − 𝑝𝑖
)  =  𝛽0 + 𝛾𝑇𝐹𝑖 + ∑
𝑗=1
𝛽𝑗𝑑𝑖𝑗+𝑈𝑖, 
where in M3; 𝛽𝑗 are the regression coefficients of the explanatory variables dij and dij are the 
explanatory variables described in the previous section with 𝑖𝑗 as the 𝑗 -th variable within the 
𝑖-th community.  
In fitting M3, I also carried out variable selection using a backward stepwise approach starting 
from the mixed effect model with all the variables included. The models were fitted in PrevMap 
using the Laplace approximation of the lme4 package [216]. The likelihood ratio test was used 
 
 
151 
 
to test for the significance of each of the variables which were removed until all were significant 
at 5% level.  
6.4 Results 
The Moran’s I results demonstrate evidence of weak spatial autocorrelation for TT, with the 
evidence slightly stronger in larger settings, namely Ethiopia and Nigeria. The scatterplots 
illustrate the autocorrelation of each community, with positive spatial autocorrelation in the 
upper right and lower left quadrants and negative spatial autocorrelation in the lower right and 
upper left quadrants (Figure 6.2). The Moran’s I statistic is visualized as the regression slope 
of the plot and is estimated as 0.33 (p-value <0.001 with 9,999 permutations).  
 
Figure 6.2 Community level TT Moran's I scatter plots, community level TT proportions are on the x axis and spatial lag is 
on the y axis. The slope of the regression line (purple) is the Moran’s I statistic using k nearest neighbour (k value of 8).  
The output of the LISA statistic identified 712 communities classified as TT hot spots (high-
high), 9,999 permutations and p-value of <0.01 ( Figure 6.3).  
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Figure 6.3 LISA TT prevalence results where significance is set to 0.01 with 9,999 permutations.  
Zero hot spots were identified in Cote d’Ivoire, Guinea, Malawi and Uganda (Table 6.1). The 
mean number of persons included in the TT estimate per hot spot is 58. The largest proportion 
of TT hot spots (where the denominator is the total number of communities included in the 
survey within each country), were in DRC (0.13), Ethiopia (0.06) and Nigeria (0.05).  
Table 6.1 Community hot spots identified through LISA analysis where the community was classified as high-high, with a p-
value <0.01 
Country Number of hot spots Community-level TT prevalence (%) 
Mean  Range SD 
Benin 4 6.2 3.2-14.0 5.2 
Cote d’Ivoire 0 - - - 
DRC 137 7.5 1.5-62.5 7.2 
Ethiopia 272 7.0 1.4-34.5 5.3 
Guinea 0 - - - 
Malawi 0 - - - 
Mozambique 2 2.3 2.1-2.6 0.3 
Nigeria 280 5.6 1.4-21.8 3.7 
Sudan 17 3.7 1.9-7.7 2.1 
Uganda 0 - - - 
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Generally, communities classified as TT hot spots also seemed to have an increased proportion 
of TF in comparison to the communities not classified as hot spots (Figure 6.4). This is 
particularly evident in DRC and Ethiopia. The model presented in this chapter tests for 
significance to determine association.  
 
Figure 6.4 Boxplot illustrating the distribution of TF proportion among hot spot and non-hot spot communities  
The proportion of identified TT positive individuals living in TT hot spots communities ranged 
from 21.6% (in Nigeria) to 37.3% (in DRC) and the proportion of communities identified as 
hot spots ranged from 5.2% (in Nigeria) to 13.3% (in DRC). On average, 24% of cases were 
found in 6.3% of communities. 
Because so few hot spots were identified in many of the countries, only DRC, Ethiopia and 
Nigeria were retained for the remaining analysis. In the mixed effect model containing all 
covariates (M3), there was variation in strength of association between countries, with 
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community-level TF prevalence only significant (P<0.05) in DRC and Ethiopia (Table 6.2).  
However, aridity index was signficiant in all three countries (P<0.05). In two countries 
(Ethiopia and Nigeria (P<0.05)) evidence of association was found in a number of WASH 
indicators (improved water source, latrine defication, and location of water source), sand/soil 
fraction and night light.  
The nested mixed effect models did not show a proportional reduction in variance (taken as 
one minus the variance explained by M1 over variance explained by M2) when TF was added 
to the model as a fixed effect.  There was also no proportional reduction in variance (taken as 
one minus the variance explained by M1 over variance explained by M3) when the 
environmental risk factors were added as fixed effects. In all countries variance was mostly 
explained by the community-level random effect.   
Through a backward stepwise approach variable selection resulted in unique models for each 
country (Table 6.2). Community-level TF prevalence, aridity index, and night light were the 
only significant covariates in DRC. In Ethiopia, community-level TF prevalence, latrine 
defecation, improved water source, aridity index, sand/soil fraction and night light were 
initially signficiant. However, when unsignificant covariates were removed, the WASH 
indcators lost their significance. In Nigeria, all covarites were significant other than distance to 
water.  
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Table 6.2  Relative increase in odds derived from a multivariate binomial logistic model where TT hot spot 
classification is dependent on a 10% increase in community-level prevalence of TF in children aged 1–9 years. 
Community-level household prevalence of improved sanitation and hygiene facilities as well as gridded covariates 
are included along with community-level TF. 
Covariate 
type 
Covariates DRC Ethiopia Nigeria 
OR CI 
(95%) 
p-value OR CI 
(95%) 
p-value OR CI 
(95%) 
p-value 
Trachoma 
transmission 
TF 
prevalenc
e 
1.46
8 
1.468-
1.469 
<0.001 1.27
6 
1.087-
1.497 
0.0029 1.01
3 
1.013-
1.013 
<0.001 
WASH Latrine 
defecation 
      1.05
9 
1.059-
1.059 
<0.001 
Improved 
latrines 
      0.98
1 
0.98-
0.981 
<0.001 
Improved 
water 
source 
      1.06
3 
1.062-
1.063 
<0.001 
Water 
source 
distance 
more than 
30 
minutes 
         
Large scale 
environmenta
l 
Aridity 
Index 
0.77
8 
0.778-
0.778 
<0.001 0.00
7 
0.007-
0.007 
<0.001 0.33
2 
0.332-
0.332 
<0.001 
Sand/soil 
fraction 
   0.26
3 
0.263-
0.263 
<0.001 1.39
3 
1.393-
1.394 
<0.001 
Poverty Stable 
night light 
(1997) 
1.04
0 
1.039-
1.04 
<0.001 0.91
9 
0.919-
0.919 
<0.001 1.18
8 
1.187-
1.188 
<0.001 
In DRC and Ethiopia, the likelihood ratio test statistics were significant when 
community-level TF alone was included in the model as a fixed effect (Table 6.3). 
However, in Nigeria both the model with community-level TF alone and the model 
with additional environmental risk factors showed significant test statistics. To 
determine which between these two models was the “best fitting” model I examined 
the AIC value for the two models. The AIC value for the model containing community-
level TF along with the significant environmental risk factors had the lowest AIC and 
so was taken as the “best fitting” model for Nigeria. 
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Table 6.3 Likelihood ratio test values from the different nested models, by country 
Model 
DRC Ethiopia Nigeria 
AIC Likelihood 
ratio test 
statistic 
p-value AIC Likelihood 
ratio test 
statistic 
p-value AIC Likelihood 
ratio test 
statistic 
p-value 
Null 811.6 
 
  2055.2   2202.8   
TF prevalence 429.4 384.2 <0.001 863.1 1194.1 <0.001 892.1 1312.6 <0.001 
TF + significant 
environmental 
covariates 
432.5 0.86 0.650 945.9 0 1 888.6 15.5 0.016 
TF + all 
environmental 
covariates 
735.2 0 1 1058.3 0 1 895.6 0 1 
6.5 Discussion 
If endemic countries can identify hot spots of TT, they can better target interventions 
to have maximum impact and thus move closer to the GET 2020 targets for eliminating 
blinding trachoma as a public health problem. Though it is important to note that hot 
spot detection should supplement and not replace current case finding techniques. In 
this analysis, half the countries did not have hot spots, yet their prevalences were often 
above the TT threshold. Whilst higher levels of TT might be expected in communities 
with higher active transmission, analyses of co-distributions have shown this is not 
always the case.  This is the first multi-country study to explore the use of geospatial 
techniques to identify clusters of TT and used a comprehensive contemporary database 
of community-level pre-intervention TT prevalence data collected during the GTMP.   
In 2015, Lietman et al. published a study where a mathematical model illustrates the 
geometric shape of ocular chlamydial infection distribution as the disease is 
disappearing in a district [148]. The model demonstrates a heavy tail post-treatment, 
suggesting that after treatment most ocular chlamydial infection goes away whilst some 
lingering cases will remain. If this model holds true in different settings, it provides 
confidence that a single cross-sectional survey demonstrates a geometric distribution of 
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infection. When district level prevalence is decreasing, the occasional high prevalence 
community is not expected to interfere with progress. These occasional communities 
are not trachoma hot spots.  
It is important to distinguish key differences between this 2015 study and the work 
shown here. Lietman et al. aimed to show what happens to ocular chlamydial infection 
over time after intervention is in place. Ocular chlamydia is a sign of infection, 
interpreted as ongoing transmission, whilst TT is the morbidity stage of the disease. 
These are two different indicators and so the modelling is inherently different. 
Furthermore, a TT hot spot is likely to be fundamentally different before and after 
intervention. Before the SAFE strategy is implemented, communities containing more 
than expected proportions of TT are likely a result of disease ecology and poverty, 
whilst after SAFE implementation a TT hot spot may identify areas that are worst 
served by the health system or missed by surgical camps. This post-implementation 
scenario is very unpredictable and so here I focus on pre-intervention TT hot spots.   
These methods loosely align with a 2012 study aiming to identify geospatial hot spots 
for TB in Beijing [150]. This study implemented a Moran’s I statistic to identify 
locations of spatial autocorrelation and Getis-Ord Gi to identify hot spots.  A hot spot 
was defined as an identified clustered pattern of high response to or elevated rate of TB 
infection. The Moran’s I statistic showed it very unlikely that neighbouring values of 
TB are the result of random pattern. The peak Z score of the LISA was used to indicate 
spatial clustering and the clustered patterns identified by Getis-Ord Gi were interpreted 
as hot spots.  These methods identified areas of clustered higher than expected disease. 
Whilst Lietman et al. warn an occasional high prevalence, community is not a hot spot, 
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here I suggest that a cluster of communities with higher than expected proportions 
(LISA high-high) of TT might be.  
This study demonstrates stronger spatial autocorrelation in larger settings (i.e. DRC, 
Ethiopia and Nigeria), which may be an outcome of larger amounts of data available in 
these settings. The proportion of identified TT positive individuals living in TT hot 
spots communities ranged from 21.6% (in Nigeria) to 37.3% (in DRC) and the 
proportion of communities identified as hot spots ranged from 5.2% (in Nigeria) to 
13.3% (in DRC). With an average of 24% of cases found in 6.3% of communities, hot 
spot communities make an important public health impact.  
The model only containing TF prevalence as a fixed effect was the best fit in DRC and 
Ethiopia, suggesting in these two settings, TF is predictive of TT hot spots. However, 
in Nigeria, the model including a series of environmental covariates model was proven 
to be the best fit. These models do not behave as expected, with variation in direction 
of association between covariates between the countries. This further suggesting that 
TT hot spots cannot be accurately predicted through proxy indicators. It is possible that 
the identified hot spots are an artefact of population migration.  
I found variation in both TF prevalence and environmental risk factors in all three 
countries. In DRC, the majority of the hot spots are located in the north-eastern districts 
of Pawa, Bambu, Nyarembe, and Angumu. Interestingly, these four districts have low 
TF prevalence and high TT prevalence. Similarly, in Nigeria hot spots were generally 
identified in areas of low TF prevalence. Whereas, in Ethiopia, the district-level TF and 
TT prevalences are both high in districts containing hot spots.  
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Less is known about the trachoma migration dynamics in DRC. Though, in Nigeria, hot 
spots are concentrated in the northern and north-eastern portion of the country and there 
appears to be a pattern around the border of Jigawa region and along the southern border 
of the Zinder region of Niger. The bordering districts in Jigawa (Ringim and Garki) 
conducted a trachoma survey in 2007 [192] which triggered implementation of the full 
SAFE strategy. Cross-border dynamics could be influencing transmission, explaining 
low TF prevalence and the high TT may be a reflection of historic transmission.   
As demonstrated here, population dynamics are difficult to predict, and the inconsistent 
association of environmental risk factors further complicate the understanding of TT 
hot spot distribution. It is additionally, inadvisable to solely rely on district-level TF 
and TT prevalence for strategizing. This analysis demonstrated that hot spots only 
account for 25% of cases and the remaining cases are widely distributed. Whilst, simply 
identifying these hot spots as a standard step in survey data analysis could provide 
insight into the specific situation in different settings a large portion of cases may be 
missed.  
6.6 Limitations 
It is important to acknowledge the limitations of identifying hot spots from trachoma 
survey data. Trachoma surveys collect data on TT incidents through a two stage random 
sampling technique, where first communities are randomly selected and then 
households within those communities [22]. Hence, it is possible, by random chance, a 
larger proportion of high prevalence communities or households were included in the 
survey. Our models also do not account for migration patterns, which may play a large 
role in TT distribution.  
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 Summary and discussion of findings 
To provide evidence in guiding strategic use of resources for implementing TT 
management campaigns the aims of my thesis are to quantify the current global 
distribution of TT, and to explore spatial heterogeneity in TT at fine spatial scales.  
Through this work I have shown that TT distribution is highly spatially heterogeneous. 
In some settings this heterogeneity is driven by TF prevalence, use of latrines for 
defecation, aridity index and night light (as a proxy for infrastructure); whilst in most 
settings it is not possible to identify the driving influences of spatial heterogeneity. For 
trachoma control programmes looking to target interventions and move towards 
certification of elimination, it is essential that robust strategies (like the TT specific 
survey designed as part of this thesis) are used to comprehensively assess burden in a 
non-biased way across implementation sites. This work also shows that spatial 
clustering is important, but that hot spots only account for 25% of cases and the 
remaining cases are widely distributed, so simply targeting hot spots risks missing a 
large portion of affected individuals.  
7.1 Discussion of findings 
Trichiasis remains a significant public health problem in many countries, with a global 
backlog estimated for 2016 at 2.8 million people, 61% of whom live in sub-Saharan 
Africa. The considerable reduction from the 2009 estimate of 8.2 million [163] is likely 
the result of a combination of factors. First, there are now more, and better data derived 
from rigorous surveys. Second, in many countries, there has been an impressive 
programmatic scale up to manage TT, conducted by a complex network of governments 
and their partners. Third, there is likely to be an effect on the incidence of TT from the 
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intensive efforts to reduce active trachoma prevalence in many contexts; such efforts 
have been ramping up in endemic countries since the World Health Assembly’s 1998 
commitment to global elimination of trachoma as a public health problem [2]. Teasing 
out the relative contribution of each of these factors is not possible at the present time, 
but regardless of cause, the reduction is welcome news for global health.  
An understanding of the backlog and distribution of trichiasis cases is necessary to 
effectively plan for surgical services and other components of management of 
individuals with trichiasis. To reduce TT prevalence in each district of each endemic 
country to <0.2% in adults aged ≥15-years, which is the defined elimination threshold 
for TT [162], at least 2.0 million people will need to have their TT appropriately 
managed. Precise data on the number of people affected with TT are essential to enable 
national control programmes to effectively target surgeries, to evaluate ongoing 
interventions, and to determine if elimination thresholds have been reached. To achieve 
these goals, it is necessary for robust strategies to be developed and implemented.  
Here, I designed and validated such a strategy. The PBPS presented is designed to 
measure TT with precision against the elimination goals. Based on the evidence shown 
here, a TT specific survey targeting 30 clusters and examining at least 2,818 adults aged 
≥15-years will enable programmes to estimate an expected TT prevalence of 0.2% with 
absolute precision of 0.2%.  Results from the validation exercise suggest this design 
provides consistent prevalence estimates with reasonable precision for public health 
decision making. 
A report of this survey design and recommendations was published by WHO with the 
accompanying protocol made available for use in national programmes in 2017 [172]. 
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The outcomes from the use of this survey design thus qualify as evidence of elimination 
as a public health problem within the dossiers of elimination. It should be noted that 
this survey is meant to measure public health significance of TT, and not patient 
management. Programmatic survey approaches are useful in understanding the 
epidemiological status of diseases within a given area, but there is an inherent risk that 
patients may not be provided a direct link to appropriate health services. TT graders 
have been trained to refer positive TT cases to nearby facilities for management, 
however, currently there is no follow-up mechanism to provide support for patients to 
arrange for treatment. This strategy is not engaged within the routine health services 
and so identifying cases does not directly translate to cases receiving treatment.  
It is important to note that, whilst this survey was designed for an expected prevalence 
of 0.2%, the TT prevalence estimates from all four validation districts were higher. This 
does potentially limit generalizability to very low prevalence settings. In Chapter 5, I 
illustrate the spatial heterogeneity of TT distribution, which may suggest that as 
prevalence decreases the design effect may increase. It may be, that after a certain 
threshold, population-based prevalence surveys using random sampling alone may not 
be appropriate and other strategies such as purposive sampling should be adopted. 
Whilst previous work has identified clustering of TF [36-38, 52], there is limited 
understanding around the spatial structure of TT. As trachoma control programmes near 
the elimination targets it becomes difficult to find the “rare” occurring TT case that 
needs management. The elimination threshold for TT (district-level prevalence >0.2% 
in adults aged ≥15-years) equates to less than two positive TT cases per 1,000 adult 
population. Understanding the spatial structure of TT could guide where to conduct 
case finding activities, hopefully resulting in a more efficient use of resources.   
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Here I use community-level TF prevalence, information on WASH and large-scale 
environmental and socio-economic indicators to model the spatial variation in 
community-level TT prevalence. I modelled the prevalence of TT in a community and 
investigated its assocation with community-level TF prevalence.  I carried out a spatial 
exploratory analysis using semi-variograms to identify spatial structure in the 
distribution of community-level TT prevalence. In countries where spatial structure was 
identified, it was used to inform a geostatistical model constructed with the TT 
prevalence data and a suite of explanatory risk factors.  
This analysis found evidence of an association between community-level TF and TT 
prevalence. The estimated regression relationship between community-level TF and TT 
was significant at 5% level in eight out of ten countries. I estimate that a 10% increase 
in community-level TF prevalence leads to an increase odds for TT ranging from 20% 
to 86% when accounting for additional risk factors.  
Whilst the models suggest community-level TF prevalence is the strongest predictor of 
TT, TF prevalence does not fully explain the variation in community-level TT 
prevalence. This implies that high prevalence TT communities will occasionally be 
found where TF is low. The models found inconsistency in association with other 
potential risk factors, implying that the clinical history of trachoma varies between 
settings and emphasising the importance of understanding local context when designing 
interventions. Furthermore, the geostatistical models identified the scale of spatial 
correlation to range from 3.0 km (Ethiopia) to 14.2 km (Mozambique). This rapid 
decline in spatial correlation indicates that clustering of TT occurs only at small spatial 
scales. The limited spatial correlation implies that a two-stage cluster sampling 
approach is appropriate for measuring TT, assuming that the appropriate number of 
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clusters are selected. In Chapter 4, through bootstrapping, I evaluated the stability of a 
30-cluster survey. The estimates for 30 clusters and 60 clusters were closely aligned 
with only slightly wider confidence intervals. This confirms that in settings similar to 
those included in the validation, the traditional method of 30 randomly selected clusters 
provides sufficient variation within a district to measure TT prevalence.  
In Chapter 3, I estimated 2.8 million TT cases requiring management are outstanding. 
However, many of these cases are found in generally low prevalence settings.  The 
logistical challenge of finding these positive cases is a serious issue country 
programmes face when planning for and implementing TT interventions. It is necessary 
to strategically place surgical clinics and resources to ensure those who need surgery 
have access to it. One way to do this may be through identifying and describing TT hot 
spots, or areas of higher-than-expected prevalence.  
A LISA statistic was used to classify communities as TT hot spots.  A series of mixed 
effect models where TT hot spots are explained by community-level random effect, 
community-level random effect with community-level TF prevalence as a fixed effect, 
and community-level random effect with community-level TF prevalence and 
environmental covariates as fixed effects were run.   
The output of the LISA statistic identified 712 communities classified as hot spots 
within 118 EUs, with the majority found in DRC, Ethiopia and Nigeria. In these 
countries 24% of TT cases were found in 6% of the communities (hot spots) and 100% 
of the hot spot communities were found in EUs above the elimination threshold. Of the 
positive cases identified, 99% were found in districts above the elimination threshold. 
The proportion of identified TT positive individuals living in TT hot spot communities 
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ranged from 21.6% (in Nigeria) to 37.3% (in DRC) and the proportion of communities 
identified as hot spots ranged from 5.2% (in Nigeria) to 13.3% (in DRC). There is 
evidence of strong association with community-level TF prevalence in DRC and 
Ethiopia, but not in Nigeria.  
I found variation in both TF prevalence and environmental risk factors in all three 
countries. In DRC and Nigeria hot spots were generally identified in areas of low TF 
prevalence. Whereas, in Ethiopia, the district-level TF and TT prevalences are both 
high in districts containing hot spots. Cross-border dynamics could be influencing 
transmission in DRC and Nigeria, explaining low TF prevalence and the high TT may 
be a reflection of historic transmission.  Population dynamics are difficult to predict, 
and the inconsistent association of environmental risk factors further complicate the 
understanding of TT hot spot distribution.  
The large proportion of cases found in these relatively few hot spot communities 
suggest that the TT survey presented in Chapter 4 may risk either missing these 
communities or selecting many of these communities in the random sampling 
potentially biasing the outcomes. However, from a public health perspective and with 
the evidence shown in the oversampling exercise, this does not appear to be the case in 
the validation settings.  
As more national trachoma control programmes approach the elimination targets it may 
be advisable to not solely rely on district-level TF and TT prevalence for strategizing. 
Through conducting surveys with geolocated data and running LISA (as described in 
Chapter 6), hot spot communities could be identified and serve as the starting point for 
case finding. Hot spot identification should not replace current case finding techniques 
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(as seen in Chapter 6 hot spots were only identified in half the countries and only 
account for 25%), but act as an additional detail useful for choosing where to begin case 
finding. 
My thesis quantified the current global distribution of TT and explored spatial 
heterogeneity in TT at fine spatial scales. Through this work I have provided evidence 
and tools for national trachoma control programmes to use as they approach elimination 
of trachoma as a public health problem and apply for their dossier.  
7.2 Future directions for trachoma programs 
The future for trachoma elimination is promising. The trachoma community has made 
huge strides to meet the goals of elimination as a public health problem by 2020. 
However, there is still work to be done, especially around addressing the TT backlog. 
The TT specific survey design presented here has since been implemented in five 
countries and there are plans to expand its implementation to the remaining areas where 
a TT survey is necessary. The outcomes of these surveys will contribute to updating the 
TT backlog estimate, which will be calculated annually, following the methods 
described here, in preparation of the Global Elimination of Trachoma 2020 meetings. 
The backlog estimate provides a measurable target which is encouraging to funders 
facilitating the expanse of resources. 
Understanding the geostatistical structure of TT provides guidance on where to focus 
resources for TT management. To bring district-level TT prevalence below the 
elimination threshold, in many areas it is necessary to conduct case finding activities. 
The TT hot spot model presented here should be further validated through field testing.  
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Trachoma can and will be eliminated as a public health problem and the methods and 
tools provided in this thesis can be used to advance this initiative.
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Appendices 
 R script for calculating TT prevalence normalized by age 
and sex 
##This script was modified from GTMP script written by Brian Chu and Rebecca Willis 
clean <- as.data.frame(read.csv("ISO_raw.csv")) 
population<- read.csv("ISO_population.csv") 
clean["tt_old"] <- 0 
clean$tt_old[clean$TT=="1"] <- 1 
 
##generate age groups for the analysis, update for data available for specific country 
library(sqldf) 
mydb_tt <- sqldf('SELECT EU, CLUSTER, (CASE 
                 WHEN AGE BETIEN 15 AND 19 THEN "15_19"  
                 WHEN AGE BETIEN 20 AND 24 THEN "20_24"  
                 WHEN AGE BETIEN 25 AND 29 THEN "25_29"  
                 WHEN AGE BETIEN 30 AND 34 THEN "30_34"  
                 WHEN AGE BETIEN 35 AND 39 THEN "35_39"  
                 WHEN AGE BETIEN 40 AND 44 THEN "40_44"  
                 WHEN AGE BETIEN 45 AND 49 THEN "45_49"  
                 WHEN AGE BETIEN 50 AND 54 THEN "50_54"  
                 WHEN AGE BETIEN 55 AND 59 THEN "55_59"  
                 WHEN AGE BETIEN 60 AND 64 THEN "60_64"  
                 WHEN AGE BETIEN 65 AND 69 THEN "65_69"  
                 WHEN AGE BETIEN 70 AND 74 THEN "70_74"  
                 WHEN AGE BETIEN 75 AND 79 THEN "75_79"  
                 WHEN AGE >= 80 THEN "80+"  
                 END) AS AGE_GROUP, SEX, 
                 COUNT(*) AS RESIDENTS,  
                 SUM(CASE WHEN tt_old=1 THEN 1 ELSE 0 END) AS tt 
                 FROM clean 
                 WHERE AGE >= 15 
                 GROUP BY EU, CLUSTER, AGE_GROUP, SEX 
                 ORDER BY EU, CLUSTER, AGE_GROUP ASC, SEX DESC') 
 
##calculate unadjusted and adjusted TT prevalence 
ttprev_male <- as.data.frame(sqldf('SELECT mydb_tt.EU, mydb_tt.CLUSTER, 
mydb_tt.AGE_GROUP, mydb_tt.SEX, mydb_tt.RESIDENTS, mydb_tt.tt, 
population.percent_age_male AS age_Iight 
                                   FROM mydb_tt 
                                   LEFT JOIN population 
                                   ON mydb_tt.AGE_GROUP = population.age_group 
                                   WHERE mydb_tt.SEX = "1"')) 
 
ttprev_female <- as.data.frame(sqldf('SELECT mydb_tt.EU, mydb_tt.CLUSTER, 
mydb_tt.AGE_GROUP, mydb_tt.SEX, mydb_tt.RESIDENTS, mydb_tt.tt, 
population.percent_age_female AS age_Iight 
                                     FROM mydb_tt 
                                     LEFT JOIN population 
                                     ON mydb_tt.AGE_GROUP = population.age_group 
                                     WHERE mydb_tt.SEX = "2"')) 
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#append the dataframes 
ttprev <- as.data.frame(rbind(ttprev_male, ttprev_female)) 
 
#This creates the new column named "prev_unadj" filled with zeros and calculates unadjusted 
prevalence for each group 
ttprev["prev_unadj"] <- 0;  
ttprev$prev_unadj <- (ttprev$tt / ttprev$RESIDENTS) 
 
#generate unadjusted EU-level prevalence for comparison purposes 
ttprev_unadjusted_cluster <- aggregate(cbind(RESIDENTS, tt) ~ EU+CLUSTER, data=ttprev, 
sum) 
ttprev_unadjusted_cluster$cluster_prev_unadj <- 
(ttprev_unadjusted_cluster$tt/ttprev_unadjusted_cluster$RESIDENTS) 
ttprev_unadjusted <- aggregate(cluster_prev_unadj ~ EU, data=ttprev_unadjusted_cluster, mean) 
colnames(ttprev_unadjusted)[colnames(ttprev_unadjusted)=="cluster_prev_unadj"] <- 
"ttprev_unadj" 
 
#This creates the new column named "adj_tt" filled with zeros and Iights the data 
ttprev["adj_tt"] <- 0;  
ttprev$adj_tt <- (ttprev$prev_unadj * ttprev$age_Iight) 
 
#collapse on cluster level and get sum of Iighted prevalence 
ttprev_cluster <- aggregate(adj_tt ~ EU + CLUSTER, data = ttprev, sum) 
 
#calculate mean of adjusted cluster prevalences  
ttprev_eu <- aggregate(adj_tt ~ EU, data = ttprev_cluster, mean) 
 
a <- merge(ttprev_unadjusted, ttprev_eu, by="EU", all=TRUE) 
 
##bootstrap to generate confidence intervals 
dataset <- ttprev_cluster 
str(dataset) 
dataset$EU <- as.factor(dataset$EU) 
dataset$cluster <- as.factor(dataset$CLUSTER) 
dataset$cluster_prev <- dataset$adj_tt 
 
#boot statistic function 
clustermean <- function(df, i) { 
  num_clusters <- nrow(df) 
  r <- round(runif(num_clusters, 1, nrow(df))) #nrow(df) allows the analysis to divide by the correct 
#clusters 
  df2 <- numeric() 
  for (i in 1:num_clusters) { 
    df2[i] <- df[r[i],]$cluster_prev 
  } 
  return(mean(df2))   
} 
 
#create empty data frame for results 
bootResult_tt <- data.frame(EU=character(), bootmean=numeric(), se=numeric(), 
ci95_low=numeric(), ci95_high=numeric(), stringsAsFactors=FALSE) 
 
#bootstrap function, looped over each EU 
library(boot) 
num_reps <- 10000 #Should be at least 1000 but preferably 10000, higher reps the more precise 
for (i in 1:nlevels(dataset$EU)) { 
  data2 <- subset(dataset, EU==levels(EU)[i]) 
  b <- boot(data2, clustermean, num_reps) 
  m <- mean(b$t) 
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  se <- sd(b$t) 
   
#calculate 2.5/97.5 percentiles as Confidence Interval 
  q <- quantile(b$t, c(0.025, 0.975)) 
  ci_loIr <- q[1] 
  ci_upper <- q[2] 
   
#write result to data frame 
  eu_temp <- as.character(data2$EU[1]) 
  bootResult_tt[i,] <- c(eu_temp, m, se, ci_loIr, ci_upper) 
   
#histogram of mean bootstrap results with CI 
  hist(b$t, breaks=50, main=paste("EU",eu_temp, "- Histogram of mean bootstrap results, n=", 
num_reps)) 
  abline(v=ci_loIr, lty="dashed", col="black" ) 
  abline(v=ci_upper, lty="dashed", col="black" ) 
  #abline(v=ci_loIrSE, lty="dashed", col="blue" ) 
  #abline(v=ci_upperSE, lty="dashed", col="blue" )       
} 
 
#merge prevalence and confidence intervals into one table 
b <- merge(ttprev_unadjusted, ttprev_eu, by="EU", all=TRUE) 
b <- merge(b,bootResult_tt, by="EU", all=TRUE) 
results_bootstrap <- merge(b,bootResult_tt, by="EU", all=TRUE) 
 
#write combined results to csv file 
write_filename <- "Results.csv" 
write.csv(results_bootstrap, write_filename) 
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Country Location 
Hygiene Sanitation 
Population TT backlog estimate Basic 
service 
Limited 
service 
No handwashing 
facility 
At least 
basic 
Limited 
service 
Open defecation Unimproved 
Angola 
rural 15% 12% 73% 21% 5% 56% 17%     
urban 37% 13% 50% 62% 27% 3% 7%     
total 25% 12% 63% 39% 15% 33% 13% 25,789,024 3,138 
Zambia 
rural 5% 24% 71% 19% 7% 25% 50%     
urban 26% 33% 41% 49% 20% 1% 30%     
total 14% 28% 59% 31% 12% 15% 41% 12,526,314 1,524 
           
Country Location 
Hygiene Sanitation 
Population TT backlog estimate Basic 
service 
Limited 
service 
No handwashing 
facility 
At least 
basic 
Limited 
service 
Open defecation Unimproved 
Botswana 
rural       39% 10% 36% 14%     
urban       75% 6% 2% 16%     
total       60% 8% 17% 15% 2,024,904 1,049 
Zimbabwe 
rural 24% 52% 25% 31% 15% 39% 15%     
urban 46% 38% 16% 54% 42% 0% 4%     
total 31% 47% 22% 39% 24% 26% 11% 13,061,239 6,765 
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Country Location 
Hygiene Sanitation 
Population TT backlog estimate Basic 
service 
Limited 
service 
No handwashing 
facility 
At least 
basic 
Limited 
service 
Open defecation Unimproved 
Burundi 
rural       51% 6% 3% 39%     
urban       46% 40% 1% 13%     
total       50% 11% 3% 36% 7,877,728 155 
Uganda 
rural 6% 22% 72% 17% 9% 7% 67%     
urban 15% 21% 64% 28% 43% 2% 27%     
total 8% 22% 71% 19% 14% 6% 60% 34,634,650 680 
           
Country Location 
Hygiene Sanitation 
Population TT backlog estimate Basic 
service 
Limited 
service 
No handwashing 
facility 
At least 
basic 
Limited 
service 
Open defecation Unimproved 
Namibia 
rural 27% 58% 15% 15% 3% 76% 5%     
urban 62% 28% 9% 55% 21% 20% 4%     
total 44% 44% 12% 34% 11% 50% 5% 2,113,077 1,094 
Zimbabwe 
rural 24% 52% 25% 31% 15% 39% 15%     
urban 46% 38% 16% 54% 42% 0% 4%     
total 31% 47% 22% 39% 24% 26% 11% 13,061,239 6,765 
           
  
 
 
191 
 
Country Location 
Hygiene Sanitation 
Population TT backlog estimate Basic 
service 
Limited 
service 
No handwashing 
facility 
At least 
basic 
Limited 
service 
Open defecation Unimproved 
Iran  
(Islamic Republic 
of) 
rural       79% 17% 2% 3%     
total       88% 10% 1% 1% 75,149,669 1,928 
urban       92% 7% 0% 1%     
Pakistan 
rural 46% 43% 11% 48% 9% 19% 24%     
total 60% 31% 8% 58% 8% 12% 22% 207,774,520 5,330 
urban 83% 12% 5% 74% 8% 0% 18%     
           
Country Location 
Hygiene Sanitation 
Population TT backlog estimate Basic 
service 
Limited 
service 
No handwashing 
facility 
At least 
basic 
Limited 
service 
Open defecation Unimproved 
Iraq 
rural 81% 7% 12% 60% 9% 0% 5%     
total 91% 4% 5% 54% 10% 0% 4% 19,184,543 492 
urban 95% 2% 2% 51% 11% 0% 3%     
Pakistan 
rural 46% 43% 11% 48% 9% 19% 24%     
total 60% 31% 8% 58% 8% 12% 22% 207,774,520 5,330 
urban 83% 12% 5% 74% 8% 0% 18%     
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Country Location 
Hygiene Sanitation 
Population TT backlog estimate Basic 
service 
Limited 
service 
No handwashing 
facility 
At least 
basic 
Limited 
service 
Open defecation Unimproved 
Mexico 
rural 80% 15% 5% 81% 8% 6% 6%     
total 88% 9% 3% 44% 7% 2% 2% 112,336,538 5,428 
urban 90% 8% 2% 45% 7% 1% 1%     
Guatemala 
rural 70% 27% 3% 53% 7% 10% 30%     
total 77% 21% 3% 67% 9% 6% 18% 11,237,196 543 
urban 83% 14% 2% 81% 10% 1% 8%     
 
          
Country Location 
Hygiene Sanitation 
Population TT backlog estimate Basic 
service 
Limited 
service 
No handwashing 
facility 
At least 
basic 
Limited 
service 
Open defecation Unimproved 
Nauru 
total       66% 31% 3% 1% 10,084 1 
urban       66% 31% 3% 1%     
Vanuatu 
rural       51% 13% 2% 34%     
total       53% 18% 2% 27% 515,870 48 
urban       61% 32% 1% 6%     
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 Estimated national-level trichiasis backlogs, 2016, with comparisons to the corresponding estimates for 2009
WHO 
region 
Country 2009 published 
estimate 
generated from 
2007 data [162]  
Source for 2016 estimate (1) 2016 estimate Year(s) of data 
collection used for 
2016 estimate (2) 
Representativeness 
A
fr
ic
a 
R
eg
io
n
 
Algeria 86,700 Retained previous estimate 86,700     
Angola no data Expert assessment (3)  0     
Benin 7,600 GTMP [168]  11,782 2014-2015 Estimate based on a backlog calculated from 12 age- and 
sex-adjusted PBPS datasets covering all districts in the 
country where evidence indicates trachoma may be a 
public health problem 
 
  
Botswana 32,900 Expert assessment (3) 0     
Burkina Faso 32,800 PBPS – no raw data available 19,443 2005-2015 Estimate based on a backlog calculated from 63 PBPS 
datasets covering all districts in the country  
  
Burundi no data Expert assessment (3) 0     
Cameroon 47,200 PBPS – no raw data available 698 2012-2014 Estimate based on a backlog calculated from 1) 35 
(70%) age- and sex-adjusted PBPS datasets, plus 2) 15 
(30%) PBPS datasets, covering all districts in the 
country where evidence indicates trachoma may be a 
public health problem 
 
  
PBPS – raw data available 10,743 2010-2014 
 
  
Central African 
Republic 
1,000 PBPS – no raw data available 6,539 2011 Estimate based on a backlog calculated from 8 (53%) 
PBPS datasets, security concerns prevented the 
remaining 7 (47%)districts in the country where 
evidence indicates trachoma may be a public health 
problem from being surveyed  
 
  
Chad 34,300 GTMP 24,597 2014-2015 Estimate based on a backlog calculated from 1) 43 
(74%) age- and sex-adjusted PBPS datasets, plus 2) 14 
(24%) PBPS datasets. At the time of publication 1 (2%) 
 
  
PBPS – no raw data available 23,024 2002 
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WHO 
region 
Country 2009 published 
estimate 
generated from 
2007 data [162]  
Source for 2016 estimate (1) 2016 estimate Year(s) of data 
collection used for 
2016 estimate (2) 
Representativeness 
 
  district where evidence indicates trachoma may be a 
public health problem remained to be surveyed 
Congo no data GTMP 0 2015 Estimate based on a backlog calculated from 1 age- and 
sex-adjusted PBPS dataset covering all districts in the 
country where evidence indicates trachoma may be a 
public health problem 
 
  
Côte d'Ivoire 59,900 GTMP 1,216 2015 Estimate based on a backlog calculated from 10 age- and 
sex-adjusted PBPS datasets covering all districts in the 
country where evidence indicates trachoma may be a 
public health problem 
Democratic 
Republic of the 
Congo 
no data GTMP[169]  33,333 2014-2016 Estimate based on a backlog calculated from 30 (75%) 
age- and sex-adjusted PBPS datasets, security concerns 
prevented 1 (3%) district from being surveyed. At the 
time of publication an additional 9 district (23%) where 
evidence indicates trachoma may be a public health 
problem remained to be surveyed. 
Eritrea 42,000 GTMP 774 2014 Estimate based on a backlog calculated from 1) 2 (5%) 
age- and sex-adjusted PBPS datasets, plus 2) 36 (92%) 
PBPS datasets, security concerns prevented the 
remaining 1 (3%) district in the country where evidence 
indicates trachoma may be a public health problem from 
being surveyed 
PBPS – no raw data available 24,793 2006-2014 
Ethiopia 1,272,600 Expert assessment [170-174] (4)  693,037 2012-2016 Expert assessment based on a backlog calculated from 
1) 196 (92%) age- and sex-adjusted PBPS datasets, 
security concerns prevented the remaining 16 districts 
(8%) in the country where evidence indicates trachoma 
may be a public health problem from being surveyed, 
minus 2) programmatic TT surgery output from 2012-
2016 
Gambia 10,500 PBPS – no raw data available 0 2016 PBPS datasets covering all districts in the country where 
evidence indicates trachoma may be a public health 
problem 
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WHO 
region 
Country 2009 published 
estimate 
generated from 
2007 data [162]  
Source for 2016 estimate (1) 2016 estimate Year(s) of data 
collection used for 
2016 estimate (2) 
Representativeness 
Ghana 3,000 PBPS – no raw data available 1,379 2007-2008 Estimate based on a backlog calculated from 23 PBPS 
datasets, covering all districts in the country where 
evidence indicates trachoma may be a public health 
problem 
Guinea 25,100 GTMP 5,523 2014-2016 Estimate based on a backlog calculated from 31 age- and 
sex-adjusted PBPS datasets, covering all districts in the 
country where evidence indicates trachoma may be a 
public health problem 
PBPS – raw data available 24,302 2011-2013 
Guinea-Bissau 16,400 PBPS – raw data available 21,255 2005 Estimate based on a backlog calculated from 11 PBPS 
datasets, covering all districts in the country where 
evidence indicates trachoma may be a public health 
problem 
Kenya 306,800 PBPS – no raw data available 30,195 2004-2012 Estimate based on a backlog calculated from 1) 3 (20%) 
age- and sex-adjusted PBPS datasets, plus 2) 12 (80%) 
PBPS datasets, covering all districts in the country 
where evidence indicates trachoma may be a public 
health problem 
PBPS – raw data available 21,363 2004 
Malawi 33,400 GTMP [175, 176] 13,446 2013-2015 Estimate based on a backlog calculated from 1) 30 
(91%) age- and sex-adjusted PBPS datasets, plus 2) 3 
(9%) PBPS datasets, covering all districts in the country 
where evidence indicates trachoma may be a public 
health problem 
PBPS – no raw data available 1,128 2012 
PBPS – raw data available 817 2014 
Mali 67,600 Expert assessment (5) 13,852   Estimate based on a backlog calculated from 55 PBPS 
datasets, covering all districts in the country 
Mauritania 2,500 PBPS – no raw data available 1,556 2004-2013 Estimate based on a backlog calculated from 29 PBPS 
datasets, covering all districts in the country where 
evidence indicates trachoma may be a public health 
problem 
Mozambique 60,500 GTMP [177]  18,817 2013-2014 Estimate based on a backlog calculated from 1) 99 age- 
and sex-adjusted PBPS datasets, covering all districts in 
the country where evidence indicates trachoma may be a 
public health problem 
PBPS – raw data available 96 2015 
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WHO 
region 
Country 2009 published 
estimate 
generated from 
2007 data [162]  
Source for 2016 estimate (1) 2016 estimate Year(s) of data 
collection used for 
2016 estimate (2) 
Representativeness 
Namibia 6,100 Expert assessment (3) 0     
Niger 59,600 PBPS – no raw data available 40,529 2009-2014 Estimate based on a backlog calculated from 49 PBPS 
datasets, covering all districts in the country where 
evidence indicates trachoma may be a public health 
problem 
Nigeria 627,300 GTMP [178-182] 193,951 2013-2014 Estimate based on a backlog calculated from 1) 294 
(66%) age- and sex-adjusted PBPS datasets, plus 2) 103 
(23%) PBPS datasets, security concerns prevented the 
remaining 47 (11%) districts in the country where 
evidence indicates trachoma may be a public health 
problem from being surveyed 
PBPS – no raw data available 90,865 2003-2014 
PBPS – raw data available 3,800 2014-2015 
Senegal 129,800 GTMP 12,707 2014 Estimate based on a backlog calculated from 1) 20 
(43%) age- and sex-adjusted PBPS datasets, plus 2) 27 
(57%) PBPS datasets, covering all districts in the 
country where evidence indicates trachoma may be a 
public health problem 
PBPS – no raw data available 30,905 2000-2012 
PBPS – raw data available 3,077 2015 
South Sudan no data Expert assessment 81,093   Estimate provided by the Ministry of Health, South 
Sudan. To date, only a quarter of South Sudan has been 
mapped – this figure is likely to be an under-estimate for 
the country 
Togo 2,900 PBPS – no raw data available 318 2009 Estimate based on a backlog calculated from 3 PBPS 
datasets covering all districts in the country where 
evidence indicates trachoma may be a public health 
problem 
Uganda 610,600 GTMP 680 2014 Estimate based on a backlog calculated from 1) 39 
(89%) age- and sex-adjusted PBPS datasets, plus 2) 5 
(11%) PBPS datasets covering all districts in the country 
where evidence indicates trachoma may be a public 
health problem 
PBPS – no raw data available 14,559 2008-2012 
PBPS – raw data available 65,329 2013-2016 
United Republic 
of Tanzania 
214,800 GTMP [183, 184] 8,096 2014 Estimate based on a backlog calculated from 97 age- and 
sex-adjusted PBPS datasets, covering all districts in the 
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WHO 
region 
Country 2009 published 
estimate 
generated from 
2007 data [162]  
Source for 2016 estimate (1) 2016 estimate Year(s) of data 
collection used for 
2016 estimate (2) 
Representativeness 
PBPS – raw data available 63,157 2004-2016 country where evidence indicates trachoma may be a 
public health problem 
Zambia 8,500 GTMP 1,524 2015 Estimate based on backlog calculated form 1) 7 (70%) 
age- and sex- adjusted PBPS datasets, plus 2) 3 (30%) 
PBPS datasets covering all districts in the country where 
evidence indicates trachoma may be a public health 
problem  
PBPS – no raw data available 2,168 2010-2015 
Zimbabwe 44,100 GTMP 6,765 2014-2015 Estimate based on a backlog calculated from 16 age- and 
sex-adjusted PBPS datasets covering all districts in the 
country where evidence indicates trachoma may be a 
public health problem 
M
ed
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Afghanistan 83,100 Retained previous estimate 83,100     
Djibouti 3,900 Expert assessment (6) 75     
Egypt 35,400 GTMP 35,362 2015 Estimate based on a backlog calculated from 1) 4 (80%) 
age- and sex-adjusted PBPS datasets, plus 2) 1 (20%) 
PBPS dataset 
PBPS – no raw data available 35,400 2015 
Iran (Islamic 
Republic of) 
49,300 Expert assessment (3) 0     
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WHO 
region 
Country 2009 published 
estimate 
generated from 
2007 data [162]  
Source for 2016 estimate (1) 2016 estimate Year(s) of data 
collection used for 
2016 estimate (2) 
Representativeness 
Iraq 43,900 Expert assessment (3) 0     
Libya 13,200 Expert assessment (7) 33,400     
Morocco 6,400 PBPS – no raw data available 0 2015 Estimate based on a backlog calculated from PBPS 
datasets covering all districts in the country where 
evidence indicates trachoma may be a public health 
problem 
Oman 600 PBPS – no raw data available 600 2005 PBPS datasets covering all districts in the country where 
evidence indicates trachoma may be a public health 
problem 
Pakistan 71,700 GTMP 5,330 2015 Estimate based on a backlog calculated from 1) 42 
(47%) age- and sex-adjusted PBPS datasets, plus 2) 31 
(35%) PBPS datasets, security concerns prevented 15 
(17%) districts from being surveyed. An additional 1 
(1%) district where evidence indicates trachoma may be 
a public health problem remains to be surveyed. 
PBPS – no raw data available 23,420 2012 
Somalia 10,300 Retained previous estimate 10,300     
Sudan 528,100 GTMP [185]  22,508 2014-2015 Estimate based on a backlog calculated from 1) 109 
(76%) age- and sex-adjusted PBPS datasets, plus 2) 22 
(15%) PBPS datasets, security concerns prevented 12 
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WHO 
region 
Country 2009 published 
estimate 
generated from 
2007 data [162]  
Source for 2016 estimate (1) 2016 estimate Year(s) of data 
collection used for 
2016 estimate (2) 
Representativeness 
PBPS – no raw data available 6,751 2006-2013 (8%) districts from being surveyed. At the time of 
publication an additional 1 (1%) district where evidence 
indicates trachoma may be a public health problem 
remained to be surveyed. 
PBPS – raw data available 36,982 2007-2010 
Yemen 270,800 GTMP 5,821 2013-2015 Estimate based on a backlog calculated from 1) 42 
(53%) age- and sex-adjusted PBPS datasets, security 
concerns prevented the remaining 38 districts in the 
country where evidence indicates trachoma may be a 
public health problem from being surveyed 
R
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Brazil 58,000 Retained previous estimate 58,000 2003-2006 PBPS datasets covering all districts in the country where 
evidence indicates trachoma may be a public health 
problem 
Colombia no data GTMP 48 2015 Estimate based on a backlog calculated from 1) 3 (25%) 
age- and sex-adjusted PBPS datasets, plus 2) 6 (50%) 
PBPS datasets. At the time of publication an additional 3 
(25%) districts where evidence indicates trachoma may 
be a public health problem remained to be surveyed. 
PBPS – no raw data available 23 2003-2009 
Guatemala 30 PBPS – no raw data available 543 2011 Estimate based on a backlog calculated from 2 PBPS 
datasets covering all districts in the country where 
evidence indicates trachoma may be a public health 
problem 
Mexico 20 Expert assessment (3) 0     
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India 443,000 Retained previous estimate 443,000     
Nepal 138,800 PBPS – no raw data available 25,240 2001-2012 Estimate based on a backlog calculated from 1) 30 
(64%) age- and sex-adjusted PBPS datasets, plus 2) 17 
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WHO 
region 
Country 2009 published 
estimate 
generated from 
2007 data [162]  
Source for 2016 estimate (1) 2016 estimate Year(s) of data 
collection used for 
2016 estimate (2) 
Representativeness 
PBPS – raw data available 3,252 2002-2009 (36%) PBPS datasets covering all districts in the country 
where evidence indicates trachoma may be a public 
health problem 
W
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Australia 1,100 Retained previous estimate 1,100     
Cambodia 29,200 GTMP [186]  4,999 2014-2015 Estimate based on a backlog calculated from 14 age- and 
sex-adjusted PBPS datasets covering all districts in the 
country where evidence indicates trachoma may be a 
public health problem 
China 2,330,600 PBPS – no raw data available 71,280   PBPS datasets covering all districts in the country where 
evidence indicates trachoma may be a public health 
problem 
Fiji 800 PBPS using the methods of the 
GTMP [187] and subsequent 
investigation [188]  
0 2013 Estimate based on a backlog calculated from 1 age- and 
sex-adjusted PBPS dataset covering all districts in the 
country where evidence indicates trachoma may be a 
public health problem 
Kiribati 100 GTMP 69 2015 Estimate based on a backlog calculated from 1 age- and 
sex-adjusted PBPS dataset covering all districts in the 
country where evidence indicates trachoma may be a 
public health problem 
Lao People’s 900 GTMP [189]  630 2013-2015 Estimate based on a backlog calculated from 16 age- and 
sex-adjusted PBPS datasets covering all districts in the 
country where evidence indicates trachoma may be a 
public health problem 
Democratic   
Republic    
Myanmar 65,800 Retained previous estimate 65,800     
Nauru 0 Expert assessment (3) 0     
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WHO 
region 
Country 2009 published 
estimate 
generated from 
2007 data [162]  
Source for 2016 estimate (1) 2016 estimate Year(s) of data 
collection used for 
2016 estimate (2) 
Representativeness 
Papua New 
Guinea 
5,800 GTMP [190]  156 2015 Estimate based on a backlog calculated from 7 age- and 
sex-adjusted PBPS datasets covering all districts in the 
country where evidence indicates trachoma may be a 
public health problem 
Solomon Islands 500 GTMP [191]  44 2013 Estimate based on a backlog calculated from 1) 3 (38%) 
age- and sex-adjusted PBPS datasets, plus 2) 5 (63%) 
PBPS datasets covering all districts in the country where 
evidence indicates trachoma may be a public health 
problem 
PBPS – no raw data available 8 2012 
Vanuatu 200 GTMP [192]  48 2014 Estimate based on a backlog calculated from 1 age- and 
sex-adjusted PBPS datasets covering all districts in the 
country where evidence indicates trachoma may be a 
public health problem 
Viet Nam 210,000 Expert assessment (6)  [108] 100,000     
1) Unless otherwise specified, “Retained previous estimate” refers to the 2009 estimate by Mariotti et al.[163] 
2) Individuals examined in these surveys were men and women aged ≥15-years 
3) Health ministry reports that there is no evidence of trichiasis being a public health problem, or that evidence indicates that trichiasis is not a public health problem 
4) Estimate provided by the Federal Ministry of Health of Ethiopia; determined by calculating the backlog indicated by the most recent population-based prevalence survey in 
each trachoma-endemic district and subtracting from it the number of individuals with trichiasis managed by the health system since those surveys 
5) Estimate provided by the Ministère de la Santé, Mali; determined by calculating the backlog indicated by the most recent population-based prevalence survey in each 
trachoma-endemic district and subtracting from it the number of individuals with trichiasis managed by the health system since those surveys 
6) Estimate derived from information provided at the 2010 WHO Alliance for GET2020 meeting 
7) Estimate informed by data from a Rapid Assessment of Avoidable Blindness (RAAB) survey 
 
 
202 
 
 A trichiasis specific survey pilot test protocol 
 
 
   
Summary ....................................................................................................................................................... 3 
Background and Rationale ............................................................................................................................ 3 
Objectives ..................................................................................................................................................... 4 
Methods ......................................................................................................................................................... 4 
Survey Design ........................................................................................................................................... 4 
Survey Sites........................................................................................................................................... 4 
Survey Population ................................................................................................................................. 5 
Recruitment Procedure .............................................................................................................................. 6 
Sample size ........................................................................................................................................... 6 
Sample selection ................................................................................................................................... 6 
Questionnaire ........................................................................................................................................ 7 
Clinical examination ............................................................................................................................. 7 
Ethical considerations ................................................................................................................................... 7 
Informed consent/assent ................................................................................................................................ 8 
Data collection tools...................................................................................................................................... 9 
 
 
 
203 
 
LIST OF ABBREVIATIONS 
 
TF  Trachomatous inflammation follicular 
TT  Trachomatous trichiasis 
UIG  Ultimate intervention goal 
WHO   World Health Organization 
MoH  Ministry of Health 
ICTC  International Coalition for Trachoma Control 
EU  Evaluation Unit 
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Summary 
A TT specific survey has been designed with the intention of measuring trachomatous 
trichiasis (TT) with precision suitable for measurement against the WHO elimination 
criteria. This survey needs to be validated in the field and so a pilot test in Cameroon, 
Chad, Uganda and Tanzania is recommended.  
The pilot will involve a 2 stage sampling of one evaluation unit (district) from each 
country where all individuals living in the selected households in half of the selected 
clusters will be examined for signs of TT based on the WHO Simplified Trachoma 
Grading Scheme and the 40-years-and-older population will be examined in the 
remaining clusters. When TT is found in an eye, the eyelid of that eye will be everted 
and inspected for trachomatous scarring (TS) based on the WHO Simplified Trachoma 
Grading Scheme. The mobile phone number of those with positive cases will be 
collected. This will help to ensure follow-up with these individuals. Data will be 
collected and stored using the LINKS electronic data collection system and GPS 
coordinates will be collected at each selected household.  
All survey activities will be implemented by national control programmes as part of 
their activities, and will allow estimation of TT prevalence for programmatic purposes. 
However, data collection will also include oversampling for the purpose of validating 
the survey design. Findings will directly inform cost-effective design of national 
trachoma elimination programmes, and may be used to further refine WHO guidelines 
for the control of trachoma.  
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Background and Rationale 
Trachoma is a leading cause of preventable blindness worldwide and is endemic in 51 
countries [1]. Prolonged conjunctival infection with Chlamydia trachomatis leads to 
inflammatory response, trachomatous follicular (TF), which results in scarring of the 
upper sub-tarsal conjunctiva. The highest rates of TF are found in young children with 
a decrease occurring around the school-age [2-4]. Over time, repeat infection and 
additional scarring can cause the eyelid to turn inward, resulting in lashes rubbing 
against the cornea. This painful state is called trachomatous trichiasis (TT) and can 
damage the cornea, leading to vision impairment or blindness [5]. TT incidence 
increase with age, being rare in children. Whilst this disease is painful and debilitating, 
there is a strategy to stop its progress. The “SAFE” strategy involves (S) surgery to 
correct trichiasis, (A) mass drug administration of azithromycin and improved 
sanitation and hygiene, focusing on (F) facial cleanliness and (E) environmental 
improvement [6].  
The World Health Assembly Resolution 51.11 of 1998 targets the elimination of 
trachoma as a public health problem by the year 2020 [6]. A series of global trachoma 
scientific meetings (GTSM) resulted in generating the ultimate intervention goal for TF 
as, less than 5% prevalence and TT as less than 1 case unknown to the health system 
per 1,000 population per health district [7].  
Because trichiasis is the blinding stage of trachoma, appropriate management of 
individuals with trichiasis is the priority of every trachoma elimination programme. 
Obtaining reasonably precise data on TT prevalence helps programmes to plan surgical 
services, monitor progress, and assess whether or not the TT prevalence components of 
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the elimination goals has been successfully accomplished. Until now, the prevalences 
of TF in 1-9 year-olds and TT in adults (or the whole population) have usually been 
measured at the same time, as has been done at baseline for >1500 districts worldwide 
as part of the Global Trachoma Mapping Project. However, as programmes evolve, 
there are four broad scenarios where a TT specific survey is necessary.  
1. If a pre-intervention survey finds TF below 5% and TT above 0.1%, an impact 
survey to again measure the prevalence of TF is not indicated.   
2. If a pre-intervention survey finds TF above 30% and TT above 0.1% the district 
will undergo a minimum of 5 years of intervention before an impact assessment 
to again measure the prevalence of TF. During this time a programme may want 
to re-evaluate TT prevalence rather than wait the full 5+ years to make 
adjustments to the surgery strategy. 
3. If a post-intervention impact assessment finds TF below 5% and TT above 
0.1%, further work to manage cases of TT should be implemented, and an 
attempt then made to re-measure the TT prevalence. 
4. If a previous survey finds TT below 0.1%, but the quality of the survey is in 
question and expert opinion suggests TT should be re-evaluated. 
Objectives 
The purpose of this survey is to estimate the prevalence of trichiasis within a population 
with precision against the WHO threshold of 1/1,000 total population. 
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Methods 
The survey will be carried out utilizing existing electronic data collection system, 
LINKS. The preferred system is LINKS because many programmes are already familiar 
with the android tool. Best practices for data management will be used. This includes 
regularly calculating descriptive statistics and generating point maps during the data 
collection process. This ensures high data quality at the completion of the survey. The 
data will be stored on a secure server which is regularly backed up, as this greatly 
reduces the risk of data loss. Age and sex adjusted prevalence calculations will be 
provided to the Ministry of Health (MOH) for review. Upon the approval from the 
MOH it is recommended that the national programme share the results with WHO to 
facilitate global monitoring of progress and assistance with alignment of resources for 
intervention with country-specific needs.   
Survey Design 
Survey Sites 
Inclusion criteria 
An evaluation unit (EU) should typically be the normal administrative unit for 
health care management, consisting of a population between 100,000-250,000 
persons [8]. In situations where population size is very large, country-specific 
protocols should be followed to create smaller evaluation units. 
Within the EU, trichiasis cases should be suspected. The basis for this suspicion 
can come from results of previous trachoma surveys, evidence of cases within 
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healthcare facilities or confirmation of individual cases by healthcare 
professionals in the field. 
Exclusion criteria 
EUs are excluded from the study if they are not “suspected” to be endemic to 
trachoma or if previous surveys accepted by national programmes estimate a TT 
prevalence of less than 0.1%.  
Survey Population 
Inclusion criteria 
All individuals living in the selected households in half the selected clusters and 
individuals 40-years-and-older in the remaining clusters are eligible for the 
study.  
Exclusion criteria 
Individuals who do not provide consent are not eligible for the study.  
Recruitment Procedure 
Sample size 
I assume intervention reduces TT uniformly across the whole population. I further 
assume the 40+ age group constitutes about 17% (this value was derived from 
reviewing national population pyramids) of the population and is responsible for 85% 
of cases of TT. If these assumptions are correct, then a prevalence of 0.1% or less in 
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the whole population would correspond to a prevalence of 0.5% or less in the 40+ age 
group (0.1% x 85% divided by 17%). 
The mean design effect was calculated from the 313 surveys. I chose to use 2 as our 
design effect, as this value covers a minimum of 80% of the EUs in the extreme 
scenarios. 
Therefore, our null hypothesis states the prevalence is 0.5%.  
n = (Z2 × P(1 – P))/e2 
z = standard normal deviate corresponding to 95% confidence intervals 
P = hypothesised prevalence 
e = precision 
 
765 = (1.962 x 0.005 (1 - 0.005) ) / 0.0052 
765*2 = 1,529 
Because we are using this survey as a validation exercise, we will over sample.  
A sample of 1,529 adults 40-years-and-old is the minimum sample. So, we will sample 
the 40-years-and-older population in half the selected clusters and all individuals 1-
year-and-older in the remaining clusters and increase the number of clusters (60 
clusters). 
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Sample selection 
The survey should be representative of the entire EU and so two stage sampling strategy 
is required.  
First, a list of clusters (villages) should be selected through a random sampling 
procedure using probability proportional to population size.  
For this step it will be necessary to obtain a list of all villages and their population in 
the EU. 
1529/(30×1.5)=34 
Sample size = 1529 
Households to visit in one day = 30 
Average number of 40+ per household = 1.5 
Minimum number of clusters = 34 
*because we are using this survey to validate the sampling we will survey 60 clusters 
in an effort to oversample suitable for computer simulations 
Second, households should be randomly selected within communities. All eligible 
individuals who live in the selected households will be included in the sample. If 
eligible individuals are not home at the time of the survey, the team should return to the 
household at a time when the individuals are expected to be home. It is important to 
avoid convenience sampling in these scenarios. 
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For this step it will be necessary to obtain a list of all households within the selected 
villages. 
If there is no list of households, compact segment sampling will be used. 
Questionnaire 
The survey team should ask the patient for basic demographic information. GPS data 
should be collected at every household. 
Clinical examination 
Examining an individual from trichiasis involves looking at the eye in its primary 
position of gaze, using a 2.5 x magnifying loupe on the examiner’s head, and 
illumination, which can be either sunlight or a household torch. The eye is examined 
from the front, and from the side. In some individuals, where there is uncertainty as to 
whether there may be eyelashes touching the eyeball (which may occur, for example, 
if the iris is very dark in colour), or where there is uncertainty as to whether there may 
be evidence of epilation, the upper eyelid may need to be gently pushed upwards by 
exerting very mild pressure on the skin overlying the upper orbital margin, without 
eversion of the eyelid, in order to expose the free edge of the eyelid. This examination 
takes less than ten seconds per eye and is simple and painless. 
In individuals who are found to have trichiasis, questions about previous management 
are asked. The eyelid is then everted to allow examination of the tarsal conjunctiva for 
evidence of trachomatous scarring (TS). Eversion requires the examiner to ask the 
subject to look down, grasp the eyelashes of the upper eyelid between thumb and 
forefinger, pull the eyelid very gently downwards, then flip the outer edge upwards over 
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the point of the index or little finger of the other hand. Such a procedure causes mild 
discomfort in children, but in adults with trichiasis, the eversion manoeuvre temporarily 
relieves the discomfort of eyelashes abrading the eyeball and is extremely well 
tolerated. 
All Graders should have completed an objective structured clinical examination 
workshop to ensure grader quality.  
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An objective structured clinical examination (OSCE) for trichiasis grading 
 
Station 1: The grader trainee will examine the grader trainer, following the standard 
sequence for examination 
The trainer will evaluate whether the trainee follows the correct sequence for 
examination, which is 
1. Grader puts on the loop and cleans hands 
2. Patient sits and looks straight 
3. With illumination the grader examines the eyes to see if the lid margin and 
lashes are visible 
4. Grader slightly lifts upper eyelid to better examine the lid margin and position 
of the lashes 
5. Grader asks patient to move the eyeball to the right and the left to see if any 
eyelashes come in contact with the cornea 
Stations 2, 3 and 4: The grader trainee will demonstrate his or her ability to identify 
trichiasis and the absence of trichiasis in a series of photographs 
Grader should be able correctly identify the following: 
• neither trichiasis nor entropion 
• upper lid trichiasis with upper lid entropion 
• upper lid major trichiasis without entropion (>5 eyelashes touching the globe) 
• upper lid minor trichiasis without entropion (1-5 eyelashes touching the globe) 
• evidence of epilation  
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When the trainee identifies an abnormal eye in a photograph, he or she will be expected 
to ask the grader trainer the appropriate questions about previous management of 
trichiasis, acting as if the eye pictured belonged to the trainer. 
Station 5: The grader trainee will demonstrate his or her ability to evert both right and 
left eyelids of a normal individual and examine the conjunctivae for trachomatous 
scarring. 
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Ethical considerations 
No personal identifiers are collected in the electronic database. Personal identifiers 
collected on the paper consent form will remain in-country. Written informed consent 
will be obtained from all individuals participating in the project. The survey team will 
be trained to not coerce persons to provide consent. The consent form will be explained 
to all participants in their local language. 
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Informed consent/assent 
Introduction 
Greetings, my name is ____________________.I work with the [Ministry of Health or 
Implementing Partner Name]. We are visiting select households in your community 
and other communities in your district to find out about trachoma control. The purpose 
of this survey is to provide information to guide planning of efficient surgical 
campaigns. Understanding where trichiasis cases are located will help ensure that all 
individuals with trichiasis who would like surgery receive surgery. 
Procedures 
First, I would like to talk with you for about 10 minutes and ask a few standard 
questions. I am going to ask you some questions about yourself. 
I will then look at the eyelids of everyone aged 40 year and above in your household to 
see if they have trichiasis. The eyes will be visually examined from the front, and from 
the sides. If there is uncertainty as to whether there may be eyelashes touching the 
eyeball, or where there is uncertainty as to whether there may be evidence of epilation, 
the upper eyelid may need to be gently pushed upwards by exerting very mild pressure 
on the skin. This examination takes less than 10 seconds per eye and is very simple and 
painless. 
If trichiasis is found, questions about previous management will be asked. The eyelid 
will then be everted to allow examination of the tarsal conjunctiva for evidence of 
trachomatous scarring. The examiner will grasp the eyelashes of the upper eyelids 
between thumb and forefinger, pull the eyelid very gently downwards, then flip the 
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outer edge upwards over the point of the index or little finger of the other hand. This 
procedure temporarily relieves the discomfort of eyelashes abrading the eyeball and is 
extremely well tolerated in adults.  
Risks 
Examination of eyes for trichiasis is simple and painless. Everting the eyelid is very 
well tolerated in adults and often relieves discomfort. 
Benefits 
Any persons found with trichiasis will be told where they can receive free eyelid 
surgery. Information from this survey will help the programme in planning ways of 
making sure every person has access to surgery. 
Privacy 
Only the people leading the evaluation will see the results of your tests. Your name will 
not be given to anyone. Your name will not be collected in the evaluation interview – 
only on this consent form. Village test results will be shared with the district health 
officer and other health officials and programmes only for the purpose of following up 
with needed surgery. Information will be kept private as allowed by law. Your name 
will not appear in any report that comes from this evaluation.  
Right not to participate or to stop participating 
You are free to choose to be a part of this evaluation. Even if you agree to be in this 
evaluation, you may stop at any time. If you decide not to be in this evaluation, you and 
your family will not lose any benefits.   
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Whom to contact about the evaluation 
If you have any questions, feel that you have become sick because of this evaluation, 
or want to stop being in the evaluation, you may call ______ of the __________ at 
______________. 
Consent to participate in the evaluation 
By signing below, I agree that I have read this consent form or someone has explained 
it to me. I have had all my questions about the evaluation answered. I agree to 
participate in the evaluation. 
Participant (or parent/guardian) Signature  or thumb 
print 
Name (print) 
Date / Place 
Signature of witness if participant is unable to read 
By signing below, I confirm that this consent form was read in its entirety to the 
participant.  The participants had his/her questions answered and gave his/her thumb 
print freely. 
Witness Signature   
Name (print) 
Date / Place 
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Data collection tools 
Before starting the questionnaire, obtain informed consent from participants. 
No personal identifiers are collected in the electronic database. Personal 
identifiers collected on the paper consent form will remain in-country. 
Location Variables 
Name of District User entered text 
EU ID User entered text 
Cluster ID User entered text 
Recorder ID User entered text 
Name of Recorder  Linked to RECORDER_CODE 
Date and time record started Automated timestamp 
Date and time record completed Automated timestamp 
Capture GPS data—latitude Automated capture of coordinates 
Capture GPS data—longitude Automated capture of coordinates 
Capture GPS data—altitude Automated capture of coordinates 
Capture GPS data—accuracy Automated capture of coordinates 
 
Demographic Variables 
Examination status 1 Yes (with consent) 
2 Absent 
3 Refused 
4 Other 
Age (years) User entered integer (must be over 
39 years) 
Sex 1 Male 
2 Female 
 
Clinical Examination Variables (Right Eye) 
TT presence in right eye (upper lid) 0 Sign absent 
1 Sign present 
2 Not able to grade 
If TT presence in right eye (upper lid) is present 
then 
0 Sign absent 
1 Sign present 
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TS presence in right eye 2 Not able to grade 
TT presence in right eye (lower lid) 0 Sign absent 
1 Sign present 
2 Not able to grade 
If TT presence in right eye (lower lid) is present 
then 
TS presence in right eye 
0 Sign absent 
1 Sign present 
2 Not able to grade 
 
Clinical Examination Variables (Left Eye) 
TT presence in left eye (upper lid) 0 Sign absent 
1 Sign present 
2 Not able to grade 
If TT presence in left eye (upper lid) is present 
then 
TS presence in left eye 
0 Sign absent 
1 Sign present 
2 Not able to grade 
TT presence in left eye (lower lid) 0 Sign absent 
1 Sign present 
2 Not able to grade 
If TT presence in left eye (lower lid) is present 
then 
TS presence in left eye 
0 Sign absent 
1 Sign present 
2 Not able to grade 
 
  
Known to the System Variables (if TT positive in right eye) 
Have you ever been offered surgery by a health worker 
to correct the trichiasis (in-turned eyelashes) in this 
eye? 
1 Yes, a health worker informed 
me and offered me surgery, and 
I had surgery 
2 Yes, a health worker informed 
me and offered me surgery and I 
accepted the offer but I did not 
get surgery 
3 Yes, a health worker informed 
me and offered me surgery, but I 
declined it 
4 No health worker informed me 
and offered me surgery 
Have you ever been offered epilation by a health 
workers to correct the trichiasis (in-turned eyelashes) 
in this eye? 
1 Yes 
2 No 
3 Don’t know 
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Known to the System Variables (if TT positive in Left eye) 
Have you ever been offered surgery by a health worker 
to correct the trichiasis (in-turned eyelashes) in this 
eye? 
1 Yes, a health worker informed 
me and offered me surgery, and 
I had surgery 
2 Yes, a health worker informed 
me and offered me surgery and I 
accepted the offer but I did not 
get surgery 
3 Yes, a health worker informed 
me and offered me surgery, but I 
declined it 
4 No health worker informed me 
and offered me surgery 
Have you ever been offered epilation by a health 
workers to correct the trichiasis (in-turned eyelashes) 
in this eye? 
1 Yes 
2 No 
3 Don’t know 
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 R script for TT survey design validation 
TT Age Group Prevalence *modified from GTMP code written by R. Willis and B. Chu 
clean <- as.data.frame(read.csv("TT dataset.csv")) 
population<- read.csv("population dataset.csv") 
 
clean["tt_old"] <- 0 
clean$tt_old[clean$resident_left_eye_upper_tt=="1"] <- 1 
clean$tt_old[clean$resident_left_eye_loIr_tt=="1"] <- 1 
clean$tt_old[clean$resident_right_eye_upper_tt=="1"] <- 1 
clean$tt_old[clean$resident_right_eye_loIr_tt=="1"] <- 1 
 
clean["tt_true"] <- 0 
clean$tt_true[clean$resident_left_eye_upper_tt=="1" & clean$resident_scarring_left_eye=="1"] <- 
1 
clean$tt_true[clean$resident_left_eye_loIr_tt=="1" & clean$resident_scarring_left_eye=="1"] <- 1 
clean$tt_true[clean$resident_right_eye_upper_tt=="1" & clean$resident_scarring_right_eye=="1"] 
<- 1 
clean$tt_true[clean$resident_right_eye_loIr_tt=="1" & clean$resident_scarring_right_eye=="1"] <- 
1 
clean$tt_true[clean$resident_left_eye_upper_tt=="1" & clean$resident_scarring_left_eye=="2"] <- 
1 
clean$tt_true[clean$resident_left_eye_loIr_tt=="1" & clean$resident_scarring_left_eye=="2"] <- 1 
clean$tt_true[clean$resident_right_eye_upper_tt=="1" & clean$resident_scarring_right_eye=="2"] 
<- 1 
clean$tt_true[clean$resident_right_eye_loIr_tt=="1" & clean$resident_scarring_right_eye=="2"] <- 
1 
 
###Source census-specific code to generate age groups for the analysis 
library(sqldf) 
mydb_tt <- sqldf('SELECT cluster_eu, cluster_cluster, (CASE 
                 WHEN resident_age BETIEN 15 AND 19 THEN "15_19"  
                 WHEN resident_age BETIEN 20 AND 24 THEN "20_24"  
                 WHEN resident_age BETIEN 25 AND 29 THEN "25_29"  
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                 WHEN resident_age BETIEN 30 AND 34 THEN "30_34"  
                 WHEN resident_age BETIEN 35 AND 39 THEN "35_39"  
                 WHEN resident_age BETIEN 40 AND 44 THEN "40_44"  
                 WHEN resident_age BETIEN 45 AND 49 THEN "45_49"  
                 WHEN resident_age BETIEN 50 AND 54 THEN "50_54"  
                 WHEN resident_age BETIEN 55 AND 59 THEN "55_59"  
                 WHEN resident_age BETIEN 60 AND 64 THEN "60_64"  
                 WHEN resident_age BETIEN 65 AND 69 THEN "65_69"  
                 WHEN resident_age BETIEN 70 AND 74 THEN "70_74"  
                 WHEN resident_age BETIEN 75 AND 79 THEN "75_79"  
                 WHEN resident_age >= 80 THEN "80+"  
                 END) AS AGE_GROUP, resident_sex, 
                 COUNT(resident_id) AS RESIDENTS,  
                 SUM(CASE WHEN tt_old=1 THEN 1 ELSE 0 END) AS tt_old, 
                 SUM(CASE WHEN tt_true=1 THEN 1 ELSE 0 END) AS tt_true 
                 FROM clean 
                 WHERE resident_examined = 1 OR (resident_examined = 2 AND 
resident_left_eye_upper_tt is not NULL )AND resident_age >= 15 
                 GROUP BY cluster_eu, cluster_cluster, AGE_GROUP, resident_sex 
                 ORDER BY cluster_eu, cluster_cluster, AGE_GROUP ASC, resident_sex DESC') 
data.frame(mydb_tt) 
 
###Calculating unadjusted and adjusted TT prevalence from exported file 
ttprev_male <- as.data.frame(sqldf('SELECT mydb_tt.cluster_eu, mydb_tt.cluster_cluster, 
mydb_tt.AGE_GROUP, mydb_tt.resident_sex, mydb_tt.RESIDENTS, mydb_tt.tt_old, 
mydb_tt.tt_true, population.percent_age_male AS age_Iight 
                                   FROM mydb_tt 
                                   LEFT JOIN population 
                                   ON mydb_tt.AGE_GROUP = population.age_group 
                                   WHERE mydb_tt.resident_sex = "1"')) 
ttprev_female <- as.data.frame(sqldf('SELECT mydb_tt.cluster_eu, mydb_tt.cluster_cluster, 
mydb_tt.AGE_GROUP, mydb_tt.resident_sex, mydb_tt.RESIDENTS, mydb_tt.tt_old, 
mydb_tt.tt_true, population.percent_age_female AS age_Iight 
                                     FROM mydb_tt 
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                                     LEFT JOIN population 
                                     ON mydb_tt.AGE_GROUP = population.age_group 
                                     WHERE mydb_tt.resident_sex = "2"')) 
ttprev <- as.data.frame(rbind(ttprev_male, ttprev_female)) # Append the dataframes 
 
# This creates the new column named "prev_unadj" filled with zeros & then does the unadjusted 
prevalence calculation for that group 
ttprev["prev_unadj"] <- 0;  
ttprev$prev_unadj <- (ttprev$tt_true / ttprev$RESIDENTS) 
 
#Now collapse on cluster level and get sum of Iighted prevalence aggregated by age group 
ttprev_age_group <- aggregate(prev_unadj ~ AGE_GROUP + cluster_eu, data = ttprev, sum) 
data.frame(ttprev_age_group) 
 
 
 
TT Cluster Prevalence *modified from GTMP code written by R. Willis and B. Chu 
clean <- as.data.frame(read.csv("TT dataset.csv")) 
population<- read.csv("population dataset.csv") 
 
clean["tt_old"] <- 0 
clean$tt_old[clean$resident_left_eye_upper_tt=="1"] <- 1 
clean$tt_old[clean$resident_left_eye_loIr_tt=="1"] <- 1 
clean$tt_old[clean$resident_right_eye_upper_tt=="1"] <- 1 
clean$tt_old[clean$resident_right_eye_loIr_tt=="1"] <- 1 
 
clean["tt_true"] <- 0 
clean$tt_true[clean$resident_left_eye_upper_tt=="1" & clean$resident_scarring_left_eye=="1"] <- 
1 
clean$tt_true[clean$resident_left_eye_loIr_tt=="1" & clean$resident_scarring_left_eye=="1"] <- 1 
clean$tt_true[clean$resident_right_eye_upper_tt=="1" & clean$resident_scarring_right_eye=="1"] 
<- 1 
 
 
225 
 
clean$tt_true[clean$resident_right_eye_loIr_tt=="1" & clean$resident_scarring_right_eye=="1"] <- 
1 
clean$tt_true[clean$resident_left_eye_upper_tt=="1" & clean$resident_scarring_left_eye=="2"] <- 
1 
clean$tt_true[clean$resident_left_eye_loIr_tt=="1" & clean$resident_scarring_left_eye=="2"] <- 1 
clean$tt_true[clean$resident_right_eye_upper_tt=="1" & clean$resident_scarring_right_eye=="2"] 
<- 1 
clean$tt_true[clean$resident_right_eye_loIr_tt=="1" & clean$resident_scarring_right_eye=="2"] <- 
1 
 
###Source census-specific code to generate age groups for the analysis 
library(sqldf) 
 
mydb_tt <- sqldf('SELECT cluster_eu, cluster_cluster, (CASE 
                 WHEN resident_age BETIEN 15 AND 19 THEN "15_19"  
                 WHEN resident_age BETIEN 20 AND 24 THEN "20_24"  
                 WHEN resident_age BETIEN 25 AND 29 THEN "25_29"  
                 WHEN resident_age BETIEN 30 AND 34 THEN "30_34"  
                 WHEN resident_age BETIEN 35 AND 39 THEN "35_39"  
                 WHEN resident_age BETIEN 40 AND 44 THEN "40_44"  
                 WHEN resident_age BETIEN 45 AND 49 THEN "45_49"  
                 WHEN resident_age BETIEN 50 AND 54 THEN "50_54"  
                 WHEN resident_age BETIEN 55 AND 59 THEN "55_59"  
                 WHEN resident_age BETIEN 60 AND 64 THEN "60_64"  
                 WHEN resident_age BETIEN 65 AND 69 THEN "65_69"  
                 WHEN resident_age BETIEN 70 AND 74 THEN "70_74"  
                 WHEN resident_age BETIEN 75 AND 79 THEN "75_79"  
                 WHEN resident_age >= 80 THEN "80+"  
                 END) AS AGE_GROUP, resident_sex, 
                 COUNT(resident_id) AS RESIDENTS,  
                 SUM(CASE WHEN tt_old=1 THEN 1 ELSE 0 END) AS tt_old, 
                 SUM(CASE WHEN tt_true=1 THEN 1 ELSE 0 END) AS tt_true 
                 FROM clean 
 
 
226 
 
                 WHERE resident_examined = 1 OR (resident_examined = 2 AND 
resident_left_eye_upper_tt is not NULL )AND resident_age >= 15 
                 GROUP BY cluster_eu, cluster_cluster, AGE_GROUP, resident_sex 
                 ORDER BY cluster_eu, cluster_cluster, AGE_GROUP ASC, resident_sex DESC') 
data.frame(mydb_tt) 
###Calculating unadjusted and adjusted TT prevalence from exported file 
 
ttprev_male <- as.data.frame(sqldf('SELECT mydb_tt.cluster_eu, mydb_tt.cluster_cluster, 
mydb_tt.AGE_GROUP, mydb_tt.resident_sex, mydb_tt.RESIDENTS, mydb_tt.tt_old, 
mydb_tt.tt_true, population.percent_age_male AS age_Iight 
                                   FROM mydb_tt 
                                   LEFT JOIN population 
                                   ON mydb_tt.AGE_GROUP = population.age_group 
                                   WHERE mydb_tt.resident_sex = "1"')) 
 
ttprev_female <- as.data.frame(sqldf('SELECT mydb_tt.cluster_eu, mydb_tt.cluster_cluster, 
mydb_tt.AGE_GROUP, mydb_tt.resident_sex, mydb_tt.RESIDENTS, mydb_tt.tt_old, 
mydb_tt.tt_true, population.percent_age_female AS age_Iight 
                                     FROM mydb_tt 
                                     LEFT JOIN population 
                                     ON mydb_tt.AGE_GROUP = population.age_group 
                                     WHERE mydb_tt.resident_sex = "2"')) 
 
ttprev <- as.data.frame(rbind(ttprev_male, ttprev_female)) # Append the dataframes 
 
# This creates the new column named "prev_unadj" filled with zeros & then does the unadjusted 
prevalence calculation for that group 
ttprev["prev_unadj"] <- 0;  
ttprev$prev_unadj <- (ttprev$tt_true / ttprev$RESIDENTS) 
 
#Generate unadjusted EU-level prevalence for comparison purposes 
ttprev_unadjusted_cluster <- aggregate(cbind(RESIDENTS, tt_true) ~ cluster_eu+cluster_cluster, 
data=ttprev, sum) 
ttprev_unadjusted_cluster$cluster_prev_unadj <- 
(ttprev_unadjusted_cluster$tt_true/ttprev_unadjusted_cluster$RESIDENTS) 
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ttprev_unadjusted <- aggregate(cluster_prev_unadj ~ cluster_eu, data=ttprev_unadjusted_cluster, 
mean) 
colnames(ttprev_unadjusted)[colnames(ttprev_unadjusted)=="cluster_prev_unadj"] <- 
"ttprev_unadj" 
 
# This creates the new column named "adj_tt" filled with zeros & then does the Iighting 
ttprev["adj_tt"] <- 0;  
ttprev$adj_tt <- (ttprev$prev_unadj * ttprev$age_Iight) 
 
#Now collapse on cluster level and get sum of Iighted prevalence 
ttprev_cluster <- aggregate(adj_tt ~ cluster_eu + cluster_cluster, data = ttprev, sum) 
data.frame(ttprev_cluster) 
 
#Scatterplot 
plot(ttprev_cluster$cluster_cluster, ttprev_cluster$adj_tt, xlab = "cluster ID", ylab = "TT 
prevalence") 
 
 
TT EU level prevalence *modified from GTMP code written by R. Willis and B. Chu 
clean <- as.data.frame(read.csv("TT dataset.csv")) 
population<- read.csv("population dataset.csv") 
 
clean["tt_old"] <- 0 
clean$tt_old[clean$resident_left_eye_upper_tt=="1"] <- 1 
clean$tt_old[clean$resident_left_eye_loIr_tt=="1"] <- 1 
clean$tt_old[clean$resident_right_eye_upper_tt=="1"] <- 1 
clean$tt_old[clean$resident_right_eye_loIr_tt=="1"] <- 1 
 
clean["tt_true"] <- 0 
clean$tt_true[clean$resident_left_eye_upper_tt=="1" & clean$resident_scarring_left_eye=="1"] <- 
1 
clean$tt_true[clean$resident_left_eye_loIr_tt=="1" & clean$resident_scarring_left_eye=="1"] <- 1 
clean$tt_true[clean$resident_right_eye_upper_tt=="1" & clean$resident_scarring_right_eye=="1"] 
<- 1 
 
 
228 
 
clean$tt_true[clean$resident_right_eye_loIr_tt=="1" & clean$resident_scarring_right_eye=="1"] <- 
1 
clean$tt_true[clean$resident_left_eye_upper_tt=="1" & clean$resident_scarring_left_eye=="2"] <- 
1 
clean$tt_true[clean$resident_left_eye_loIr_tt=="1" & clean$resident_scarring_left_eye=="2"] <- 1 
clean$tt_true[clean$resident_right_eye_upper_tt=="1" & clean$resident_scarring_right_eye=="2"] 
<- 1 
clean$tt_true[clean$resident_right_eye_loIr_tt=="1" & clean$resident_scarring_right_eye=="2"] <- 
1 
###Source census-specific code to generate age groups for the analysis 
library(sqldf) 
 
mydb_tt <- sqldf('SELECT cluster_eu, cluster_cluster, (CASE 
                 WHEN resident_age BETIEN 15 AND 19 THEN "15_19"  
                 WHEN resident_age BETIEN 20 AND 24 THEN "20_24"  
                 WHEN resident_age BETIEN 25 AND 29 THEN "25_29"  
                 WHEN resident_age BETIEN 30 AND 34 THEN "30_34"  
                 WHEN resident_age BETIEN 35 AND 39 THEN "35_39"  
                 WHEN resident_age BETIEN 40 AND 44 THEN "40_44"  
                 WHEN resident_age BETIEN 45 AND 49 THEN "45_49"  
                 WHEN resident_age BETIEN 50 AND 54 THEN "50_54"  
                 WHEN resident_age BETIEN 55 AND 59 THEN "55_59"  
                 WHEN resident_age BETIEN 60 AND 64 THEN "60_64"  
                 WHEN resident_age BETIEN 65 AND 69 THEN "65_69"  
                 WHEN resident_age BETIEN 70 AND 74 THEN "70_74"  
                 WHEN resident_age BETIEN 75 AND 79 THEN "75_79"  
                 WHEN resident_age >= 80 THEN "80+"  
                 END) AS AGE_GROUP, resident_sex, 
                 COUNT(resident_id) AS RESIDENTS,  
                 SUM(CASE WHEN tt_old=1 THEN 1 ELSE 0 END) AS tt_old, 
                 SUM(CASE WHEN tt_true=1 THEN 1 ELSE 0 END) AS tt_true 
                 FROM clean 
                 WHERE resident_examined = 1 OR (resident_examined = 2 AND 
resident_left_eye_upper_tt is not NULL )AND resident_age >= 15 
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                 GROUP BY cluster_eu, cluster_cluster, AGE_GROUP, resident_sex 
                 ORDER BY cluster_eu, cluster_cluster, AGE_GROUP ASC, resident_sex DESC') 
data.frame(mydb_tt) 
###Calculating unadjusted and adjusted TT prevalence from exported file 
 
ttprev_male <- as.data.frame(sqldf('SELECT mydb_tt.cluster_eu, mydb_tt.cluster_cluster, 
mydb_tt.AGE_GROUP, mydb_tt.resident_sex, mydb_tt.RESIDENTS, mydb_tt.tt_old, 
mydb_tt.tt_true, population.percent_age_male AS age_Iight 
                                   FROM mydb_tt 
                                   LEFT JOIN population 
                                   ON mydb_tt.AGE_GROUP = population.age_group 
                                   WHERE mydb_tt.resident_sex = "1"')) 
 
ttprev_female <- as.data.frame(sqldf('SELECT mydb_tt.cluster_eu, mydb_tt.cluster_cluster, 
mydb_tt.AGE_GROUP, mydb_tt.resident_sex, mydb_tt.RESIDENTS, mydb_tt.tt_old, 
mydb_tt.tt_true, population.percent_age_female AS age_Iight 
                                     FROM mydb_tt 
                                     LEFT JOIN population 
                                     ON mydb_tt.AGE_GROUP = population.age_group 
                                     WHERE mydb_tt.resident_sex = "2"')) 
 
ttprev <- as.data.frame(rbind(ttprev_male, ttprev_female)) # Append the dataframes 
 
# This creates the new column named "prev_unadj" filled with zeros & then does the unadjusted 
prevalence calculation for that group 
ttprev["prev_unadj"] <- 0;  
ttprev$prev_unadj <- (ttprev$tt_true / ttprev$RESIDENTS) 
 
#Generate unadjusted EU-level prevalence for comparison purposes 
ttprev_unadjusted_cluster <- aggregate(cbind(RESIDENTS, tt_true) ~ cluster_eu+cluster_cluster, 
data=ttprev, sum) 
ttprev_unadjusted_cluster$cluster_prev_unadj <- 
(ttprev_unadjusted_cluster$tt_true/ttprev_unadjusted_cluster$RESIDENTS) 
ttprev_unadjusted <- aggregate(cluster_prev_unadj ~ cluster_eu, data=ttprev_unadjusted_cluster, 
mean) 
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colnames(ttprev_unadjusted)[colnames(ttprev_unadjusted)=="cluster_prev_unadj"] <- 
"ttprev_unadj" 
 
# This creates the new column named "adj_tt" filled with zeros & then does the Iighting 
ttprev["adj_tt"] <- 0;  
ttprev$adj_tt <- (ttprev$prev_unadj * ttprev$age_Iight) 
 
#Now collapse on cluster level and get sum of Iighted prevalence for histrograms comparing the 15 
and 40 age groups turn on appropriate cluster name 
ttprev_cluster <- aggregate(adj_tt ~ cluster_eu + cluster_cluster, data = ttprev, sum) 
ttprev_cluster15 <- aggregate(adj_tt ~ cluster_eu + cluster_cluster, data = ttprev, sum) 
#ttprev_cluster40 <- aggregate(adj_tt ~ cluster_eu + cluster_cluster, data = ttprev, sum) 
 
#Mean of adjusted cluster prevalences to get EU prevalence 
ttprev_eu <- aggregate(adj_tt ~ cluster_eu, data = ttprev_cluster, mean) 
data.frame(ttprev_eu) 
 
TT Bootstrap comparing 60 and 30 clusters *modified from GTMP code written by R. Willis and 
B. Chu 
 
#Load, transform data 
dataset <- ttprev_cluster 
str(dataset) 
dataset$cluster_eu <- as.factor(dataset$cluster_eu) 
dataset$cluster_cluster <- as.factor(dataset$cluster_cluster) 
dataset$cluster_prev <- dataset$adj_tt 
 
#Boot statistic function = mean of XX random clusters 
clustermean <- function(df, i) { 
  num_clusters <- 60 
  r <- round(runif(num_clusters, 1, nrow(df))) #nrow(df) allows the analysis to divide by the correct 
# clusters 
  df2 <- numeric() 
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  for (i in 1:num_clusters) { 
    df2[i] <- df[r[i],]$cluster_prev 
  } 
  return(mean(df2))   
} 
 
#create empty data frame for results 
bootResult_tt60 <- data.frame(cluster_eu=character(), bootmean=numeric(), se=numeric(), 
ci95_low=numeric(), ci95_high=numeric(), stringsAsFactors=FALSE) 
 
#Bootstrap function, looped over each EU 
library(boot) 
num_reps <- 10000  
for (i in 1:nlevels(dataset$cluster_eu)) { 
  data2 <- subset(dataset, cluster_eu==levels(cluster_eu)[i]) 
  b <- boot(data2, clustermean, num_reps) 
  m <- mean(b$t) 
  se <- sd(b$t) 
   
  #calculate 2.5/97.5 percentiles as Confidence Interval 
  q <- quantile(b$t, c(0.025, 0.975)) 
  ci_loIr60 <- q[1] 
  ci_upper60 <- q[2] 
   
   #write result to data frame 
  eu_temp <- as.character(data2$cluster_eu[1]) 
  bootResult_tt60[i,] <- c(eu_temp, m, se, ci_loIr, ci_upper) 
       
} 
 
#Boot statistic function = mean of XX random clusters 
clustermean <- function(df, i) { 
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  num_clusters <- 30 
  r <- round(runif(num_clusters, 1, nrow(df))) #nrow(df) allows the analysis to divide by the correct 
# clusters 
  df2 <- numeric() 
  for (i in 1:num_clusters) { 
    df2[i] <- df[r[i],]$cluster_prev 
  } 
  return(mean(df2))   
} 
 
#create empty data frame for results 
bootResult_tt30 <- data.frame(cluster_eu=character(), bootmean=numeric(), se=numeric(), 
ci95_low=numeric(), ci95_high=numeric(), stringsAsFactors=FALSE) 
 
#Bootstrap function, looped over each EU 
library(boot) 
num_reps <- 10000  
for (i in 1:nlevels(dataset$cluster_eu)) { 
  data2 <- subset(dataset, cluster_eu==levels(cluster_eu)[i]) 
  b2 <- boot(data2, clustermean, num_reps) 
  m <- mean(b2$t) 
  se <- sd(b2$t) 
   
  #calculate 2.5/97.5 percentiles as Confidence Interval 
  q <- quantile(b$t, c(0.025, 0.975)) 
  ci_loIr30 <- q[1] 
  ci_upper30 <- q[2] 
   
  #write result to data frame 
  eu_temp2 <- as.character(data2$cluster_eu[1]) 
  bootResult_tt30[i,] <- c(eu_temp2, m, se, ci_loIr, ci_upper) 
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} 
data.frame(bootResult_tt30) 
 
#histogram of mean bootstrap results with CI 
hist(b$t,xlab = "TT prevalence", breaks=50, main="Budaka 40+",col = 'blue') 
hist(b2$t, breaks=50,main="overlap",border = 'red',add=T) 
abline(v=ci_loIr60, lty="solid", col="blue" ) 
abline(v=ci_upper60, lty="solid", col="blue" ) 
abline(v=ci_loIr30, lty="dashed", col="red" ) 
abline(v=ci_upper30, lty="dashed", col="red" ) 
legend("topright",c("60 clusters", "30 clusters"),fill=c("blue","red")) 
box() 
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2 stage simulation 
###############40pls simulation################################## 
 
require(sampling) 
###pull dataset into R 
population<- read.csv("population dataset.csv") ##update!! 
df <- read.csv ("TT dataset 40pls.csv")  ## update with “true” dataset from EU prevalence code!! 
 
 
###create a function 
library(data.table) 
simulate <- function(tt_prev) { 
 
###create cluster list 
cluster <-1:60 
 
###create cluster subset 
selected_clusters <- c(sample(cluster,size = 30, replace = FALSE)) 
 
###using selected clusters create subset of households 
cluster_subset <- subset(df,df$cluster_cluster %in% selected_clusters) 
cluster_subset <- cluster_subset[order(cluster_subset$cluster_cluster,cluster_subset$household_id),] 
 
###create list of unique household_ids from the selected clusters 
list<- subset(cluster_subset,select = c(cluster_cluster,household_id)) 
list<- unique(list)  
order(list$cluster_cluster,list$household_id) 
###randomly select the households within the selected clusters 
library(plyr) 
count<-  
household_subset <-ddply(list,.(cluster_cluster),function(x) x[sample(nrow(x),20),]) 
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###subset from the original dataset using the selected households and clusters 
clean <- subset(df,df$household_id %in% household_subset$household_id) 
 
###calculate prevalence 
 
###update dataset with 5 year age brackets 
library(sqldf) 
mydb_tt <- sqldf('SELECT cluster_eu, cluster_cluster, (CASE 
                 WHEN resident_age BETIEN 40 AND 44 THEN "40_44"  
                 WHEN resident_age BETIEN 45 AND 49 THEN "45_49"  
                 WHEN resident_age BETIEN 50 AND 54 THEN "50_54"  
                 WHEN resident_age BETIEN 55 AND 59 THEN "55_59"  
                 WHEN resident_age BETIEN 60 AND 64 THEN "60_64"  
                 WHEN resident_age BETIEN 65 AND 69 THEN "65_69"  
                 WHEN resident_age BETIEN 70 AND 74 THEN "70_74"  
                 WHEN resident_age BETIEN 75 AND 79 THEN "75_79"  
                 WHEN resident_age >= 80 THEN "80+"  
                 END) AS AGE_GROUP, resident_sex, 
                 COUNT(resident_id) AS RESIDENTS,  
                 SUM(CASE WHEN tt_old=1 THEN 1 ELSE 0 END) AS tt_old, 
                 SUM(CASE WHEN tt_true=1 THEN 1 ELSE 0 END) AS tt_true 
                 FROM clean 
                 WHERE resident_examined = 1 OR (resident_examined = 2 AND 
resident_left_eye_upper_tt is not NULL )AND resident_age >= 15 
                 GROUP BY cluster_eu, cluster_cluster, AGE_GROUP, resident_sex 
                 ORDER BY cluster_eu, cluster_cluster, AGE_GROUP ASC, resident_sex DESC') 
 
###Calculating unadjusted and adjusted TT prevalence from clean dataset 
ttprev_male <- as.data.frame(sqldf('SELECT mydb_tt.cluster_eu, mydb_tt.cluster_cluster, 
mydb_tt.AGE_GROUP, mydb_tt.resident_sex, mydb_tt.RESIDENTS, mydb_tt.tt_old, 
mydb_tt.tt_true, population.percent_age_male AS age_Iight 
                                   FROM mydb_tt 
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                                   LEFT JOIN population 
                                   ON mydb_tt.AGE_GROUP = population.age_group 
                                   WHERE mydb_tt.resident_sex = "1"')) 
 
ttprev_female <- as.data.frame(sqldf('SELECT mydb_tt.cluster_eu, mydb_tt.cluster_cluster, 
mydb_tt.AGE_GROUP, mydb_tt.resident_sex, mydb_tt.RESIDENTS, mydb_tt.tt_old, 
mydb_tt.tt_true, population.percent_age_female AS age_Iight 
                                     FROM mydb_tt 
                                     LEFT JOIN population 
                                     ON mydb_tt.AGE_GROUP = population.age_group 
                                     WHERE mydb_tt.resident_sex = "2"')) 
 
ttprev <- as.data.frame(rbind(ttprev_male, ttprev_female)) # Append the dataframes 
 
 
### This creates the new column named "prev_unadj" filled with zeros & then does the unadjusted 
prevalence calculation for that group 
ttprev["prev_unadj"] <- 0;  
ttprev$prev_unadj <- (ttprev$tt_true / ttprev$RESIDENTS) 
 
###Generate unadjusted EU-level prevalence for comparison purposes 
#ttprev_unadjusted_cluster <- aggregate(cbind(RESIDENTS, tt_true) ~ cluster_eu+cluster_cluster, 
data=ttprev, sum) 
#ttprev_unadjusted_cluster$cluster_prev_unadj <- 
(ttprev_unadjusted_cluster$tt_true/ttprev_unadjusted_cluster$RESIDENTS) 
#ttprev_unadjusted <- aggregate(cluster_prev_unadj ~ cluster_eu, data=ttprev_unadjusted_cluster, 
mean) 
#colnames(ttprev_unadjusted)[colnames(ttprev_unadjusted)=="cluster_prev_unadj"] <- 
"ttprev_unadj" 
 
### This creates the new column named "adj_tt" filled with zeros & then does the Iighting 
ttprev["adj_tt"] <- 0;  
ttprev$adj_tt <- (ttprev$prev_unadj * ttprev$age_Iight) 
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###Now collapse on cluster level and get sum of Iighted prevalence for histrograms comparing the 
15 and 40 age groups turn on appropriate cluster name 
ttprev_cluster <- aggregate(adj_tt ~ cluster_eu + cluster_cluster, data = ttprev, sum) 
#ttprev_cluster15 <- aggregate(adj_tt ~ cluster_eu + cluster_cluster, data = ttprev, sum) 
#ttprev_cluster40 <- aggregate(adj_tt ~ cluster_eu + cluster_cluster, data = ttprev, sum) 
 
###Mean of adjusted cluster prevalences to get EU prevalence 
ttprev_eu <- aggregate(adj_tt ~ cluster_eu, data = ttprev_cluster, mean) 
#data.frame(ttprev_eu) 
 
} 
 
r<- do.call(rbind,replicate(10000,simulate(),simplify = FALSE)) 
 
m40 <- mean(r$adj_tt) 
se40 <- sd(r$adj_tt) 
 
#calculate 2.5/97.5 percentiles as Confidence Interval 
q <- quantile(r$adj_tt, c(0.025, 0.975)) 
ci_loIr40 <- q[1] 
ci_upper40 <- q[2] 
 
 
#write result to data frame 
eu_temp2 <- c(m40,se40,ci_loIr40,ci_upper40) 
data.frame(eu_temp2) 
 
#histogram of meresults with CI 
hist(r$adj_tt,xlab = "TT prevalence", breaks=50, main="Monduli 40+",col = 'blue') 
box() 
 
##################################15pls##################################  
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require(sampling) 
###pull dataset into R 
population<- read.csv("population dataset.csv") ##update!! 
df <- read.csv ("TT dataset 15pls.csv")  ## update with “true” dataset from EU prevalence code!! 
 
###create a function 
library(data.table) 
simulate <- function(tt_prev) { 
   
   
  ###create cluster list 
  cluster <-1:60 
   
  ###create cluster subset 
  selected_clusters <- c(sample(cluster,size = 30, replace = FALSE)) 
   
  ###using selected clusters create subset of households 
  cluster_subset <- subset(df,df$cluster_cluster %in% selected_clusters) 
  cluster_subset <- 
cluster_subset[order(cluster_subset$cluster_cluster,cluster_subset$household_id),] 
   
  ###create list of unique household_ids from the selected clusters 
  list<- subset(cluster_subset,select = c(cluster_cluster,household_id)) 
  list<- unique(list)  
  order(list$cluster_cluster,list$household_id) 
   
   
  ###randomly select the households within the selected clusters 
  library(plyr) 
  household_subset <-ddply(list,.(cluster_cluster),function(x) x[sample(nrow(x),20),]) 
   
  ###subset from the original dataset using the selected households and clusters 
 
 
239 
 
  clean <- subset(df,df$household_id %in% household_subset$household_id) 
   
  ###calculate prevalence 
 
  ###update dataset with 5 year age brackets 
  library(sqldf) 
  mydb_tt <- sqldf('SELECT cluster_eu, cluster_cluster, (CASE 
                 WHEN resident_age BETIEN 15 AND 19 THEN "15_19"  
                   WHEN resident_age BETIEN 20 AND 24 THEN "20_24"  
                   WHEN resident_age BETIEN 25 AND 29 THEN "25_29"  
                   WHEN resident_age BETIEN 30 AND 34 THEN "30_34"  
                   WHEN resident_age BETIEN 35 AND 39 THEN "35_39"  
                   WHEN resident_age BETIEN 40 AND 44 THEN "40_44"  
                   WHEN resident_age BETIEN 45 AND 49 THEN "45_49"  
                   WHEN resident_age BETIEN 50 AND 54 THEN "50_54"  
                   WHEN resident_age BETIEN 55 AND 59 THEN "55_59"  
                   WHEN resident_age BETIEN 60 AND 64 THEN "60_64"  
                   WHEN resident_age BETIEN 65 AND 69 THEN "65_69"  
                   WHEN resident_age BETIEN 70 AND 74 THEN "70_74"  
                   WHEN resident_age BETIEN 75 AND 79 THEN "75_79"  
                   WHEN resident_age >= 80 THEN "80+"  
                   END) AS AGE_GROUP, resident_sex, 
                   COUNT(resident_id) AS RESIDENTS,  
                   SUM(CASE WHEN tt_old=1 THEN 1 ELSE 0 END) AS tt_old, 
                   SUM(CASE WHEN tt_true=1 THEN 1 ELSE 0 END) AS tt_true 
                   FROM clean 
                   WHERE resident_examined = 1 OR (resident_examined = 2 AND 
resident_left_eye_upper_tt is not NULL )AND resident_age >= 15 
                   GROUP BY cluster_eu, cluster_cluster, AGE_GROUP, resident_sex 
                   ORDER BY cluster_eu, cluster_cluster, AGE_GROUP ASC, resident_sex DESC') 
   
  ###Calculating unadjusted and adjusted TT prevalence from clean dataset 
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  ttprev_male <- as.data.frame(sqldf('SELECT mydb_tt.cluster_eu, mydb_tt.cluster_cluster, 
mydb_tt.AGE_GROUP, mydb_tt.resident_sex, mydb_tt.RESIDENTS, mydb_tt.tt_old, 
mydb_tt.tt_true, population.percent_age_male AS age_Iight 
                                     FROM mydb_tt 
                                     LEFT JOIN population 
                                     ON mydb_tt.AGE_GROUP = population.age_group 
                                     WHERE mydb_tt.resident_sex = "1"')) 
   
  ttprev_female <- as.data.frame(sqldf('SELECT mydb_tt.cluster_eu, mydb_tt.cluster_cluster, 
mydb_tt.AGE_GROUP, mydb_tt.resident_sex, mydb_tt.RESIDENTS, mydb_tt.tt_old, 
mydb_tt.tt_true, population.percent_age_female AS age_Iight 
                                       FROM mydb_tt 
                                       LEFT JOIN population 
                                       ON mydb_tt.AGE_GROUP = population.age_group 
                                       WHERE mydb_tt.resident_sex = "2"')) 
   
  ttprev <- as.data.frame(rbind(ttprev_male, ttprev_female)) # Append the dataframes 
   
   
  ### This creates the new column named "prev_unadj" filled with zeros & then does the unadjusted 
prevalence calculation for that group 
  ttprev["prev_unadj"] <- 0;  
  ttprev$prev_unadj <- (ttprev$tt_true / ttprev$RESIDENTS) 
   
  ###Generate unadjusted EU-level prevalence for comparison purposes 
  #ttprev_unadjusted_cluster <- aggregate(cbind(RESIDENTS, tt_true) ~ cluster_eu+cluster_cluster, 
data=ttprev, sum) 
  #ttprev_unadjusted_cluster$cluster_prev_unadj <- 
(ttprev_unadjusted_cluster$tt_true/ttprev_unadjusted_cluster$RESIDENTS) 
  #ttprev_unadjusted <- aggregate(cluster_prev_unadj ~ cluster_eu, data=ttprev_unadjusted_cluster, 
mean) 
  #colnames(ttprev_unadjusted)[colnames(ttprev_unadjusted)=="cluster_prev_unadj"] <- 
"ttprev_unadj" 
   
  ### This creates the new column named "adj_tt" filled with zeros & then does the Iighting 
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  ttprev["adj_tt"] <- 0;  
  ttprev$adj_tt <- (ttprev$prev_unadj * ttprev$age_Iight) 
   
  ###Now collapse on cluster level and get sum of Iighted prevalence for histrograms comparing the 
15 and 40 age groups turn on appropriate cluster name 
  ttprev_cluster <- aggregate(adj_tt ~ cluster_eu + cluster_cluster, data = ttprev, sum) 
  #ttprev_cluster15 <- aggregate(adj_tt ~ cluster_eu + cluster_cluster, data = ttprev, sum) 
  #ttprev_cluster40 <- aggregate(adj_tt ~ cluster_eu + cluster_cluster, data = ttprev, sum) 
   
 
  ###Mean of adjusted cluster prevalences to get EU prevalence 
  ttprev_eu <- aggregate(adj_tt ~ cluster_eu, data = ttprev_cluster, mean) 
  #data.frame(ttprev_eu) 
   
} 
 
r2<- do.call(rbind,replicate(10000,simulate(),simplify = FALSE)) 
 
 
m <- mean(r2$adj_tt) 
se <- sd(r2$adj_tt) 
 
#calculate 2.5/97.5 percentiles as Confidence Interval 
q <- quantile(r2$adj_tt, c(0.025, 0.975)) 
ci_loIr <- q[1] 
ci_upper <- q[2] 
 
 
#write result to data frame 
eu_temp <- c(m,se,ci_loIr,ci_upper) 
data.frame(eu_temp) 
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#histogram of meresults with CI 
hist(r2$adj_tt,xlab = "TT prevalence", breaks=50, main="Monduli 40+",col = 'blue') 
box() 
 
#histogram of mean bootstrap results with CI 
hist(r2$adj_tt, xlab="TT prevalence",breaks=50, xlim = c(0.001,0.05), ylim = c(0,900), 
main="Monduli 2 stage comparing results from 15+ and 40+ with 30 clusters",col = 'blue') 
hist(r$adj_tt, breaks=50,main="overlap",border = 'red',add=T) 
legend("topright",c("15 and older", "40 and older"),fill=c("blue","red")) 
box() 
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 GTMP WASH indicators 
Responses are classified as improved are marked ■. 
S1) Where do you and other adults in the 
household usually defecate? 
 
number of households reporting that adults 
living in the household defecate in either a 
shared public latrine or a private latrine / 
number of households enrolled in the 
survey 
1) Shared or public latrine  
2) Private latrine  
3) No structure, outside near the house  
4) No structure, in the bush or field  
9) Other  
S2) Improved latrine: What kind of toilet 
facility do the adults in the household use? 
Observed. 
 
number of households where an improved 
latrine is observed / number of households 
enrolled in the survey 
1)      Flush/pour flush to piped sewer system  
2)      Flush/pour flush to septic tank  
3)      Flush/pour flush to pit latrine  
4)      Flush/pour flush to open drains  
5)      Flush/pour flush to unknown place  
6)      Ventilated improved pit latrine (VIP)  
7)      Pit latrine with slab  
8)      Pit latrine without slab/open pit  
9)      Composting toilet  
10)   Bucket  
11)   Hanging toilet/hanging latrine  
12)   No facilities or bush or field  
99)   Other  
H3) Improved Water source: In the dry 
season, what is the main source of water 
used by your household for washing faces? 
 
number of households reporting to access 
improved water sources / number of 
households enrolled in the survey 
1)      Piped water into dwelling  
2)      Piped water into yard/pot  
3)      Public tap/standpipe  
4)      Tubewell/borehole  
5)      Protected dug well  
6)      Unprotected dug well  
7)      Protected spring  
8)      Unprotected spring  
9)      Rainwater collection  
10)   Water vendor  
11)   Surface water (e.g. river, dam, lake, canal)  
99)   Other  
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H4) Wash near: Washing water: If 
you collected water there to bring 
back to the house, how long does it 
take to go there, get water, and come 
back? 
 
number of households reporting 
access to improved water sources 
and those water sources are on the 
premises / number of households 
enrolled in the survey 
0)      All face washing done at the water 
source 
 
1)      Water source in the yard  
2)      Less than 30 minutes   
3)      Between 30 minutes and 1 hour   
4)      More than 1 hour   
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 Raster images of environmental risk factors 
5 kilometre gridded climate raster maps 
Annual mean temperature Annual mean precipitation 
 
 
Aridity index PET 
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5 kilometre gridded Euclidean distance to water raster map 
Euclidian distance to water 
 
5 kilometre gridded soil composition sand fraction raster map 
Sand/soil fraction 
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5 kilometre gridded remoteness raster map 
Stable night light (1997) Accessibility 
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 R script TT spatial models 
rm(list=ls()) 
library(PrevMap) 
library(rgdal) 
library(lme4) 
library(geoR) 
 
 
df <- as.data.frame(read.csv("cluster_full.csv")) #cluster level data set 
 
#subset by country 
data<- subset(df, Country == "BEN") #change this depending on what country you are interested in 
 
##cluster level random effect 
#To measure effect size run the model with cluster level random effect first with no covariates, then 
with TF, then with all 
 
REnull <- glmer(cbind(tt_pos,tt_examined-tt_pos) ~ (1 | cluster_id), family = binomial("logit"), 
data = data, control=glmerControl(optimizer="bobyqa")) 
summary(REnull) 
 
RETF <- glmer(cbind(tt_pos,tt_examined-tt_pos) ~ tf_prev + (1 | cluster_id), family = 
binomial("logit"), data = data, control=glmerControl(optimizer="bobyqa")) 
summary(RETF) 
 
REall <- glmer(cbind(tt_pos,tt_examined-tt_pos) ~ tf_prev + S1 + S2 + imp_un_water + 
water_yard  +  ai + sand_5cm_s + stlight97_s + (1 | cluster_id), family = binomial("logit"), data = 
data, control=glmerControl(optimizer="bobyqa")) 
summary(REall) 
 
#only include significant indicators identified in the REall model  
REsig <- glmer(cbind(tt_pos,tt_examined-tt_pos) ~ tf_prev + sand_5cm_s + (1 | cluster_id), family 
= binomial("logit"), data = data, control=glmerControl(optimizer="bobyqa"))  
summary(REsig) 
 
##extract the residuals of random effect 
 
#conversion of the coordinates from LONG-LAT into Web Mercator  
#the distance between locations is now measured in kilometers 
coords.ll <- SpatialPoints(data[,c("LNG","LAT")],CRS("+init=epsg:4236")) 
coords.web <- SpatialPoints(coords.ll,CRS("+init=epsg:3857")) 
data$web_x <- coordinates(coords.web)[,1]/1000 
data$web_y <- coordinates(coords.web)[,2] 
 
#only include REsig indicators  
data2 <- data[complete.cases(data[,c("tt_pos","tf_prev", "sand_5cm_s", "cluster_id",                                
"web_x","web_y")]),]  
 
REsig <- glmer(cbind(tt_pos,tt_examined-tt_pos) ~ tf_prev + sand_5cm_s + (1 | cluster_id), family 
= binomial("logit"), data = data2, control=glmerControl(optimizer="bobyqa")) 
summary(REsig) 
 
#this line extracts the random effects from the mixed model 
rand.eff <- ranef(REsig)$cluster_id[,1] 
 
#calculate the maximum distance between locations 
points <- subset(data2, select = c(web_x, web_y)) 
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dist <- dist(points[,-1]) 
maxd <- max(dist) 
 
coords <- as.matrix(data2[, c("web_x", "web_y")]) 
 
vari <- variog(coords=data2[,c("web_x","web_y")],data=rand.eff, uvec = seq(0,maxd/2, 
length=15)) 
 
vari.fit <- variofit(vari, ini.cov.pars = c(0.5,1.0), cov.model = "matern", fix.nugget = FALSE, 
nugget = 0 , fix.kappa = TRUE, kappa = 0.5) 
 
vari.sim <- variog.mc.env(obj.variog = vari, cords = data2 [,c("web_x","web_y")], data = 
rand.eff,nsim = 1000) 
 
matplot(vari$u,cbind(vari.sim$v.upper, vari$v, vari.sim$v.lower), type="l", col = c(2,1,2),lty = 
c("dashed", "dashed", "dashed"), xlab="distance",ylab="semivariance") 
 
#matplot(lines(vari.fit), type = "l", add=TRUE, lwd=2) 
 
##geostatistical modelling 
#now estimate the geospatial model using Monte Carlo maximum likelihood (use the best model 
from above) 
 
# 1 is the variance of the residual spatial correlation 
# 10 is the scale of the spatial correlation in meters 
par2 <- c(REsig@beta,1,10)  
 
#This function defines the options for the MCMC algorithm used in the Monte Carlo maximum 
likelihood method. 
c.mcmc <- control.mcmc.MCML(n.sim=10000,burnin=2000,thin=8,h= (1.65)/(nrow(data2)^(1/6))) 
str(c.mcmc) 
 
#only include indicators from REsig model  
fit.MCML3 <- binomial.logistic.MCML(tt_pos ~ tf_prev + sand_5cm_s, units.m=~tt_examined, 
coords=~web_x+web_y, par0=par2,control.mcmc = c.mcmc, fixed.rel.nugget = 0,kappa=0.5,                                    
start.cov.pars = 10,data=data2, method = "nlminb")  
 
summary.fit <-summary(fit.MCML3) 
fit.MCML3$log.lik 
 
#scale of the spatial correlation  
exp(summary.fit$cov.pars[2,1])*log(20) # km 
 
#95% confidence interval 
exp(summary.fit$cov.pars[2,1]+c(-1,1)*qnorm(0.975)*summary.fit$cov.pars[2,2])*log(20) # km 
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 Binomial mixed effect model R outputs 
Benin 
Null model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   601.6    608.3   -298.8    597.6      211  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.5974 -0.4871 -0.4253  0.3697  0.9761  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 2.253    1.501    
Number of obs: 213, groups:  cluster_id, 213 
Fixed effects: 
            Estimate Std. Error z value Pr(>|z|)     
(Intercept)  -5.0649     0.1863  -27.19   <2e-16 *** 
TF only model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   565.1    575.2   -279.6    559.1      210  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.9528 -0.5326 -0.4362  0.4484  1.2856  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.296    1.138    
Number of obs: 213, groups:  cluster_id, 213 
Fixed effects: 
            Estimate Std. Error z value Pr(>|z|)     
(Intercept)  -5.4023     0.1896 -28.494  < 2e-16 *** 
tf_prev       6.0655     0.8843   6.859 6.94e-12 *** 
TF prevalence + 
risk factors model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + S1 + S2 + 
imp_un_water +   
    water_yard + ai + sand_5cm_s + stlight97_s + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   566.2    599.8   -273.1    546.2      203  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-1.0134 -0.5338 -0.3864  0.4153  1.7015  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.176    1.084    
Number of obs: 213, groups:  cluster_id, 213 
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Cote d’Ivoire 
Null model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   198.2    205.3    -97.1    194.2      254  
Scaled residuals:  
     Min       1Q   Median       3Q      Max  
-0.10289 -0.07618 -0.07288 -0.06605  0.46770  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 13.75    3.708    
Number of obs: 256, groups:  cluster_id, 256 
Fixed effects: 
            Estimate Std. Error z value Pr(>|z|)     
(Intercept)   -9.413      1.174  -8.018 1.07e-15 *** 
TF only model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   198.7    209.4    -96.4    192.7      253  
Scaled residuals:  
     Min       1Q   Median       3Q      Max  
-0.15848 -0.09210 -0.08337 -0.07566  0.59333  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 10.28    3.206    
Number of obs: 256, groups:  cluster_id, 256 
Fixed effects: 
            Estimate Std. Error z value Pr(>|z|)     
(Intercept)   -9.400      1.310  -7.177 7.12e-13 *** 
tf_prev        3.487      2.646   1.318    0.187     
TF prevalence + 
risk factors model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + S1 + S2 + 
imp_un_water +   
    water_yard + ai + sand_5cm_s + stlight97_s + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   199.6    235.1    -89.8    179.6      246  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.4829 -0.1842 -0.1238 -0.1007  2.2171  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 2.953    1.718    
Number of obs: 256, groups:  cluster_id, 256 
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DRC 
Null model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
  3018.5   3028.3  -1507.2   3014.5     1021  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.7402 -0.5966 -0.1094  0.3914  2.0896  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.521    1.233    
Number of obs: 1023, groups:  cluster_id, 1023 
Fixed effects: 
            Estimate Std. Error z value Pr(>|z|)     
(Intercept) -4.40726    0.06655  -66.23   <2e-16 *** 
TF only model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
  2864.7   2879.5  -1429.4   2858.7     1020  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-1.4608 -0.5579 -0.2798  0.4170  2.7763  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.234    1.111    
Number of obs: 1023, groups:  cluster_id, 1023 
TF prevalence + 
risk factors model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + S1 + S2 + 
imp_un_water +   
    water_yard + ai + sand_5cm_s + stlight97_s + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
  2795.7   2845.0  -1387.8   2775.7     1013  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-1.4488 -0.5453 -0.2834  0.4139  3.0121  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.048    1.024    
Number of obs: 1023, groups:  cluster_id, 1023 
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Ethiopia 
Null model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
 12605.3  12618.1  -6300.7  12601.3     4478  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.8142 -0.6160 -0.5088  0.4562  1.7023  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.217    1.103    
Number of obs: 4480, groups:  cluster_id, 4480 
Fixed effects: 
            Estimate Std. Error z value Pr(>|z|)     
(Intercept) -4.53562    0.03073  -147.6   <2e-16 *** 
TF only model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
 12182.0  12201.2  -6088.0  12176.0     4477  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-1.0466 -0.5887 -0.4671  0.4728  2.5096  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.006    1.003    
Number of obs: 4480, groups:  cluster_id, 4480 
TF prevalence + 
risk factors model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + S1 + S2 + 
imp_un_water +   
    water_yard + ai + sand_5cm_s + stlight97_s + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
 12029.9  12094.0  -6004.9  12009.9     4470  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-1.1047 -0.5939 -0.4334  0.4923  2.6740  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 0.919    0.9587   
Number of obs: 4480, groups:  cluster_id, 4480 
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Guinea 
Null model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   341.2    348.6   -168.6    337.2      293  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.4189 -0.2980 -0.2843 -0.2674  1.4111  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.876    1.37     
Number of obs: 295, groups:  cluster_id, 295 
Fixed effects: 
            Estimate Std. Error z value Pr(>|z|)     
(Intercept)  -6.5984     0.2888  -22.84   <2e-16 *** 
TF only model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   342.3    353.4   -168.2    336.3      292  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.3994 -0.2972 -0.2825 -0.2619  1.4218  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.865    1.366    
Number of obs: 295, groups:  cluster_id, 295 
TF prevalence + 
risk factors model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + S1 + S2 + 
imp_un_water +   
    water_yard + ai + sand_5cm_s + stlight97_s + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   349.3    386.2   -164.7    329.3      285  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.4981 -0.3145 -0.2774 -0.2230  1.9768  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.664    1.29     
Number of obs: 295, groups:  cluster_id, 295 
  
 
 
255 
 
Malawi 
Null model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   794.9    803.9   -395.4    790.9      694  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.4681 -0.2907 -0.2684 -0.2300  1.4442  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 2.17     1.473    
Number of obs: 696, groups:  cluster_id, 696 
Fixed effects: 
            Estimate Std. Error z value Pr(>|z|)     
(Intercept)  -6.2583     0.2033  -30.79   <2e-16 *** 
TF only model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   783.9    797.5   -388.9    777.9      693  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.5216 -0.2926 -0.2615 -0.2220  1.6484  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.956    1.399    
Number of obs: 696, groups:  cluster_id, 696 
TF prevalence + 
risk factors model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + S1 + S2 + 
imp_un_water +   
    water_yard + ai + sand_5cm_s + stlight97_s + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   785.0    830.4   -382.5    765.0      686  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.5639 -0.3152 -0.2625 -0.1940  3.4738  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.733    1.316    
Number of obs: 696, groups:  cluster_id, 696 
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Mozambique 
Null model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
  1854.8   1865.9   -925.4   1850.8     1946  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.2187 -0.1822 -0.1730 -0.1613  1.6067  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 4.449    2.109    
Number of obs: 1948, groups:  cluster_id, 1948 
Fixed effects: 
            Estimate Std. Error z value Pr(>|z|)     
(Intercept)  -7.2466     0.2278   -31.8   <2e-16 *** 
TF only model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
  1821.3   1838.1   -907.7   1815.3     1945  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.6170 -0.1956 -0.1771 -0.1625  2.2368  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 3.522    1.877    
Number of obs: 1948, groups:  cluster_id, 1948 
TF prevalence + 
risk factors model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + S1 + S2 + 
imp_un_water +   
    water_yard + ai + sand_5cm_s + stlight97_s + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
  1810.5   1866.2   -895.2   1790.5     1938  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.6033 -0.2180 -0.1814 -0.1462  2.3079  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 3.084    1.756    
Number of obs: 1948, groups:  cluster_id, 1948 
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Nigeria 
Null model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
 13437.7  13450.9  -6716.8  13433.7     5362  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.6629 -0.4916 -0.4384  0.4427  1.5356  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.929    1.389    
Number of obs: 5364, groups:  cluster_id, 5364 
Fixed effects: 
            Estimate Std. Error z value Pr(>|z|)     
(Intercept) -5.13003    0.03822  -134.2   <2e-16 *** 
TF only model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
 13312.0  13331.8  -6653.0  13306.0     5361  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.9981 -0.4917 -0.4343  0.4481  1.4304  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.821    1.35     
Number of obs: 5364, groups:  cluster_id, 5364 
TF prevalence + 
risk factors model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + S1 + S2 + 
imp_un_water +   
    water_yard + ai + sand_5cm_s + stlight97_s + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
 11898.1  11963.9  -5939.0  11878.1     5354  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-1.1294 -0.4989 -0.2747  0.3235  4.6856  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 0.998    0.999    
Number of obs: 5364, groups:  cluster_id, 5364 
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Sudan 
Null model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
  1264.6   1273.6   -630.3   1260.6      665  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.5020 -0.4079 -0.3798  0.6002  1.0650  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.975    1.405    
Number of obs: 667, groups:  cluster_id, 667 
Fixed effects: 
            Estimate Std. Error z value Pr(>|z|)     
(Intercept)   -5.436      0.134  -40.57   <2e-16 *** 
TF only model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
  1244.6   1258.1   -619.3   1238.6      664  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.7947 -0.4005 -0.3658  0.5623  1.1083  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.845    1.358    
Number of obs: 667, groups:  cluster_id, 667 
TF prevalence + 
risk factors model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + S1 + S2 + 
imp_un_water +   
    water_yard + ai + sand_5cm_s + stlight97_s + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
  1158.5   1203.5   -569.3   1138.5      657  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.8231 -0.4473 -0.2898  0.2510  3.0878  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 1.18     1.086    
Number of obs: 667, groups:  cluster_id, 667 
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Uganda 
Null model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   117.9    123.3    -56.9    113.9      107  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.5515 -0.4583 -0.4264 -0.3920  4.0309  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 0        0        
Number of obs: 109, groups:  cluster_id, 109 
Fixed effects: 
            Estimate Std. Error z value Pr(>|z|)     
(Intercept)  -5.7650     0.2186  -26.38   <2e-16 *** 
TF only model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   119.1    127.1    -56.5    113.1      106  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.5732 -0.4563 -0.4187 -0.3738  3.6379  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 0        0        
Number of obs: 109, groups:  cluster_id, 109 
TF prevalence + 
risk factors model 
Generalized linear mixed model fit by maximum likelihood (Laplace 
Approximation) ['glmerMod'] 
 Family: binomial  ( logit ) 
Formula: cbind(tt_pos, tt_examined - tt_pos) ~ tf_prev + S1 + S2 + 
imp_un_water +   
    water_yard + ai + sand_5cm_s + stlight97_s + (1 | cluster_id) 
   Data: data 
Control: glmerControl(optimizer = "bobyqa") 
     AIC      BIC   logLik deviance df.resid  
   119.9    146.8    -49.9     99.9       99  
Scaled residuals:  
    Min      1Q  Median      3Q     Max  
-0.8797 -0.4156 -0.3128 -0.2073  3.5966  
Random effects: 
 Groups     Name        Variance Std.Dev. 
 cluster_id (Intercept) 0        0        
Number of obs: 109, groups:  cluster_id, 109 
 
 
